Back Matter (PDF)

Author Indexâ€”1988

Aaron,756(ab)Aarsvold,A, 972(ab)Alavi,EW, 1943Anghileri,DA, 952(ab), 789(ab)Bailey,KE, 753(ab)Beasley,WH, 760(ab)Abadal,JA, 747(ab),751(ab),A, 132, 2020Anson,LJ, 663, 593Baird,DL, 1307Beatty,CW, 874(ab), 1893Abbeele,L, 759(ab),777(ab),758(ab), 871(ab),876(ab)Anthony,CP, 867(ab), 766(ab)BaiF, 926(ab)Beatty,BG, 103, 923(ab)Abbott,ADVD, 817(ab),825(ab),788(ab), (ab)Baker,rey, CN. 741 926(ab)Beaumier,JD, 773(ab),920(ab)Abbott,GL, 836(ab),852(ab),830(ab), 908(ab)Antich,G, 411Baker,K, 5(ab)Beaumier,P, 8 1 883(ab),910(ab),857(ab), 890(ab)Antico,P, 1189Balch,T, 908(ab), 777(ab),929(ab)Beck,PA, 94I(ab)Abdel-Dayem,J, 744(ab), 935(ab),1015Alazraki,915(ab), 850(ab)Antunes,V, 854(ab)Baldwin,CM, 982(ab)Abdel-Dayem,H, 942(ab)Aoyama,ML. 929(ab)Baldwin,RM. 122, 873(ab)Becker,T, 130,750(ab), HM, 939(ab),941N, 329, 985(ab)Apicella,Y, 761(ab)Ball.RW, 753(ab)Becker,DV, 814(ab),838(ab),752(ab), (ab)Alazraki, 852(ab)Apostolides,A, 1526Ballance,ME. 293, 976(ab), 9(ab),938(ab),LC, 44 1,81 (ab).980(ab),868(ab), 971 793(ab),910(ab),NP. 888(ab)Apparo.DL. 846(ab)Ballester,C. 1539Becker, 986(ab)Abdel-Nabi,985(ab), 1860Alderson,944(ab), 1230Appelbaum.M. 1893Balliet,M, 832(ab)Beckers,V, 2(ab),898(ab),H, 81 764(ab).855(ab),PO, 168, 757(ab)Araki,F. 822(ab)Ballinger.R, 1826Beckett,C, 311, 978(ab)Abe, 1710,1748Aledort,925(ab), (ab)AraÃ±o,Y, 741 902(ab),919(ab),JR, 572, 898(ab)Beekhuis,ML, 886(ab)Abe,M, 934(ab)Araujo,Y, 928(ab), 984(ab),985(ab),978(ab). 907(ab),908(ab)Beers.H, 805(ab)Abedl-Dayem,R, 787(ab)Alger,LM. 783(ab)Aravantinos,L, 241, 1998Ban. 320Abdel. H, 846(ab)Alger,E, 1910Arbeille. G, 7(ab)Bandyopadhyay,T. 8 1 304Behrendt,B, 1 (ab)Aboul-Enein,W, 921 (ab)Ali,EA, 761 893(ab)Arcangioli,B, 657Banket, D, (ab)Beihn, H, 791 427Aboutaleb, HY, 835(ab)Alijani,SA, 1790Archibald,O. 902(ab)Banner,WJ. 877(ab)Beil,R, 862(ab)Abrams,AS, 1364Alivisatos,MR. 984(ab)Areeda,MB. 829(ab)Baran,H, 915(ab)Bekerman,C, 866(ab), 897(ab)Abrams,P, 1Allard. B. 63 770(ab),861J, 741(ab). 779(ab)Baranczuk,GA, 756(ab)Belani,C, 834(ab)Abreu,PG, 39, 878(ab)Allen,CD, 876(ab), (ab)Armbrecht,(ab), 951 853(ab),979(ab)Barber,RA, 982(ab)Beller,N, 780(ab)Abubacker,SH, 764(ab), 897(ab)Allen,JI, 782(ab),808(ab).J, 804(ab)Beller,G, 320Aburano,KC, 982(ab)Allen,ML, 942(ab), 937(ab)Armstrong, (ab)Barber.DC, 791 850(ab),955(ab)Belletire.GA, 819(ab), 750(ab),812(ab),T, 897(ab)Allen,MO, 348Armstrong,C, 1101Barclay,HB, 878(ab), 857(ab),895(ab)Ackerman,827(ab), 898(ab)Allo,S, 768(ab),945(ab)Arnaud,PW, 876(ab),878(ab)Barden,AB. J,801(ab)Bellil, 10Allred,MD, 1 768(ab)Bellina,D, 821(ab),836(ab),RH, 929(ab)Allwright,JF, 835(ab), 883(ab).973(ab)Amett,SB, 882(ab)Barest,HS, 1833Bello,CR, 920(ab)Ackermann, 763(ab),780(ab)Al-Malki,SJ, 803(ab)Barkan.G. 816(ab)Beizberg,A, 743(ab),861RJ, 933(ab)Aronen,CD, 1644Barker.AL. 726Benamor,ASB, 928(ab)Ackery,(ab), (ab)Al-Nahhas,A, 971 1194Arora,H, 899(ab), 852(ab),912(ab)Barnes.WW. 898(ab)Bendriem,M, 763(ab),971DM, 549, 147Al-Nahhas,A, 875Arrichiello,G, 1 879(ab)Benedetto,B, 1153Adam,(ab), 986(ab), 850(ab)Alpert,AM. 1786Arsenault,P, 974(ab)Baron,WE. 1610Benko,AR, 1114, 926(ab)Adam,MJ, 773(ab),821(ab),NM, 864(ab)Arzoumanian,A. 9(ab)Barrett,JC,822(ab), 91 423Benua.H, 744(ab),818(ab),WE, 836(ab),876(ab),832(ab), 1498Asano, A. 101Barrett.HB, 1 904(ab)Berent,RS, 946(ab)Adams, 920(ab)Al-Rasheed, l(ab)Ash.Y, 93 760(ab).878(ab)BarreÂ«.HH. 913(ab)Berg,S, 1057Adams,GK, III, 320Alspaugh,A, 792(ab)Ashburn,JM, 791(ab), 867(ab)Berg,G, 852(ab), 888(ab),899(ab),GP, 217, 825(ab)Altschuler.JP, 765(ab)Askienazy,WL, 900(ab)Barrio,J, 889(ab), 643Berger,J, 922(ab)Adams, (ab).839(ab)Alvarez,L. 821 946(ab)Asli,S, 866(ab),950(ab)Bartenstein.JR, 809(ab). 805(ab),806(ab),H, 746(ab), 772(ab)Adams,HR, 1724Assey,IN, 851(ab),905(ab),825(ab), 976(ab)Adatepe,R, (ab)Alvarez,V, 901 955(ab)Atcher,ME. 902(ab)Barthel.P, 923(ab)Berger, 2022Adatepe,MFH, 5(ab)Alves,VL, 81 858(ab)Atcher,R, 854(ab)Bartholomew.L, 746(ab)Bergmann,HJ, 745(ab), 900(ab)Adcock,MH, 910(ab)Alves,W, 830(ab), 1810Atkins.RW. 576. 812(ab),893(ab),RM. 807(ab),818(ab),SR, 1462Adcock,DM, 852(ab)Al-Wafai,WM, 1697Attas,HL. 886(ab), 1688Bartlett.895(ab), 1223,2018Berkopec,848(ab), 1462Adelstein,KA, 980(ab)Alyea,I, 898(ab)Attie,L. 789(ab)Bartzokis,J. 923(ab)Adhikesavulu,SJ, 766(ab)Amano,K, 974(ab)Aumont,JN, (ab),839(ab)Bascom,G. 821 875(ab)Berman,JM. 800(ab)Adler. D, 878(ab)Amartey,M, 808(ab)Awano,MC, 7(ab)Berman,C. 8 1 879(ab)Adzamli,S, 908(ab)Amemiya,J, 954(ab)Ayers,JWT,N, 742(ab),916(ab)Basic,MJ, (ab).755(ab),D, 741 847(ab)Agner,IK, 802(ab)Ames,H, 1644Baas, 770(ab),793(ab),768(ab), 820

Page numbers followed by (ab) indicate abstracts. Page numbers followed by (le) indicate letters. N preceding a page number indicates an article appearing in Newsline.

2032 The Journal of Nuclear Medicine Cheung

Besett, J, 760(ab) Bodenheimer, M, 819(ab), 916(ab). 942(ab) Burbank, K, 749(ab) Cascella, NG. 840(ab). Besnard, JC, 2008 832(ab) Brennan, MF, 902(ab) Burckhardt. DD, 903(ab) 911(ab) Besnard, J-C, 893(ab), Boivin,MJ, 913(ab) Bretille, J, 946(ab) Burgess. BA. 758(ab) Casset-Senon, D, 771(ab) 911(ab) Bok,B,981(ab),1118 Brewer, LA, III, 799(ab) Burgess, C, 953(ab) Cassidy, MM, 943(ab) Betebenner, DA. 926(ab) Bol,A,866(ab),914(ab), Briandet, P, 744(ab) Burgiss. SG, 880(ab) Castle, V, 892(ab) Betocchi, S, 1786 1633,1826 Bricker, JA, 813(ab), 1169 Burke, JF, 789(ab), 934(ab) Castro. R. 950(ab) Bettinardi, V. 749(ab), 1971 Boiman, RM, III, 1223 Briggs, WS, 810(ab) Burke, TS. 411 Castronovo, FP. Jr, 1152 Betz, AL, 784(ab) Bolomey, L, 1526 Brihaye, C, 841(ab), 927(ab) Burnett, KG, 1688 Catz, Z, 894(ab), 895(ab) Beydon, L, 764

Author Index â€¢1988 2033 Chiao

Chiao, P. 76(Xab) 1826Cohen, 1810Datz,Gupta, TK, DeSantis, M, 8l9(ab) Chiariello, M, 1786 268Cohen,BL, 803(ab),1668Counsel!,MW, 356, 130,329,574,751(ab)Daube-Witherspoon,FL, Deshpande, SV, 217, Chien, D, 836(ab) l(ab)Cohen,I, 770(ab), 95 824(ab), 888(ab), 922(ab) Chien, S, 1710 1200Cohen,MB, 869(ab), 503Coupai,RE, MEâ€ž385Daube-Witherspoon, DeSisto, W, 874(ab) Chikamori, T. 781(ab), 759(ab),796(ab),RM, 904(ab),905(ab),JJ, 765(ab), DeSouza, M, 791(ab) 782(ab) 852(ab)Colapinto,820(ab), 980(ab)Coveney, ME,867(ab), De Spiegeleer. B, 1107 ChillÃ³n,HM. 857(ab), 835(ab)Colas-Linhart,EV, (ab),906(ab),JR, 801 1558Daugherty, Deussen, A, 755(ab) 981(ab) (ab).1118Colcher,N, 981 908(ab)Cowan, 848(ab)Dauth,A, Deutsch, E, 801(ab), 847(ab), Chin, H, 769(ab) 485Cowan,RA, 759(ab)David,J, 934(ab), 935(ab) Chin, M, 840(ab) 1022Cole,D, 857(ab)COX.JL,RC, 1688Davidson,GS, Deutsch, EA, 776(ab) Chin, O, 869(ab) 799(ab),873(ab),P, 742(ab), 1223Cox, 1587Davis,JK, DeVito, RP, 798(ab), Chinol, M, 846(ab), 1428 944(ab)Coleman,916(ab), 851(ab)Coyle,JJ,PH, 1662Davis,MJ, 953(ab), 845(ab) Chiou, PF, 863(ab), 936(ab) 695Coleman,P, 817(ab)Coyle, 263Davison,PS, De Voider, AG, 914(ab) Chiou, RK, 872(ab) (ab)Coleman,R, 871 944(ab)Cradduck,JJ, Jr, 820(ab)Deakin,A, 55, Devos, P, 752(ab), 909(ab) Chirakal, R, 363 786(ab),897(ab),RE, 684Crisp, TD, 485Dean,DP, Devous, MD, Sr, 760(ab), Chiron, C, 743(ab), 792(ab), 1398Collea,J1045, 1354, 914(ab)Croft,S, 905(ab)Dean,R, 911(ab), 912(ab), 1875 869(ab), 892(ab) 1364Collen,V, N1871.717.816(ab),BY, 746(ab),851RT, 745(ab), deVries, DJ, 845(ab) Chisholm, RJ, 768(ab), 752(ab)Coller,MJ, N1477Crone-Escayne,N1475, 923(ab)Decoran,(ab), Dewanjee, M, 897(ab) 945(ab) 825(ab)Collier,BS, 663Cronin, M-C, 980(ab)Deecke,MA, Dewanjee, MK, 794(ab) ChiÃ¹,KW, 789(ab) 856(ab),868(ab),BD. 752(ab)Crook,B, 920(ab)DeFilippi,L, Dewes, W, 891(ab) Chiueh, CC, 759(ab), 1761Collins,976(ab), 925(ab)Crosser,JE, 764(ab)DeGalan,VJ, Dewey, SL, 767(ab), 933(ab) 820(ab) 834(ab)Collins,C, (ab)Crossley,M, 921 503De MR, Dewez, S, 927(ab) Chou, J-S. 868(ab) 850(ab)Colombo,L, 873(ab)Crouse,R, 806(ab)Degeorges,Geeter, F. de Wit, H, 840(ab) Choy, DH-L, 701 (ab).934(ab)Combs,F, 801 (ab).979(ab)Crouzel,DA, 901 828(ab)DeGrado,M, Dey, HM, 945(ab) Christensen, RC, 742(ab) 808(ab),822(ab),TR, de Zeeuw, D, 907(ab), Christian, P, 329 886(ab)Combs,MJ, 828(ab),940(ab)Crouzel,C, 808(ab), 939(ab)Deisenhammer, 908(ab) Christian, PE, 130,574,616, 933(ab)Comerata,R, 759(ab)DeJager, E, Dhawan, V, 839(ab) 751(ab) 844(ab)Comet,A, 808(ab),828(ab),M, 846(ab)deR, Dhekne, RD, 766(ab), Christiansen. C, 248 1230,1486Comunale,M, 951(ab), 940(ab)Crowther, 932(ab)deJesus, OJ, 982(ab) Christie, MJ, 1347 485Crowther,D, 927(ab)deJong, BM, Diamond, G, 949(ab) Chu, YK, 826(ab) 973(ab)Condon,JP. 599Crues, M, 908(ab)deJong, PE, Diamond, M, 839(ab) Chugani, HT, 772(ab), 32Conforti,BR, 1 (ab)Crues,J, 891 (ab).798(ab)Delaloye,Kraker, J, 791 Diaz, P, 760(ab) 831(ab) 1786Conlon,G, 802(ab)Cuchet,J, III, Dibos, PE, 972(ab) Chui, C. 803(ab) 902(ab)Connell,KC, 1230Cuckler,P, l(ab)Deland,B, 804(ab), 81 DiChiro, G, 421, 852(ab), Chun, S, 937(ab) 1746Connett,JMC, 883(ab)Cull,JM, 980(ab)deFH, 1603 Chung, J. 903(ab) 814(ab),835(ab)Connolly,JM, 975(ab),983(ab)Cullom,R, 971(ab), 778(ab)deLange, MJ, Diebler, C, 792(ab) Chung, J-K, 745(ab) 837(ab)Delbeke,Launoit, Y, Dietemeyer, JA, 794(ab) Churchod, S, 81I(ab) 473Connolly,BT, 810(ab),863(ab),SJ, 1454Delecluse,D, 763(ab), Dietz, G. 684 Churchwell, A, 91 835(ab)Conrad,P, 876(ab)Culver, 911(ab)Delforge,F, Dietz, H, 853(ab) Churchwell, AL, 1901 1169Constantinesco,GR. 813(ab), 873(ab)Cumming,CM, 863(ab)Delling.J, Digby, W, 832(ab) Cicogna, R, 946(ab) 26Constantinides,A, 934(ab)Cummings,SA, 882(ab)Dellis,G, Digby, WM, 983(ab) Cierny, G., III, 763(ab), 838(ab),982(ab),C, 776(ab)Cummings,DD. 1761Dell'Italia,CJ, Diksic, M, 370, 422, 631, 883(ab) 985(ab)Conti, 821(ab),839(ab)Cuocolo,J, 1368Del LJ, 784(ab), 915(ab), 930(ab), Ciliax, BJ, 767(ab), 930(ab) 904(ab)Conway,PS, 903(ab), 833(ab),897(ab)Demaison,Vecchio, S, 1957 Cinotti, L, 764(ab), 861(ab) 1957Cook,T, 775(ab)Curtet,A, 772(ab), Dillon, M, 905(ab) Civelek, AC, 756(ab), 979(ab)Cook,L, 853(ab), 811(ab)Custer,C, 1230DÃ©mangeÃ¢t,L, Dilsizian, V, 769(ab), 799(ab), 873(ab), 944(ab) 62Cooke.CD,N, 872(ab)Dacie,T, 26Demer, J-L, 945(ab) Cladellas, M, 1893 810(ab)Cooper, 973(ab)DeLL, Ding, Y, 760(ab) Clanton, JA, 981(ab) 931(ab)Cooper,AJL, 850(ab)Daddona,JE, 1107Demonceau.Moerloose, P, Di Paola, R, 861(ab) Claringbold, PG, 762(ab) 1842Cooper,JA, 898(ab)Dae,PE, 747(ab),758(ab)DeNardo.GL,G, Di Piero, V, 1507 Clark, O, 885(ab) 839(ab),840(ab),MD, 840(ab),941M, 744(ab), DiResta, E, 904(ab) Clark, RV, 859(ab) 932(ab),977(ab)Cooper,912(ab), (ab)Dae, 217,824(ab), 203, DiSciascio. G, 1283 Clarke, G, 801(ab) 781(ab),942(ab)Daghighian,MW, 302, 847(ab),871(ab),845(ab), Di Simone, RN, 725 Clarke, K, 826(ab) 763(ab),780(ab)Copeland,RA, 888(ab),899(ab),872(ab), DiSisto, W, 948(ab) Clarke, LP, 810(ab), 863(ab), 832(ab)Dahlbom,F, 1795DeNardo,922(ab), Doctor, DG, 764(ab) 876(ab) 742(ab)Coptcoat,JG, 241Daily, M, 217,824(ab),SJ, 203, Doerr, R, 898(ab) Clarke, SEM, 33, 1747 779(ab)Corbally,MJ, 833(ab)D'V, 847(ab),871(ab),845(ab), Doherty, MD, 876(ab) Clausen, M, 744(ab), 902(ab)CorbeÂ«,MT, (ab)Daley,Aleo, C, 901 888(ab),899(ab),872(ab), Doherty, PD. 846(ab) 756(ab), 799(ab), 818(ab), 760(ab),805(ab),JR, 948(ab)D'Amour,N, 922(ab)Denays, Doherty, PW, 1428 946(ab) 944(ab),948(ab)Corday,841(ab), 860(ab)DaÃ±Ã¡is,P, 893(ab)Dence,R, Doi,Y, 781(ab), 782(ab) Clements. JP, 977(ab) 843(ab)Danforth,S, 743(ab), 807(ab)denCS, Domino, EF, 767(ab) Cleynhens, B, 909(ab) 783(ab)Cordes,E, (ab)Danforth,J, 781 FCA,798(ab)Depaepe,Hartog Jager, Donohoe. K, 133,980(ab) Clinthorne, N, 917(ab) 977(ab)Coruja.M, 943(ab)Danilov,JW, Donohoe. KJ, 882(ab) Clinthorne, NH, 195, 981(ab),1568Corpuz,M, 977(ab), 1951Dann,SM, 954(ab)DePuey,A, DÃ¶rken,B. 899(ab) 760(ab), 785(ab), 797(ab) 132Dannais,R, 793(ab),859(ab),EG, Dorsey, D, 853(ab) Cloninger, K, 91, 1901 795(ab)Correia,S, 784(ab)Dannais,R, 950(ab).951944(ab), Doudet, D, 820(ab) Clonus, JH, 751(ab), 776(ab) 773(ab),821JA, 796(ab),809(ab),RF, 1479Derbekyan,(ab), Douesnard, JM, 747(ab), Clothier, J, 852(ab) 872(ab),920(ab)Corstens,(ab), 836(ab), 840(ab),852(ab),820(ab), 1050Derenzo,V, 844(ab) Coakham, HB, 897(ab) 911(ab),921853(ab), 760(ab)DeSE, Douglass, K, 784(ab) Coates, G, 824

2034 The Journal of Nuclear Medicine Gelbard

Drew, H, 789(ab). 873(ab) Elliott. AT. 1096 Faversham, JL. 944(ab) Folks. RD. 793(ab), 859(ab) 826(ab). 930(ab) Drew. HH, 1927 Elliott. AT, 1587 Fawcett. H, 813(ab) Folland, E, 947(ab) Fujino, A, 954(ab) Driedger, AA, 684, 947(ab) Ellison, D, 62 Fawcett. HD, 1745 Folstein, M. 916(ab) Fujisue. R. 451 Driscoll, JS. 837(ab) Elmaleh, DE, 68 Fawdry. R. 765(ab). 850(ab) Folstein. S. 9l6(ab) Fujita. H. 915(ab). 919(ab) Drost, DJ, 880(ab) Elmaleh, DR, 935(ab) Fawwaz, RA, 757(ab). Fommei. E, 907(ab) Fujita, T. 802(ab). 843(ab). Drury, JK., 783(ab) El-sayed. M, 814(ab) 925(ab) Foon. KA, 39 844(ab). 877(ab). 918(ab). Duara, R, 852(ab), 912(ab) El-Sayed. M, 971(ab) Fay.J, 118 Ford, E, 846(ab) 922(ab).1130 Dubinett. SM, 902(ab) Eisinga. PH, 524, 1419 Fayad, F, 909(ab) Ford, EH. 757(ab). 761(ab). Fukuchi.M,906(ab) Duboc. D. 828(ab) Elson. MK. 856(ab). 875(ab). Fazekas, F, 836(ab), 852(ab), 833(ab). 898(ab) Fukuda.H,809(ab).838(ab). Dubois, F, 1230 882(ab), 897(ab) 910(ab), 915(ab) Fordyce-Baum. MA, 829(ab) 941(ab) Dubovsky, E, 255, 1189 El-Tahtawy. A. 837(ab) Fazio, F. 749(ab). 80l(ab). Forell, BW. 875(ab) Fukuda. N. 838(ab). 941(ab) Dubovsky, EV, 908(ab), Embree, L, 807(ab) 934(ab). 1507, 1971 Forrest. I, 884(ab) Fukuda. T, 883(ab) 1730, 1931 Emran, AM, 1881 Feduska. NJ. 795(ab) Forstrom, LA, 838(ab) Fukunaga, M. 1448, 1460 duCret, RP, 974(ab) Emrich, D, 761(ab) Feiglin. D. 836(ab) Foster. NL. 743(ab). 915(ab) Fukuyama. H. 843(ab). Duda. RB, 103 Endo. K, 235, 766(ab). Feindel. W, 422 Fotiou. S. 1910 844(ab). 918(ab) Dudczak, R, 794(ab), 837(ab), 889(ab). 890(ab), Feinendegen, LE, 832(ab), Fouchard, J, 828(ab) Funch-Rosenberg, H, 850(ab) 1130,1436 851(ab). 877(ab), 938(ab), Foucher. G, 26 905(ab) Dufresnc, F, 17 Endo, M, 838(ab), 866(ab), 1582 Fournier, D, 808(ab), Furlan, AJ. 9l3(ab) Dulac, O, 743(ab), 792(ab), 941(ab) Feinsod. M. 881(ab) 940(ab) Furukawa. T. 1448 869(ab), 892(ab) Endres, JA. 943(ab) Feinsod. M, 187 Fowler. JS. 767(ab), 933(ab) Fuster, V. 1237 Dumont, A, 17 Engelbretson, D, 816(ab) Feld. T, 800(ab) Fox, LM. 769(ab) Futatsuya, R. 780(ab) Dumont, M, 906(ab) Engelsman, EE. 798(ab) Feldkamp, MJ. 942(ab) Fox, MR, 800(ab) Duncan, R, 1675 Engelstad, B. 795(ab) Feldman. M. 852(ab) Fox, SM. 769(ab) Gaab, MR, 853(ab) DÃ¼nn,D. 91, 756(ab), Engelstad. BL. 913(ab). Felix, R, 977(ab) Franceschi, D, 819(ab). 1539 GachÃ³n, P, 48, 939(ab) 938(ab), 945(ab) 982(ab) Fer, MF. 834(ab) Franceschi. M. 851(ab) Gadodia, G, 756(ab) DÃ¼nn,DW, 1901 Engenhart. R. 751(ab) Feremans, W. 807(ab) Franceschini. M. 933(ab) Gagne, GM, 83 Dunn, EK, 561 Englert, J, 39 Fernandez. JA. 909(ab) Francis. BE. 772(ab) Gagnon, A. 804(ab), 844(ab) DÃ¼nn,W. 855(ab) English, D, 1246 Fernandez-Ulloa. M, 1744 Frank, G, 1150 Gagnon, D. 864(ab) Dunn, WL, 881(ab) Entine, G, 880(ab) Ferrant, A, 1633, 1826 Frank, R, 809(ab) Gagnon, M, 17 Dupras, G. 781(ab), 793(ab). Epenetos, AA, 762(ab). 1910 Ferroni. P. 1022 Frank, TL, 441, 938(ab). Gainey, MA. 689 864(ab) Epperly, MW. 900(ab) Fetissof. F, 893(ab) 1539 Gal, R, 745(ab) Duroux, P, 824(ab) Epps, L, 905(ab) Fetterman, R. 804(ab) Frater. Sl. 695 Galante, M, 885(ab) Durrani. L, 761(ab) Epps, LA, 745(ab). 746(ab) Fettich, J. 147 Fratkin. MJ, 411. 888(ab). Gale, DR, 118 Durski. K, 756(ab), 799(ab), Epstein, AL. 847(ab). Feun, L, 897(ab) 1283 Galinsky, R, 907(ab) 944(ab) 888(ab) Ficken. VJ, 864(ab) Frederiksen. PB. 479 Gallagher. K, 938(ab) Duna. A. 777(ab) Eriksson, L, 820(ab), 984(ab) Fielding. SL. 798(ab) Freeman. I. 819(ab) Gallagher, R, 862(ab) Duwel, CMB. 851(ab), 1934 Erlandsson, K., 1719 Figueras, J. 1776 Freeman. MR. 768(ab). Galle. P, 824(ab) Dworkin, HJ, 753(ab), Erman, J, 1853 Filc-DeRicco. S, 931(ab) 871(ab), 945(ab) Galt, JR. 797(ab) 873(ab) Erturk. E, 849(ab) Filice, D, 791(ab) Frenas, JE, 859(ab) Gambhir, SS. 828(ab), Dydek, GJ, 407 Eshima. D, 616,669. Fill, H. 1382 French. WJ. 159 907(ab). 909(ab), 936(ab) 862(ab) Findley, DO. 875(ab) Frenkel, A, 187. 879(ab), Gambino, JJ, 903(ab) Esmaili. J, 1724 Findley. SL, 385 881(ab). 1341 Eakin, DA, 893(ab) Essandoh. LK. 945(ab) Can. M, 1200 Eakin, DE, 812(ab) Fine, DR, 549 Frey. KA. 808(ab), 932(ab) Gandevia. B. 701 Esser, PD, 168,717, 1748 Fink-Bennett, D, 826(ab). Friden. A. 897(ab) Eary. JF, 757(ab). 834(ab), Essiambre, R. 793(ab), Gandsman. EJ. 798(ab) 835(ab) 887(ab) Fridrich, R. 804(ab) Ganey, MV. 788(ab) 804(ab) Fink-Bennett, DM. 753(ab). Friedland. RP. 867(ab) Eaton, S. 891(ab) Esteban, J. 1022 Gansow, OA, 1810 Eckelman. WC, 891(ab) 873(ab) Friedman. DM. 893(ab). Gami, G, 774(ab) Esteban, JM, 926(ab) Finn. R, 772(ab), 820(ab) 895(ab), 925(ab) Eckerman, KF, 859(ab) Esterhai, JL, 1015 Ganz, SS. 887(ab) Finn, RD. 181, 772(ab), Friedman, HS, 835(ab) Eden, PJ, 851(ab) Estorch, M, 573, 1893 Ganz. W. 909(ab) 796(ab). 822(ab), 852(ab). Friedman, J. 741(ab), Edery, S, 861(ab) Etani, H, 1264 Ganz, WI. 887(ab) 939(ab) 793(ab). 802(ab). 891(ab) Eenigevan. MJ, 1934 Evans. AC, 422, 866(ab). Garan, H, 769(ab) Firnau, G, 363 Friedman, R. 571 Efange, SMN, 777(ab) 915(ab) Garcia. AM, 83 Fischer. M. 778(ab) Friend. K. 908(ab) Eftekhari,M, 1724 Evans, H, 816(ab) Garcia, E. 951(ab) Egdell, RG, 789(ab) Even-Sapir, E, 187 Fischman, AJ, 830(ab). Frincke. JM. 835(ab). Garcia. EV, 793(ab). 843(ab). 887(ab) 893(ab) Eggli. DF, 752(ab), 892(ab) Eyre, H, 329 797(ab). 810(ab), 944(ab) Fish. MB, 1596 Frischauf. H. 575 Ehrhardt. GJ, 923(ab) Ezquerra, NF, 810(ab) Garg, PK, 834(ab). 835(ab) Ehrhardt, JC, 348, 676 Fisher, D, 757(ab) Fritzberg. A. 847(ab), Garibian. G. 742(ab), Eichung, JO, 874(ab), 1961 Fisher. RS, 796(ab) 935(ab) 943(ab) Eidelberg. D, 839(ab) FaÃŸbender,D, 940(ab) Fisher, SK. 933(ab) Fritzberg, AR, 777(ab), Garnett, ES, 363 Einhorn, TA, 787(ab) Faber, TL, 805(ab) Fissekis, J, 903(ab), 904(ab) 800(ab). 815(ab), 834(ab). Garren. K, 913(ab) Eisdorfer, C, 829(ab) Fagnani, RL, 893(ab) Fitz, R. 765(ab) 929(ab) Garrity, ST, 788(ab) Eisen, HJ, 1223, 2018 Fagret. C, 951(ab) Fitzpatrick, DA, 873(ab) Froelich. JW, 1714 Garty, I. 750(ab) Eisenberg, B, 883(ab) Fagret, D, 1486 FjÃ¤lling,M, 1638 Front, A. 879(ab) Garvin. PJ. 779(ab) Eisenhut, M, 906(ab) Fahey, FH. 752(ab). 1364 Fleming, JS, 1153 Front, D, 187, 879(ab), Garza, D, 951(ab) Eisner, R, 91 Fairbank, JT, 977(ab) Fleming. RM. 803(ab) 881(ab). 1341 Gasthuisberg. UZ, 752(ab) Eisner, RL. 756(ab), 938(ab). Fajman. WA, 825(ab), Fletcher, MA, 829(ab) Frost, JJ, 796(ab), 809(ab), Gates, GF, 1467 945(ab), 1466, 1901 910(ab) Fleuren, GJ, 1078 921(ab), 1207 Gatley. SJ. 828(ab). 930(ab). Eklund, A. 905(ab) Fanwick, PE, 927(ab) Flor. WG. 927(ab) FrÃ¼hling,J. 837(ab) 1443 Elam, DA, 799(ab) Farcot. J-M. 26 Rower, MA, 752(ab). Fuccello, AJ. 851(ab) Gay. TA, 794(ab) EI-Dadah. M, 971(ab) Farde, L, 754(ab), 767(ab), 798(ab), 877(ab) Fuchs, H. 786(ab) Geatti, O. 900(ab). 1304 ELgazzar, AH, 814(ab) 820(ab) Floyd, C, 871(ab) Fudemoto, Y, 1738 Geckle. WJ, 441 Elgazzar, AH, 971(ab) Farhangi, M, 775(ab) Floyd, CE, 786(ab), 869(ab) Fudo, T, 827(ab), 828(ab), Gee, D, 1943 Elkanovitch, R, 1150 Farkas. R, 1022 Floyd, CE, Jr. 797(ab) 1181 Gelbard. AS, 902(ab). Eil, PJ, 9l2(ab) Faus, R, 1916 Fogelman, I. 1045. 1354 Fujibayashi, Y, 778(ab), 931(ab)

Author Index â€¢1988 2035 Goldenhuys

Geldenhuys, EN, 538 898(ab) Greenwell, K, 1200 Hack, SN, 1842 Hartmann. A, 936(ab) Gelfand, MJ, 892(ab) Goldenberg, H, 757(ab), Greer. DM. 356, 803(ab). Hackney, D, 852(ab) Hartsough. NE. 878(ab) Geltman. EM, 818(ab) 833(ab) 1668 Hadeishi, H. 9l5(ab) Hartwig, QL, 424 Generalli, T, 9IO(ab) Goldenberg. DM. 758(ab) Greer, K. 871(ab) Haden, HT, 1781 Hartwig, W. 932(ab) Genna, S. 786(ab) Coldfarb. CR, 707, 1150 Greer. KL. 1398 Hadley. SW. 777(ab), Hartz. RK. 879(ab) Gennarelli, T, 830(ab). Goldfarb. H. 789(ab) GrÃ©goire,J, 781(ab). 793(ab). 929(ab) Harwood, SJ, 896(ab) 910(ab) Goldfarb. HW, 73 804(ab) Hagan, P, 329 Hasegawa. BH. 267. 1466 Gensburg, RS, 1279 Goldfogel, G, 812(ab) GrÃ©goire,M, 744(ab) Hagan. PL. 812(ab), 893(ab), Hasegawa. Y. 1738 George. EA, 779(ab) Goldie. J, 975(ab) Grenier, RP. 745(ab) 895(ab). 925(ab). 1688 Hashimoto. S. 762(ab), Georgi. B. 779(ab) Goldman. S. 852(ab), Gress, D. 836(ab), 920(ab) Hagge. RJ, 864(ab) 950(ab). 1126 Georgi. P. 817(ab), 906(ab) 91l(ab) Greyson. ND, 768(ab), Hagius. JT, 786(ab) Hashimoto. T. 827(ab), Georgiou, E, 881(ab) Goldman-Leikin, R, 174. 945(ab) Haka. MS. 767(ab) 828(ab). 1181 Gerard, P, 911(ab) 901(ab) Grierson. JR, 926(ab) Hakim. AM. 866(ab). Hasikawa. K. 1264 Gerii, A, 936(ab) Goldsmith, SJ, 764(ab), Griffin, JC. 744(ab) 915(ab). 920(ab) Haspel. MV, 833(ab) Germano, G, 983(ab) 787(ab). 814(ab), 862(ab), Griffin, T, 846(ab). 1428 Hakki, A-H, 742(ab) Hassall, EG. 979(ab) Gereon. B, 902(ab) 921(ab), 1237, 1878 Griffith. MH. 1795 Hakki. H, 943(ab) Hassan. IM, 838(ab), Gerstenbrand. F, 1382 Goldstein. HA, 1364 Griffith, MH, Jr, 872(ab) Halders, S, 885(ab) 982(ab), 985(ab) Gerundini, P. 801(ab). Goldstein, RA, 973(ab) Griffiths, D. 893(ab) Hales, CA, 1268 Hassine. H, 129 934(ab), 1507 Gole, DJ, 767(ab) Grimmond, HE, 375 Halgren, E, 831(ab) Hata, M. 883(ab) Geuting. B, 851(ab), 938(ab) Goll, S, 1015 Grochow, L, 799(ab) Halker, R, 320 Hatano. K. 931(ab) Geyer, AB, 760(ab) Gona. J, 898(ab) GroÃŸmann,K, 851(ab), Hall, H. 767(ab) Hatano. M, 741(ab) Ghione. S, 907(ab) Gonzalez, A, 921(ab) 938(ab) Hall, J. 972(ab) Hatazawa, J, 931(ab) Gibbons, RJ. 838(ab), Good, S. 363 Gronka. ML, 783(ab) Hall, KM. 747(ab) Hattner, R, 795(ab), 883(ab) 945(ab) Goodgold. HM. 779(ab). Gronka, R, 830(ab) Hall. T. 846(ab) Hattner, RS. 302. 913(ab) Gibson, RE, 922(ab), 978(ab) Gross. M, 503, 796(ab). Hall.TC, 761(ab). 898(ab) Hauck-Newman. A. 796(ab) 927(ab) Goodman, MM, 777(ab). 859(ab) Hall. TR, 862(ab) Haumont, D, 893(ab) Gibson. RW. 293 843(ab), 1697 Gross, MD, 744(ab), Halldin, C, 754(ab), 767(ab), Hausen, D. 791(ab) Guardi, MC, 878(ab), 1971 Goodwin, DA, 226 859(ab), 917(ab), 918(ab). 931(ab) Hawk. TC, 821(ab) Gilbert. S, 766(ab), 825(ab) Gordon. L, 571,954(ab), 1368. 1644 Halperin. JL, 787(ab) Hawkins. LA. 147 Gilday. DL, 791(ab), 792(ab) 955(ab) Grossman. M, 915(ab) Halpem, SE. 812(ab). Hawkins. RA. 809(ab), Gildersleeve. DL, 930(ab) Goris, ML. 946(ab) Grossman, ZD, 1212 893(ab), 895(ab), 925(ab), 839(ab). 862(ab). 866(ab), Gilgien, W, 811(ab) Goris, MM, 717 Groth, S, 904(ab), 905(ab) 1688 1768 Gilland, DR, 643, 748(ab), Cose, EE. 974(ab) Grothe, RA Jr, 530 Harn. HR. 893(ab), 2020 Hawkins. WG. 868(ab) 749(ab), 786(ab). 870(ab) Gotfredsen, A. 248 Grover-McKay, M, 241 Harnacher. K, 755(ab) Hay. RV. 803(ab) Gillen,GJ, 1096, 1587 Gottschalk. A, 893(ab) Grubb. RL, Jr, 831(ab) Hamada, S, 1868 Hayashi, H. 900(ab) Gillet, P, 792(ab) Gotzamani-Psarrakos, Aâ€ž Gruenewald, S, 765(ab) Hamamoto, K. 765(ab), Hayashida. K. 914(ab). 1868 Gillis, E, 1107 1152 Gruenewald, SM, 850(ab) 791(ab). 829(ab). 888(ab) Haydock, C, 858(ab) Gillispie. SB. 867(ab). Gould, KL. 774(ab). 879(ab). Grunwald, AM. 819(ab) Hamashige, N, 781(ab), Hayes, G, 884(ab) 871(ab) 951(ab), 973(ab) Grunwald. F. 896(ab), 782(ab) Haynie, MP. 973(ab) Gilman, S, 913(ab) Gould, LK, 839(ab) 936(ab) Hamill, JJ, 798(ab), 845(ab) Haynie, TP, 125, 787(ab), Gini, A. 977(ab) Goutay. E, 129 Gu, XM, 832(ab), 984(ab) Hamilton, D, 485 854(ab). 894(ab), 1921, Ginjaume, M, 1893 Govelitz, GF, 375 GuÃ©rin,F, 828(ab) Hamilton, DR. 797(ab) 2014 Ginsberg HN, 1237 Grabnic. M. 760(ab) Guerra. UP, 946(ab) Hammes. RJ. 980(ab) Haynor, DR. 748(ab). Giombetti, R, 913(ab) Grady, CL, 867(ab) Guerrant, RL, 790(ab) Hanada. J. 909(ab) 871(ab) Gionet, M. 762(ab), 846(ab). Grady, PJ. 903(ab) Guerreau. D, 847(ab) Handa. S, 950(ab) Hays. MT. 822(ab) Guertler-Krawczynska, E, 1428 GraelT. RW. 787(ab) Handmaker. H, 780(ab) Haze, K, 802(ab) 1479. 1860 Giordani, B, 913(ab) Grafman, J, 852(ab) Hanna, MG, Jr, 833(ab) Heacock, C, 901(ab) Giorgi, MCP, 805(ab) Graham, AR, 742(ab) Guibourg. H, 938(ab) Hanna. R. 729 Heal, A, 897(ab). 1675 Giubbini, R, 946(ab) Graham, CCJr, 1083 Guillaume, M, 841(ab), Hannelin. M. 873(ab) Heal, AV, 777(ab) 927(ab) Givel.JC, 811(ab) Graham, LS, 267, 869(ab). Hansen. C. 841(ab) Healy, SA. 766(ab) Guilloteau. D, 885(ab), Given, B, 977(ab) 1200 Hansen. HJ. 757(ab), Heather, JD. 878(ab) 893(ab), 911(ab). 2008 Gjedde, A, 809(ab), 820(ab), Graham. M. 783(ab), 898(ab) Hebold, I. 821(ab) Gulenchyn. KY, 572, 915(ab) 830(ab) Hansen, L. 616. 907(ab) Hecht. HS. 769(ab) 902(ab), 919(ab), 978(ab), Glass, EC. 944(ab), 1154 Graham. MM, 717, 773(ab), Hansen. WP, 651 Hefti. F, 777(ab) 984(ab), 985(ab), 1998 Gleichmann, U, 940(ab) 879(ab), 920(ab). 933(ab) Hanson. RN. 68 Hegyaljai, T. 894(ab) Gullberg, GT, 749(ab). Glick, S. 868(ab) Granowska, M, 599, Hanson. WA, 982(ab) Heiba, S, 712, 887(ab) 786(ab), 870(ab) Glick, S3, 748(ab), 749(ab), 899(ab), 1031 HarÃ¡.T, 921(ab) Heidendal, GAK. 885(ab) Gungon, RL, 73 864(ab), 870(ab), 1980 Grant. R, 132 Guo. Y-Z, 777(ab). 788(ab), Harby. K. N283, N287, Heindel. ND. 873(ab) Glickman, S, 1768 Graveline, R, 843(ab) N429. N431.N583. N586, Heindel. W, 785(ab) 935(ab) Gloor. P, 920(ab) Gravelle, D, 684 N588, N1003, NI01I. Heiss, W-D, 785(ab), 821(ab) Gupta, N, 825(ab) N1159. NII62. N1469 Heistad, D, 348 Glover, DK, 792(ab) Gray. LL, 842(ab) Gupta, S, 977(ab) Glowniak, JV, 842(ab), 1156 Grdina, D, 858(ab) N1611.N1751.NI889 Helfrich.GB. 1364 Gur, RC, 830(ab), 910(ab) Go, RT, 913(ab), 946(ab) Greager. JA, 1810 Harcke, HT, 881(ab) Hellman. RS, 776(ab), Gur, RE, 83(Xab) Gober, A, 938(ab), 945(ab) Green, CE, 769(ab) Hardy, M. 757(ab) 976(ab) Gusella, J. 853(ab) Green. MA, 417, 848(ab), Harp, GD, 1393 Gober, AM, 1901 Gustavson, L, 935(ab) Hellman. RS. 1761 927(ab), 1549 Harpen. MD, 1750 Hellwig. B. 509, 1577 Goeckeler, WF. 903(ab) Gutelius, CA. 980(ab) Goeldel. NH. 949(ab) Green, MV, 385, 772(ab), Guth-Tougelides. B, 854(ab) Harper. PV, 803(ab) Hellwig. D, 744(ab), 818(ab) Goethals, P, 1107 775(ab), 1558 Guyot, M, 914(ab), 1515 Harris, BA, 883(ab). 973(ab) Helus, F, 208. 751(ab), Green, SL. 897(ab), 901(ab) Harris. JR, 473 776(ab). 817(ab) Goffinet, AM, 914(ab) Guzzardi, R, 1833 Golazeski, T, 742(ab) Greenberg, E. 751(ab) Gyobu, T. 558, 917(ab) Harrison, RC, 940(ab) Heminger. LA. 766(ab) Gold, HK, 825(ab), 851(ab) Greenberg, JH. 747(ab) Harrison, RL. 867(ab). Hendee, WR, 267, 1466 Goldenberg, DM, 757(ab), Greene, R, 938(ab), 945(ab) 871(ab) Henderson, EB, 841(ab) 761(ab), 833(ab). 846(ab), Greenspan, F. 885(ab) Haber, E, 746(ab). 939(ab) Hartig. PR. 809(ab) Hendricks. PJ, 263 858(ab), 874(ab), 890(ab), Greenspan, RL, 764(ab) Habibian, MR. 973(ab) Hartling. OJ, 1155 Hendrix. GH. 954(ab),

2036 The Journal of Nuclear Medicine Kanno

955(ab) HofTman, JM, 809(ab), 941(ab), 950(ab), 983(ab) Ireton, R, 978(ab) Jinnouchi, S, 1627 Hendrix, T, 789(ab) 821(ab). 832(ab), 866(ab) Huberty, J, 795(ab), 840(ab), Ine, T, 809(ab) Jivan, S, 926(ab) Henkes, H. 977(ab) HofTman, RF, 762(ab) 883(ab) Isaka, Y, 1264 Jochelson, M, 799(ab) Henkin, RE, 927(ab) HofTman, RG, 1761 Huberty. JP, 913(ab) Ishida. Y, 949(ab) Johansen, KL, 928(ab) Henry. LA, 865(ab) Hoffmann, JM, 853(ab) Huesman, RH, 760(ab), Ishii, R, 1460 John, E, 927(ab) Henry, RE. 896(ab) Hoflpauir, J, 933(ab) 773(ab), 916(ab) Ishikawa, M, 843(ab), Johnes, J, 851(ab) Hensley, KS, 984(ab) HÃ¶gberg,T, 767(ab) Huffman, JC, 417 844(ab). 918(ab), 1126 Johnson, DK, 824(ab), Henze, E, 744(ab). 8I8(ab), Holberg, BL, 270 Hughes, J, 904(ab) Ishimura, J, 906(ab) 924(ab), 926(ab) 946(ab) Holbert, BL, 2022 Huguet, F, 911(ab) Ishiwata, K, 524, 931(ab), Johnson, J, 542, 812(ab) Heo, J, 742(ab), 943(ab) Holcomb, HH, 853(ab) Huisman, RM. 907(ab) 1419 Johnson, JA, 1347 Herholz, K. 785(ab) Holden. JE. 808(ab), Hull, JE, 825(ab) Isitman, AT. 1761 Johnson, L, 825(ab) Herman, PC, 974(ab) 822(ab), 939(ab) Hull, R, 824(ab) Iskandrian, A, 742(ab), Johnson, LL, 806(ab), Herman, T, 799(ab) Holland. G. 910(ab) Humphries, LL, 882(ab) 943(ab) 841(ab), 942(ab) Hermann. G, 943(ab) Holland, MJ, 933(ab) Hundeshagen, H, 853(ab) Iskandrian, AS, 742(ab) Johnson, S, 834(ab) Hermansen, F, 904(ab) Hollenberg. NK, 948(ab) Hung,CY, 981(ab) Isobe, M, 746(ab) Johnson, TK, 267. 1466 Hernandez, J, 789(ab) Hollingsworth, J, 975(ab) Hung, JC, 747(ab), 935(ab), Ison. KT, 779(ab) Jolly, D, 930(ab) Herning, RI. 840(ab) Hollins. WJ. 955(ab) 981(ab), 1568 Israel, O, 187, 879(ab), JoÃ±as,U, 1078 Hero, AO, 785(ab) Holman, BL, 55, N289, 567. Hungerford, JL, 1031 881(ab). 1341 Jones, AG, 55. 820(ab) Heros, RC. 920(ab) 82(Xab), 851(ab), 874(ab), Hunt, R, 975(ab) Ito, S, 923(ab) Jones, GS, 935(ab) Herranz, R, 1916 N1006, 1704 Hunter, R, 846(ab), 1428 Ito, T, 809(ab) Jones, GS Jr, 68 HerrÃ©.J, 840(ab) Holman, LB, 948(ab) Huntley, TE, 856(ab), Itoh, H, 829(ab), 888(ab) Jones, MT, 938(ab), 945(ab) Herscovitch. P. 772(ab), Holmes, RA. 775(ab), 882(ab) Itoh, J, 918(ab) Jones, PL, 823(ab) 822(ab), 874(ab). 1961 832(ab), 903(ab), 935(ab), Hupf, HB, 270 Itoh, K, 985(ab) Jones, RH, 1492 Herzog, H, 877(ab), 1582 977(ab), 981(ab), 984(ab), Hurford, WE, 947(ab) Itoh, M, 890(ab), 931(ab) Jones, T, 878(ab) Hesslewood, SR, 1301 1568 Hurtig, HI, 836(ab), 852(ab) Itti, R, 771(ab), 793(ab), Jonker. GJ, 907(ab) Hester, JP, 787(ab) Holt, AR, 921(ab) Hurwitz, GA, 947(ab) 885(ab), 911(ab) Josephson. MA, 817(ab), Hetherington, EL. 762(ab) Holt, JA, 853(ab), 979(ab) Hutchins, GD, 774(ab), Iwanaga, S, 950(ab) 944(ab) Hibbein, J. 948(ab) Holt, S, 975(ab), 983(ab) 783(ab), 807(ab), 904(ab), Iwasaki. T, 451 Joshi, SS, 979(ab) Hichwa, RD, 784(ab), Holte, S, 877(ab), 984(ab) 938(ab) Iwata, K, 1990 Jouve, B, 841(ab), 842(ab) 808(ab) Homra, L, 1347 Huyghens. L. 806(ab) lyo. M, 809(ab) Jovkar, S, 821(ab) Hickernell, TS. 1101 Honda, N, 745(ab), 879(ab) Huysmans. D, 1360 Izard, ME, 815(ab) Joyce, JM, 587(ab), 980(ab) Hickingbotham. NB, 608 Honda, T, 873(ab) Huysmans, D, 860(ab) Jukic, S, 1152 Hicks, KW, 774(ab) Honma. H, 802(ab). 891(ab) Hwang, D-R, 750(ab), Junck, L, 913(ab) Jabir, AM, 829(ab), 986(ab) Higano, S, 915(ab), 9l9(ab) Hood, TW, 854(ab) 776(ab), 807(ab) Jungwiwattanaporn, P. Jackson, JA, 1451 Higashi, S, 844(ab), 917(ab), Hooker. G, 1910 Hwang, PA, 792(ab) 935(ab) Jacobs, M, 836(ab) 1724 Hooper. HR. 895(ab) Hylarides, MD, 777(ab), Juni, J, 770(ab) 929(ab) Jacobsen, J, 839(ab) Juni, JE, 259, 623, 790(ab), Higazi, E, 814(ab) Hooper. R, 894(ab) Jacobson, AF, 947(ab) Higgins, WL. 266 Hoory. S. 657, 819(ab) 948(ab) Jacobsson, L, 1638 JuniJ, 1272 Higley, B. 934(ab) Hopkins, JM, 903(ab) Iber, F, 974(ab) Jafle.JH, 840(ab), 911(ab) Hildebrand, P, 744(ab) Hopkins, K. 973(ab) Juri, PN, 800(ab) Ichise, M, 914(ab) Jafri. RA, 147, 1878 Jurisson, S, 800(ab) Hilditch, TE, 1096, 1587, HÃ¶r,G, 834(ab) Ichiya, Y, 916(ab) Jagust, WJ, 743(ab), 773(ab), 1746 Horgan. JG, 907(ab), 1656 Ido, T, 931(ab) 916(ab) Hill. RD. 973(ab) Horiuchi, K, 928(ab), Ihara, H, 780(ab) Jahan, S. 814(ab) Kabalka, GW, 777(ab) Hill, TC, 876(ab) 934(ab) li, M, 558, 917(ab) Jain, R, 907(ab), 1656 Kaden, T, 924(ab) Hill, VA, 980(ab) Hornykiewicz, O, 920(ab) lida, H, 783(ab), 867(ab), Jalali, S, 975(ab) Kadmon. D, 750(ab) Hilson, AJW, 779(ab) Horowitz, J, 858(ab), 878(ab), 894(ab), 915(ab), Jambaque, I, 892(ab) Kagaya, A, 838(ab), 941(ab) Hiltunen, J, 873(ab) 874(ab) 919(ab) Jamieson, DG, 836(ab), Kahan. A, 828(ab) Himelman, R, 942(ab) Horowitz, JA, 761(ab), linuma. T, 838(ab), 866(ab). 852(ab) Kahn, D, 795(ab) Himi, T, 838(ab), 941(ab) 846(ab), 898(ab) 941(ab) Jan, K-M, 1710 Kahn. E, 861(ab) Himmelsbach, M. 923(ab) Horowitz. M. 39 lio, A, 765(ab), 888(ab) Janicek, M, 948(ab) Kahn, JK, 805(ab), 948(ab), Hindie, E. 981(ab), 1118 Horwitz, B, 392 lio. M, 741(ab), 743(ab), Jankel, W, 852(ab) 1605 HiÃ±es,J, 858(ab) Hoschl, R, 701 748(ab), 865(ab), 890(ab), Jansen, DE, 841(ab) Kairemo, KJA, 899(ab) Hinton, PJ, 752(ab), 798(ab) Hosenpud, JD, 842(ab) 917(ab), 921(ab) Janssoll. S, 1638 Kairento, AL, 842(ab) Hiramori, K, 802(ab) Hoshi, H, 1627 Ikeda, H, 883(ab) Jara, BJ, 689 Kaiser. KP, 851(ab), 938(ab) Hirano, Y, 1460 Hosoba, M. 745(ab). Ikeoka, N, 460 Jarkewicz. G, 760(ab) Kaizu. H. 745(ab), 879(ab) Hirata, K, 817(ab) 879(ab), 883(ab) Imai, K, 741(ab), 844(ab). Jass,JR, 899(ab) Kajihara, Y, 1460 Hironaka, FH, 805(ab) Hosoi, S, 235 917(ab), 1724 Jaszczak, R, 871(ab) Kakishita. M. 780(ab) Hirose, Y, 878(ab) Hosteller. D, 897(ab) Imai, S, 1460 Jaszczak, RJ, 786(ab), KÃ¤lble,T, 906(ab) Hirsch, JI. 801(ab). 888(ab) Hottenrott, C, 834(ab) lmai/umi. M, 1264 797(ab), 798(ab), 869(ab), Kaldany, A, 923(ab) Hirth, W, 800(ab) Hotze, A, 813(ab), 829(ab), Imakita, S, 914(ab) 1398 Kalir, A, 767(ab) Hisada, K, 558, 750(ab), 891(ab), 896(ab) Inagaki, Y, 838(ab), 941(ab) Jatlow, A, 825(ab) Kaltovich, F, 789(ab) 812(ab), 827(ab), 844(ab), Houle, S, 884(ab) Inao, G, 917(ab) Jaurrieta, E, 1776 Kamada, T, 949(ab), 1264 857(ab), 895(ab), 917(ab), Houston, FM, 815(ab) Ing, SJ, 799(ab) Jay, M, 903(ab), 904(ab) Kamata, R, 741(ab) 1724 Hovda, DA, 772(ab) Inglese, E, 804(ab) Jazmati, B, 947(ab) Kambara, H, 801(ab), Hitchens. RE. 879(ab) Hoving,J, 1302 Inoue, G, 1130 Jeandot, R, 9l4(ab), 1515 827(ab), 828(ab), 1181 Hnatowich, DJ, 762(ab), Howell, RW, 375 Inoue, O, 809(ab) Jeffers, LJ, 712 Kamei, T, 780(ab) 846(ab), 889(ab), 1428 Howman-Giles, R, 133 Inoue, S, 877(ab) Jeghers, O, 2020 Kaminski, MS, 904(ab) Hoefnagel, CA, 791(ab), Howse, D, 874(ab), 1961 Inoue, Y, 883(ab) Jennings, CA, 473 Kanclerz, A, 1252 798(ab) Hu, HB, 748(ab), 749(ab), Intenzo, C, 985(ab) Jerushalmi, J, 881(ab), 1341 Kander, N, 770(ab) Hoekstra. A, 1259 786(ab), 870(ab) Interrante, VL, 786(ab) Jewell, WR, 853(ab), 979(ab) Kang, H, 816(ab) Hoell, K, 759(ab) Huang, SC, 241, 782(ab), Inugami, A, 915(ab), Jewett, DM, 754(ab), Kanke, M, 954(ab) HofTer, PB, 863(ab), 893(ab) 809(ab), 818(ab), 828(ab), 919(ab), 920(ab) 755(ab), 768(ab), 808(ab), Kanno, I, 783(ab), 867(ab), Hoffman, EJ, 241,832(ab), 832(ab), 837(ab), 862(ab), losilevsky. G, 187, 879(ab), 931(ab), 932(ab) 878(ab), 894(ab). 915(ab), 837(ab), 950(ab). 983(ab) 865(ab), 866(ab), 940(ab), 881(ab) Jhingran, S, 816(ab) 919(ab), 920(ab)

Author Index â€¢1988 2037 Kanwar

Kanwar. N. 871(ab) Kelly. KA. 856(ab) Klein. HA. 1848 760(ab), 797(ab). 861(ab) 9l6(ab). 935(ab), 980(ab). Kaplan. E. 886(ab). 974(ab). Kelly, RF. 901(ab). 979(ab) Klein, JL. 810(ab) Korkotsidis. A. 881(ab) 1675 977(ab) Kelso. T. 935(ab) KJein, L. 951(ab) Kornguth. ML. 808(ab). Kung. HK, 9l3(ab) Kaplan. EH. 174. 757(ab). Kemerink. G. 885(ab) Klepser. C. 782(ab). 953(ab) 939(ab) Kung. MP. 758(ab), 759(ab) 90l(ab) Kera. M. 1621 Kletter. K, 575, 794(ab). Kosaka. N. 741(ab). 743(ab). Kuni. CC, 974(ab) Kaplan. IL. 974(ab) Kern. KA, 181 816(ab). 850(ab) 748(ab). 865(ab). 917(ab) Kunieda. E, 950(ab) Kaplan, P. 851(ab) Kern. RZ. 792(ab) Klibanov, AL. 1951 Koster, K. 804(ab) Kunimatsu. M, 235 Kaplan. WD. 324. 473. Keshavarzian. A, 886(ab) Kline. SJ. 926(ab) Kosuda. S, 1126 Kuperus.J, 913(ab) 799(ab). 1745 Ketchum. LE. NI. N7, Kling. P. 754(ab) Kothari. P. 9l2(ab) Kupfer, S, 862(ab) Kapoor. R. 773(ab). 920(ab) N137. 577 Klinger. M. 898(ab) Kotler. J, 897(ab) Kurai. O. 460 Kapp. M. 817(ab) Ketring. AR. 903(ab) Klippenstein. DL. 1549 Kotler, T, 949(ab). 951(ab) Kuroki. T, 460. 2021 Kar. S. 783(ab) Kewan, Y. 838(ab) Kloppenborg. P. 1360 Kotoura. Y. 235 Kuschnir, E, 942(ab). Karatzas. ND. 1675 Keyes. JW. Jr. 769(ab) Kloppenborg. P. 860(ab) Kottou. S. 827(ab), 942(ab) 950(ab) Karcher. G. 793(ab). 952(ab) Keyeux. A. 311. 1826 Kluin. KJ. 913(ab) Kouris, K, 868(ab). 982(ab) Kushner, B. 846(ab) Karczewski. DA. 800(ab) Khafagi. FA. 593 Knapik. G. 747(ab) Koutoulidis. K. 1910 Kushner, M, 747(ab). Karcsh. SM. 927(ab) Khan. A. 974(ab) Knapp. FF. 84 Hab). 842(ab). Kowalsky. WP. 921(ab) 910(ab), 915(ab) Kariya. K. 890(ab) Khare. SS. 903(ab) 891(ab) Kozuka. T. 949(ab). 1264 Kushner. MJ. 852(ab) Kanyone. S. 954(ab) Khaw. B-A. 651 Knapp. FF, Jr, 777(ab). Kradin, RL, 902(ab) Kusic. Z. 753(ab) Karlsson. U. 847(ab) Khaw. BA. 746(ab), 825(ab). 829(ab). 835(ab). 843(ab). KrÃ¤hwinkel,W, 1582 Kusubov, N, 784(ab) Karonen. S-L. 899(ab). 1194 830(ab). 851(ab). 887(ab). 848(ab). 927(ab). 928(ab). Krajewski. A. 9l4(ab) Kuten, A, 1341 Karreman. AJP. 1934 905(ab). 939(ab) 1697 Kramer. E. 785(ab) Kuwabara, H, 866(ab). Karsch. KR. 952(ab) Khawli. LA, 923(ab) Knapp. WH. 208. 817(ab). Kramer. EL. 829(ab), 1607 915(ab) Kasabali. B. 756(ab). 823(ab) Kiat. H. 768(ab). 770(ab). 940(ab) Kramer. M. 857(ab) Kuwabara. Y. 916(ab) Kasal. B. 1152 793(ab). 861(ab). 942(ab). Knaus. EE. 1252 Krasnow, AZ. 1761 Kuzume. O, 781(ab). KÃ¤se.KR. 846(ab), 1428 948(ab). 949(ab). 951(ab) Knesaurek. K. 749(ab). Krause. Th. 949(ab) 782(ab) Kashab. M. 911(ab) Kijewski. MF. 1704 868(ab) Krawczynska. E. 941(ab) Kwai, AH, 324 Kasi. LP. 787(ab). 888(ab). Kikuchi. H. 843(ab) Knesewitsch. P. 856(ab). Krawczynska. EG. 950(ab) Kwiatkowski, M. 847(ab) 1921 Kilbourn. MR. 112(ab). 949(ab) Kremer Hovinga. TK. Kwong. KK. 773(ab), Kasina. S. 800(ab). 815(ab) 754(ab). 755(ab). 767(ab). Knezevic. S. 773(ab) 908(ab) 836(ab), 920(ab) Kasliwal. R. 759(ab). 777(ab) 768(ab). 931(ab). 932(ab) Knight. LC. 494. 745(ab). Krepshaw, JD, 98 Kasper. W. 949(ab) Kim. BH. 949(ab) 746(ab) Kriegel. H. 900(ab) Labar, D, 1633 Kassis. AI. 923(ab). 948(ab) Kim. CK.. 1878 Knittel. BL. 916(ab) Krishnamurthy. GT. 623. La Canna. G. 946(ab) Kataoka. M. 765(ab). Kim. CK. 764(ab). 862(ab) Knop. J. 882(ab) 825(ab). 1144 Lack. E. 181 829(ab). 888(ab) Kim. EE. 731.8541 ab). Knopp. R. 813(ab). 829(ab) Krishnamurthy, S, 825(ab). Lacy, JL. 293. 976(ab). 1526 Katz. BP. 788(ab) 894(ab) Knust. EJ. 94(Xab) 1144 Ladwig. EJ, 982(ab) Kim. HJ. 889(ab) Kobayashi. H. 802(ab) Katz. PC, 1781 Krishnan. L. 853(ab). Laffin, SM, 473 Kim. S. 985(ab) 979(ab) Katzenellenbogen. JA. Kobayashi. K. 460 Laflamme. L, 781(ab). Kobayashi. T. 1738 Krivokapich. J. 782(ab). 768(ab). 795(ab) Kimball. DA. 1169 793(ab). 804(ab) Kaufman. L. 943(ab) Kimmig. B. 751(ab) Kobayashi. H. 1066 8l8(ab). 837(ab). 867(ab), LaFrance, N, 784(ab) Kaufman. PN. 857(ab) Kimsey. P. 793(ab) Kodama. Y. 985(ab) 940(ab). 950(ab) LaFrance, ND. 110. 742(ab). Kavula. M, 939(ab) Kimura. K. 949(ab). 1264 Koeppe. RA. 774(ab). Krohn. K. 757(ab). 807(ab) 745(ab), 779(ab), 789(ab), Kawabata. S. 75(Xab). Kimura. Y. 765(ab) 784(ab). 808(ab). 913(ab). Krohn. KA. 773(ab). 873(ab), 9l6(ab), 1057, 827(ab). 857(ab). 895(ab) King, JL, 946(ab) 915(ab). 932(ab) 783(ab). 835(ab). 920(ab). 1927 Kawai. C. 801(ab). 827(ab). King. M. 684. 868(ab). Koh. C-S. 745(ab) 933(ab) Lagunas-Solar. MC, 842(ab) 828(ab). 1181 983(ab) Kohlen. S. 842(ab) Kroiss. A. 423 Lahiri. A. 62, 805(ab) Kawai. K. 778(ab) King. MA. 717. 748(ab), Koide. H, 1181 Kronauge. JF. 55. 820(ab) Lai, KH. 826(ab) Kawai. R. 796(ab) 749(ab). 863(ab). 864(ab). Koizumi. K. 750(ab) Kroop. S. 898(ab) Lai, YL, 905(ab), 980(ab) Kawakatsu. S. 1621 870(ab). 1980 Koizumi. M. 235. 766(ab). Kropp. J. 936(ab) Lake. RR. 869(ab). 1200 Kawakobo. K. 741(ab) King. T. 765(ab) 837(ab). 889(ab). 890(ab). Kubasic. H, 8l4(ab) Lambert. B, 914(ab) Kawamura. M. 765(ab). Kinney. B. 894(ab) 1130. 1436 Kubier, W. 776(ab), 817(ab) Lamben. R. 792(ab) 829(ab) Kinoshita. F. 982(ab). Koizumi. T. 883(ab) Kubo. A, 762(ab). 950(ab). Lambrecht. RM. N1758 Kawamura. Y. 766(ab). 986(ab) Kojima. S. 516 1126 Lamki. LM. 731,787(ab). 837(ab). 889(ab). 890(ab). Kinoshita. K. 1627 Kolkmeier. J. 842(ab) Kubo. S. 826(ab). 844(ab). 833(ab), 834(ab). 854(ab). 1436 Kinsey. BM. 923(ab) Koller. DW. 1057 886(ab). 918(ab) 886(ab). 888(ab). 894(ab). Kawamuru. M. 888(ab) Kinuya. S. 750(ab), 812(ab). Kolodny. GM. 879(ab). Kubo. Y. 900(ab) 1921 Kawanaka. M. 906(ab) 827(ab). 857(ab). 895(ab) 881(ab) Kubota. K. 843(ab), 1697 Lamki, N. 579 Kawashirna. Akira. 1279 Kipper. SL. 794(ab) Kolodny. GM. 187 Kuczynski. BL. 800

2038 The Journal of Nuclear Medicine McArthur

Lappe, F. 875(ab) 781(ab), 793(ab), 804(ab), Loisel, ML, 792(ab) 900(ab) Martin, GV, 783(ab) Laragh, J, 908(ab) 844(ab) Lollo, C, 893(ab) Magata, Y, 928(ab) Martin, LJ, 976(ab) LaRaia, P, 805(ab) Lever, J, 796(ab), 921(ab) Lomangino, L, 921(ab) MÃ¤her,R, 849(ab) Martin, NL, 763(ab), Laroche, B, 906(ab) Lever, SZ, 73, 789(ab), 1465 Lomas, F, 729 Maheu, LJ, 788(ab), 814(ab), 853(ab), 971(ab), 979(ab), Larson, SM, 39, 181,385, Levin, HS, 913(ab) LomeÃ±a,F, 1916 934(ab) 982(ab), 983(ab), 986(ab) 758(ab), 796(ab), 833(ab), Levine, AS, 75l(ab) London, ED, 840(ab), Mahmarian, JJ, 755(ab) Martin, SE, 938(ab), 945(ab) 852(ab), 897(ab), 901(ab), Levy, AV, 774(ab) 911(ab) Mahmood, A, 789(ab) Martin-Comin, J, 1776 939(ab), 1022 Levy, DE, 839(ab) Long, SE, 766(ab), 982(ab) Mahmoud, A, 814(ab) Martindale, AA, 762(ab) Larsson, K, 905(ab) Levy, LM, 974(ab) Longino, MA, 503 Mahmoud, AR, 985(ab) Marty, J, 940(ab) Laschinger, JC, 1223 Levy, R, 757(ab) Longmore, D, 891(ab) Mahmoud, S, 97l(ab) Martynov, AV, 1951 Laska. E, 774(ab) Lew, A, 768(ab) Longo, D, 833(ab) Maire, JP, 914(ab) Marzilli, L, 936(ab) Lassen, N, 869(ab), 919(ab) Lewellen, BL. 879(ab) Loo, C-Y, 1406 Maisey, MN, 33, 952(ab), Mash, D, 777(ab) Lassen, NA, 916(ab), 1464 Lewellen, TK, 717, 866(ab), Loos, U, 891(ab) 1747 Mashiter, G, 1354 Lastoria, S, 897(ab) 867(ab), 871(ab), 876(ab) Lora, ME, 758(ab) Majd, M, 778(ab) Massardo, T, 745(ab) Laterre, C, 311 Lewis, CA, 779(ab) Lorenz, M, 834(ab) Maki, A, 1130 Masterson, ME, 803(ab) Latham, IA, 789(ab) Lewis, a, 943(ab) Lorenz, WJ, 776(ab) Makino, N, 919(ab), 985(ab) Masuda, K, 916(ab) Lathrop, KA, 803(ab) Li, JP, 832(ab), 984(ab) Losse, B, 851(ab) Makler, T, 805(ab) Masuda, Y, 838(ab), Lattimer, JC, 903(ab) Li.Q-S, 1539 Lotter, MO, 538 Maksuda, J, 787(ab) 866(ab), 941(ab) Laube, BL. 1057 Li, QS, 819(ab), 938(ab) Lotze, MT, 758(ab), 897(ab), Makuch, J, 747(ab) Masuoka, LS, 1083 Laughlin, JS, 904(ab) Li, S, 676, 760(ab) 901(ab) Malamitsi, J, 1910 Matarrese, M, 801(ab), Laurin, NR, 947(ab) Liang, Z, 871(ab) LÃ¶we,S, 835(ab) Malawer, M, 181 934(ab) Lauterbach, K, 742(ab) Liberman, H, 91 LÃ¶wenhielm,P, 1719 Malessa, S, 920(ab) Mather, SJ, 599, 899(ab) Lauterbach, KW. 832(ab) Libson, KF, 776(ab) Lowenstein, E, 947(ab) Malki, AA, 814(ab) Mathes, SJ, 787(ab) Laven,D, 896(ab) Lieh, L, 747(ab) Lucignani, G, 862(ab) Malko, JA, 1466, 1901 Mathias, CJ, 747(ab), Laven, DL, 981(ab) Lichtenberg, GS, 973(ab) Luck, D, 921(ab) Mallette, S, 812(ab) 750(ab), 768(ab), 795(ab), Lavender, JP, 940(ab) Lieberman, DA, 623 Luettgen, J, 788(ab) Maloney, PJ, 901(ab) 8l4(ab), 835(ab), 848(ab), Laxer, KD, 913(ab) Lieben, M, 900(ab), 1304 Luger, RC, 972(ab) Maltais, F, 769(ab) 929(ab) Layer, K, 208 Liewendahl, K, 899(ab), Lui, D, 912(ab) Maltese, A, 853(ab) Mathieu, E, 793(ab) Lazarus, CR, 33 1194 Lukash, F, 971(ab) Mamiya, T, 745(ab), 879(ab) Mathieu, J-P, 1230 Lazarus, R, 1747 Lim, E, 781(ab) Luke, RG, 1730 Manabe,T, 1436 Mathis. CA, 773(ab), 916(ab) Lazzari, S. 762(ab) Lin, LC, 896(ab) Luna, E, 951(ab) Manciet, G, 1515 Matsuda, H, 558, 844(ab), Le, N-A, 1237 Lin, TH, 929(ab) Lundeen, B, 771(ab), Mandeli, J, 862(ab) 917(ab), 1724 Lear, JL, 907(ab), 1387, Lin, W-C, 868(ab) 816(ab) Mandelkern, M, 83l(ab) Matsuda, T. 801(ab) 1656 LindbÃ¤ck,S, 976(ab) Luthy, P, 1088 Mandelkern. MA, 817(ab) Matsueda, GR, 825(ab), LeBlanc, A, 816(ab) Lindberg, S, 1638 Luxen, A, 937(ab) Mandeli, GA,881(ab), 1015 905(ab) LeBlanc, AD, 1526 Linder. K. 800(ab) Lynch, K, 947(ab) Maneval, DC, 908(ab) Matsumoto, K, 930(ab) Leclerc, JR, 1498 Linder, KE, 800(ab), 935(ab) Lynn, F, 889(ab) Manglos, SH, 869(ab) Matsumoto, S, 791(ab) Lee, HB, 849(ab) Lindgren, J, 1194 Lyon, IW, 980(ab) Mangner, TJ, 783(ab), Matsumoto, T, 895(ab) Lee, HK, 905(ab) Line, BR, 1842 Lyons, E, 742(ab), 943(ab) 784(ab), 932(ab) Matsuoka, D, 1393 Lee, J. 978(ab) Ling, M, 885(ab) Mann, S, 908(ab) Matsushima, H, 934(ab) Lee, JT, 799(ab) Lingen van. A, 1934 MacDonald, AC, 947(ab) Mann, SL, 979(ab) Mattar, AG, 947(ab) Lee, KH. 869(ab) Link, JM, 783(ab) Macey, DJ, 203, 845(ab), Mantil. J, 836(ab) MatterÃ ,J. 804(ab), 954(ab) Lee, MC, 745(ab), 1207 Links, J, 784(ab), 840(ab), 847(ab), 871(ab), 872(ab) Mantovanelli, A, 907(ab) MatterÃ ,JA, 1865 Lee, RE, 757(ab), 761(ab), 852(ab), 853(ab), 911(ab), MacGregor, RR, 767(ab) MÃ ntyla,M, 899(ab), 1194 Mattis, JA, 494, 923(ab) 833(ab), 858(ab), 874(ab), 944(ab) Mach, JP, 811(ab) Mar, BM, 929(ab) Matzku, S, 899(ab) 898(ab) Links, JM, 441,717, Mach, RH, 777(ab), 788(ab), Marani, S, 774(ab) Maublant, J, 793(ab) Lee, W, 781(ab) 796(ab). 820(ab), 832(ab), 935(ab) March, DE, 263 Maublant, JC, 48, 129, Lee, Y-CC, 925(ab) 1057 Machac, J, 787(ab) Marchand, L, 906(ab) 939(ab), 951(ab), 1486 Lefebvre. B, 844(ab) Lipszyc, H, 921(ab) Machida, K, 745(ab), Marciano, D, 1768 Maurer, AH, 494, 745(ab), Le Roch, Ã–L,2008 Lipton, JJ, 941(ab) 879(ab) Marcus, AJ, 850(ab) 746(ab), 844(ab) Lefort, G, 1515 Lisbona, R, 1050 Machulla, H-J, 940(ab) Marcus, CS, N142, N1477 Mausner, LF, 849(ab), Le Guludec, D, 744(ab). Lister-James, J, 55, 923(ab) Maclntyre, WJ, 913(ab), Marcus, M, 771(ab), 953(ab) 924(ab) 808(ab), 841(ab), 842(ab), Little, JR, 913(ab) 946(ab) Marder, S, 839(ab) Mavroudakis, N, 91 l(ab) 872(ab) Litton, J, 984(ab) Mackay, BC, 821(ab), Marder, SM, 82l(ab) Maxey, R, 975(ab), 983(ab) Lehner, B, 751(ab), 776(ab) Litton, JE, 916(ab) 836(ab) MargoulefT, D, 898(ab) Maxon, HR, 766(ab), Lehtinen, S. 913(ab) Liu, B-L, 789(ab) MacKay, DR, 815(ab) Mariani, G, 923(ab) 776(ab) Leichner, PK, 868(ab) Liu, RS, 826(ab), 863(ab), Mackenson, D, 835(ab) Marin-Grez, M, 751(ab) Mayberg, H, 852(ab) Leinbach, RC, 851(ab) 936(ab) Mackey, ST, 794(ab) Markel, DS, 913(ab) Mayberg, HS. 796(ab) Leisure, GP, 880(ab) Livni, E, 68 MacLean, J, 951(ab) Marks, R, 777(ab) Mayne, B, 887(ab) Leitha, T, 794(ab), 850(ab) Llaurado, JG, 799(ab) MacMathuna, P, 466 Markwell, R, 811(ab), Maze, M, 940(ab) Lemaire, F, 764(ab) Lloyd, LK, 255 Maddahi, J, 755(ab), 870(ab) Mazess, RB, 131,882(ab) Leners, N, 1826 Loats, H, 852(ab) 768(ab), 770(ab), 793(ab), Marquez, VE, 837(ab) Maziere, B, 828(ab) Lenkinski, R, 910(ab) Loats, HL, 853(ab) 802(ab), 804(ab), 805(ab), Marrett, S, 866(ab) Mazoyer, B, 743(ab) Lenzi.GL, 1507 Loats, P, 852(ab) 861(ab), 891(ab), 942(ab), Marsden, PK, 877(ab) Mazoyer, BM, 822(ab), Loc'h, C, 828(ab) Leppo, J, 805(ab) 948(ab), 949(ab), 951(ab) Marsh, JD, 820(ab) 863(ab), 869(ab), 9l9(ab) Leppo, JA, 746(ab), 819(ab), Locke, E, 887(ab), 939(ab) Madden, JA, 810(ab) Marsh, JI, 726 Mazziotta, JC, 809(ab), 972(ab) LoefTler,W, 759(ab) Mader, J, 813(ab) Marsh, JL, 813(ab) 821(ab), 831(ab), 839(ab), Lerario, L, 897(ab), 901(ab) Loesse, B, 832(ab) Mader, J. T., 763(ab), Marshall, BJ, ll,790(ab) 853(ab), 983(ab) Lerch, RA, 1088 Loewenstein, DA, 852(ab), 883(ab) Marshall, S, 39 Mazziotta, JM, 866(ab) Lesley, TM, 834

Author IndexÂ» 1988 2039 McCabe

McCabe, R, 833(ab) Merion, RM, 259, 790(ab) 787(ab)Moeller.Modesto, RR, 870(ab),877(ab),844(ab), Narra, V, 891(ab) McCabe, RP, 889(ab) Merlet, P. 744(ab), 841(ab), 839(ab)Moerlein,JR, 922(ab)Mukherjee,918(ab), Naruki, Y, 901(ab) McCall, MJ, 217, 226, 842(ab). 872(ab) 776(ab),835(ab),SM. 932(ab)Mulholland,J, Nash, P, 763(ab) 824(ab), 888(ab), 922(ab) Merli, G, 985(ab) 929(ab)Mogami,848(ab), 754(ab),768(ab),GK, Nason, T. 823(ab) McCallum. RW, 790(ab), Mertens, J, 848(ab) 888(ab)Mohammed,H, 829(ab), (ab).932(ab),808(ab), 931 Natale, R, 8l2(ab) 886(ab) Mertz, H, 789(ab) 838(ab)Mohan,MMJ, 933(ab)Mullani, Natarajan, TK, 852(ab), McCann, B, 823(ab) Merz, R. 793(ab) 803(ab)Mohr,R. 839(ab)Mullani,N, 921(ab) McCarthy, K, 1015 Messa, C, 1507 743(ab)Moi.G, 774(ab),879(ab)MÃ¼ller,NA, Naul, LG, 1451 McCarthy, MS, 742(ab) Metman, E, 885(ab) 217Moins,MK, Nauta, H, 852(ab) McCartney, WH, 643, Metra, M, 946(ab) 939(ab)Moldenhauer,N, 48, 920(ab)MÃ¼ller,C. Navratil, DL, 838(ab) 749(ab), 786(ab), 870(ab) Metter, EJ, 869(ab) 899(ab)MÃ¶llenstiÃ¤dt.G, 1704MÃ¼ller-Schauenburg,SP, Neacy, WP, 858(ab), 1795 McClanahan, T, 938(ab) Metz, J, 839(ab) 900(ab)Momose.S, W,952(ab)Mumper, Neal.C, 971(ab),975(ab), McClellan, C, 759(ab) Meyer, DL, 835(ab) (ab).743(ab),T, 741 983(ab) McCormick, CA, 473 Meyer, E. 422, 866(ab). 865(ab),917(ab)Monks,748(ab), 903(ab)Munck,RJ, Nedelman, M, 651 McCready, VR, 752(ab), 915(ab), 917(ab) 1155Munhoz.O, Nedelman, MA, 746(ab) 877(ab) Meyer, G-J, 853(ab) 1411Monna,R, 805(ab)MuÃ±oz,ACL. Needle, LB. 814(ab) McDonald, A, 916(ab) Meyers. L. 859(ab) 460Monroe,T, 840(ab)MÃ¼nz.L, Neely, H, 766(ab) McElhany, K, 915(ab) Meyers, U. 861(ab) 766(ab)Monroe,L. 761(ab)Murakami,DL, Neils, EW, 1744 McElvany, K.616 Miale, A, Jr, 975(ab) 766(ab)Monteiro.LA, 783(ab),867(ab),M, Nelles, MJ, 651 McEwan, AC, 763(ab), Michaux, JL, 1633 948(ab)Montgomery,K, 906(ab),9l5(ab),894(ab). Nelp, W, 757(ab) 971(ab), 986(ab) Michel, C, 1633, 1826 368Montgomery,DG, 1 919(ab)Muramatsu, Nelp. WB. 834(ab), 835(ab) McEwan, AJ, 549, 895(ab) Michel, Ch, 866(ab), 9l4(ab) 1451Moore, J L, 745(ab),879(ab)Muranaka,M, Nelson, AD. 775(ab). McEwan, AJB, 775(ab), Michigishi, T, 827(ab) (ab)Moore,JG, 574, 751 833(ab), 880(ab) 894(ab) Mietling, SW, 972(ab) 695Moore,MM, 1448Murase,A. Nelson, CW, 952(ab) McFarland, WC, 984(ab) Milanesi, L, 1971 832(ab)Moore,R, 888(ab)Murphy,K, 79l(ab), Nepola,JV, 813(ab) McFarland. WD, 797(ab), Miller, JH. 2001 1714Moore,RH, 940(ab)Murphy,GJP, Neumann, FJ, 817(ab) 832(ab), 984(ab) Miller, MB. 114 1704Moore,SC, 845(ab), 726Murphy,KC, Neumann, G, 798(ab) McGahan, JP, 847(ab) Miller, R. 757(ab) 766(ab),874(ab).WH. 874(ab),982(ab),PH, Neumann, RD, 860(ab), McGrath, PW, 783(ab) Miller, RJ, 932(ab) 1157,1467Mora,982(ab), 1881Murphy,1307, 897(ab) McGuire, A, 971(ab). Miller, SF, 1454 932(ab)Murphy,SN, Neumayr, A, 423 975(ab), 983(ab) Miller, SJ, 788(ab), 814(ab), 1776Moretti,J, 725Murray,WD, Newman, ES, 757(ab) McGuire, AH, 795(ab) 934(ab) 952(ab)Morgan,JL, 793(ab), 834(ab)Murray,JL, 833(ab), Ng, CK, 808(ab), 822(ab), McKeever, PE, 854(ab) Miller, TR, 530, 864(ab) 39Morgan,AC, 852(ab)Murray,K, 939(ab) McKenzie, AT, 927(ab) Milligan. F. 789(ab) 758(ab).788(ab)MorgaÃ±o,RA, 886(ab)Murray,LJ, Nguyen. Q, 908(ab) McKillop, JH, 750(ab), 1587 MillÃ³n,C, 829(ab) 1746Murray,T, Nichols. K, 741(ab), 861(ab) McKnight, R, 858(ab) Mills, BG, 1083 1786Morguet,G, 883(ab)Musa,W, Nickles, RJ. 8IO(ab), McKusick, K, 1268 Mills, SL, 847(ab) 952(ab)Mori,AJ, 868(ab)Muschel,A. 822(ab), 880(ab), 932(ab) McKusick, KA, 769(ab), Milroy, R, 750(ab) 1130Monconi,K, 841(ab)Musset,MJ, Nicol, PD, 939(ab) 1714 Muster, TD, 760(ab) 907(ab)Morimoto.L. 824(ab)Mustonen,D, Nielsen, CM, 903(ab), McLaughlin, AF, 593 Milton, W, 329 269Morin, I, 842(ab)Muswick,J, 904(ab) McLean, JR. 838(ab) Minami. S, 801(ab) 855(ab)Morita,R, 775(ab),833(ab),GJ, Nielsen, V-AH, 248 McLellan, AR, 1746 Mineura, K, 919(ab) 1460Morita,K. 1448. 880(ab)Mut, Niemiro, M, 977(ab) McLellan, CA, 820(ab) Minn, H, 1521 1460Morris,R, 1448, 1768Muzi,F, Nienaber, C, 241. 827(ab), McNamara. D, 743(ab), Minnaar, PC, 538 91Morris,JD, 920(ab)Muzic,M, 773(ab), 867(ab) 860(ab) Mintun, MA, 773(ab), 780(ab)Morris,P, 833(ab)Muzykantov,RF, Jr, Nienaber, CA, 771(ab), McNeil, G, 972(ab) 795(ab) 1268Morrison.TA, 1951Myers, VR, 782(ab), 783(ab), 818(ab), McNeill, GC, 742(ab) Mintz, G, 805(ab) 871(ab)Morrissey,M, 982(ab)Mylavarapu,HJ, 828(ab), 937(ab), 940(ab) 375Myler, VB, McPherson, D, 933(ab) Miraldi, F, 775(ab), 833(ab) 684Mortelmans,GJ, Nierhaus, A, 936(ab) McQuitty, A, 934(ab) Miraldi, FD, 880(ab) 752(ab)Morten,L, 769(ab)Nadel,RK, Niino, M, 791(ab) McTigue M, 226 Mirell, SG, 804(ab), 855(ab) 774(ab)Mortensen,B, Nikkinen, P, 1194 Meares, CF, 217, 226, Mirzadeh, S, 849(ab) 905(ab)Morton,J, 979(ab)Nagahiro,HR. Nikula, T, 873(ab) 824(ab), 888(ab), 922(ab) Mishkin, S, 1050 1200Morton,DL, 784(ab)Nagai,H, Nilas, L, 131,248 Mease, RC, 924(ab) Missala, K, 784(ab) (ab)Moscatelli.KA, 751 1460Nagano.K, 1448, Nimmon, CC, 147, 599, Meekin, GK, 1608 Mitsuka, S, 866(ab) 762(ab)Moseley,G. (ab)Nagata,Y, 801 1031, 1878 Meerdink, DJ, 746(ab), Mitta, A, 950(ab) 897(ab)Moser.R, 920(ab)Nagata,K, Nishikawa, J, 741(ab), 819(ab), 972(ab) Mittal, R, 974(ab) 949(ab)Moses,E. 856(ab), 886(ab)Nahmias,Y, 743(ab), 748(ab), 865(ab), Mehta, RC, 414 Miura, S, 783(ab), 867(ab), 760(ab)Mosimann,WW. 363Nair, C, 890(ab), 917(ab) Meignan, M, 824(ab) 878(ab), 894(ab), 915(ab), 811(ab)Moskowitz,F. 982(ab),985(ab)Najm.M, 838(ab), Nishimura, T, 802(ab), Meijer, S, 778(ab) 919(ab) (ab).974(ab),GW. 971 9l4(ab), 1868 Meinertz, Th, 949(ab) Miyagawa, M, 765(ab), 975(ab)Moss, 952(ab)Nakagawara,YC, Nishio, M, 809(ab) Meinken, GE, 924(ab) 791(ab) 1354Motte,DW, 880(ab)Nakajima,J. Nishishita, S, 1460 Melin, J, 866(ab) Miyagawa, N, 765(ab), 744(ab)Moulton,G, 827(ab)Nakajima,K, Nishiyama, H, 766(ab) Melin, JA, 770(ab), 1826 791(ab) 776(ab)Mountz,JS, 900(ab)Nakajo,S. Nishizawa, S, 843(ab), Melograna, JM, 927(ab) Miyake, H, 820(ab) 743(ab),854(ab),JM, 1066Nakamura,M, 844(ab), 870(ab), 877(ab), Meltzer, RS, 973(ab) Miyake, Y, 916(ab) 918(ab),928(ab),917(ab), 762(ab)Nakamura,K, 918(ab), 922(ab) Mena, I, 159, 913(ab) Miyao, NP, 899(ab) 1644Mourino, 889(ab)Nakano,T, Nitsch, J, 842(ab) Meneguetti, JC, 805(ab) Miyaoka, RS, 871(ab) 785(ab)Mousa,M, 1738Nakano,S. 1627, Nizze, A, 1200 Mensch, J, 824(ab) Miyazaki, A, 783(ab) 934(ab),942(ab)Moyes,S, 814(ab), 1130Nakashima,Y, 801(ab), NoÃ«l,P, 893(ab) Merchant, B, 833(ab), 1688 Mlcoch, A, 977(ab) 766(ab)Nakatsuka,T, 235, Noever, T, 91 Merchant, EB, 812(ab), Mobarak, AL, 985(ab) 798(ab)Mueller,JS, 922(ab)Nally,I, Noland, L, 816(ab) 893(ab) Mochizuki,T, 791(ab) 854(ab)Mueller-Brand,SP, 849(ab)Nally,JV, NolibÃ©,D, 847(ab) Merchant, SL. 972(ab) Mock, BH, 23, 729, 840(ab). 894(ab)Mukai, J, 576Narcisse,JV Jr, Nonaka, M, 921(ab) Merhige, ME, 951(ab) 1246, 1651 1126Mukai.M, l(ab)Narra,G, 91 Nordahl, T, 796(ab) Merino, MJ, 860(ab) Modell, H, 830(ab) T, 817(ab), 827(ab),843(ab), RK. 800(ab) Nergaard, H, 248

2040 The Journal of Nuclear Medicine Rackover

Norman,780(ab)Norman,JEdeB, 885(ab)Okerlund, 875(ab)Palmer,DF, Penney, JB, 774(ab) 820(ab) 1057Norris,PS, 795(ab),913(ab)Oldendorf,MD, 776(ab),976(ab),DW, Penninckx, F, 752(ab) Pizer, SM, 786(ab) 914(ab)Northover,JW, 1761Palmer,1302, Pepino, P, 757(ab) Pizo, P, 852(ab) 899(ab)Norton,JMA, 855(ab)OldmanWH, 769(ab)Palmer,EL, Perani, D, 1507 PJ Maloney, 758(ab) 181,860(ab)Nosco,JA, 39Olea, RK, 773(ab)Palombo,MR, Perentesis, P, 39, 833(ab), Plamchon, B, 806(ab) 908(ab)Noska,DL, 801(ab), 816(ab),846(ab)Olewole,E, 771(ab), 907(ab)Pan,C, 1022 Plankey, MW, 790(ab), 835(ab)Nossiff,MA, 759(ab),777(ab)Pannek,S, 758(ab), Perentesis, PJ, 897(ab), 886(ab) 746(ab),825(ab),ND, 757(ab)Olofsson,S, 901(ab) Poans, AMJ, 524 905(ab)Notardonato,887(ab), 779(ab)Omar,S, 902(ab)Panzer,HW, Perez Baiino, N, 942(ab), Pochaczevsky, R, 975(ab) 794(ab),921 H, 985(ab)O'Meara,YT, 208Paoni,M, 950(ab) Pedenphant, J, 248 (ab)Notivol, (ab)O'Neil,JR, 781 1842Papageorgiou,RA, Perkins, AC, 761(ab) Podoloff, DA, 854(ab), 573Noto,R, 948(ab)O'Neill,W, 1088Papakostas,I, Perlman, SB, 414, 822(ab), 888(ab), 894(ab) 883(ab)Notohamiprodjo,RB, 770(ab)Ongseng,WW, 1910Papapoulos,P, 980(ab) Podreka, I, 920(ab) 940(ab)Novales-Diaz,G, 1150Ono, F, 707, 884(ab)Paplanus,SE, Perlmutter, JS, 773(ab), Poggenburg, K, 1688 1050Nowak, JA, 783(ab)OnoY, 742(ab)Pappas,SH, 795(ab) Pohl, J, 778(ab) 91,756(ab)Nowotnik,D, 1460Onoyama,S, 1448, 1675Paras,D, Perlmutter, NS, 953(ab) Pohl, P, 1382 934(ab)Noz,DP, 883(ab)Oomura,Y, 753(ab)Paris,P, N 145, Perry, JR, 643, 748(ab), Pohost, G, 942(ab) 785(ab)Ntalles,M, 883(ab)Oosterwijk,M, 833(ab)Park,E, 749(ab), 786(ab), 870(ab) Poliner, RB, 1750,2022 (ab)Nuechterlein,K, 881 1078Oppel, E, 972(ab)Park,BJ, Perry, SE, 933(ab) Pollycove, M, N1477 826(ab)Nunn, P, 902(ab)Oppenheim,F, 985(ab)Park,C, Persson, A, 931(ab) Polonsky, K. 977(ab) 935(ab)NÃ¼rnberger,AD, 800(ab), 98O'Rear. BE, 799(ab).1038Park.CH, 263, Pert, C, 796(ab) Pomper, MG, 768(ab) 816(ab)Nusynowitz,N, 869(ab)Orenstein,J, Peters, AM, 791(ab), 940(ab) Pons, F, 1916 1114Nutt, ML, 1848Origitano,SR, 23Park,H-M, Petiet, A, 981(ab), 1118 Ponto, JA, 1169 832(ab)Nuttall,R, 927(ab)Ortman-Nabi,TC, 1651Parker,HM, Petretta, M, 1786 Port, R, 776(ab) 485Gates,PM, 812(ab),978(ab)Osaka,J, 947(ab)Parkey,JA, Petronis, J, 2018 Port, S, 745(ab) 890(ab)Parkin,RW, Petry, N, 859(ab) Porter, AT, 775(ab) 908(ab)Oshima,G, 747Parks,A, 1 Petry, NA, 743(ab), 812(ab), Poston, JW, 875(ab) 1122,1607,E, 118, 780(ab), 985(ab)Oster,M, 919(ab), 1347Parmentier,PF, Jr, 928(ab) Potvin, WJ, 576 1871Gates, 886(ab),1154,ZH, 843(ab), 1790Partain, C, Pettavel, J, 811(ab) Pouleur, H, 1826 1Gates,J, 9 1697Ostertag, 763(ab)Pascal,CL, 135, Pettigrew, RI, 825(ab) Pourcelot, I, 893(ab) JA, 1901 H, 208 O, 872(ab) Peycelon, P, 951(ab), Pourcelot, L, 911(ab), 2008 Oba,917(ab),1724Obata,H, 844(ab), 802(ab),891(ab),948(ab)Oswald,Ostrzega, E, Pascal,852(ab)Passafiume,S, 952(ab), 1486 Powe, J, 910(ab) 507Patel, D, 1 Pezzullo, JC, 695 Powe, JE, 947(ab) 919(ab)Obrador,Y, 764(ab),780(ab)SG, 816(ab)Patel,B, PfafT,A, 893(ab), 895(ab), Powers, J, 825(ab) 1893O'Byrne,D, 783(ab)Ochi,GT, BR, 979(ab) 925(ab) Powers, TA, 763(ab), Oswald,1856O'Toole,WM, Patel,985(ab)Patel,J, Pham, D, 791(ab) 973(ab) H, 460, 883(ab), 2021 JJ, 747(ab) MM, 977(ab) Phaneuf, DC, 781(ab), Powers, WJ, 83l(ab), Ochs, R, 920(ab) O'Connell,(ab),982(ab)JW, 941 Otsuka, M, 916(ab) Patel, SR, 769(ab) 793(ab), 804(ab) 874(ab), 1961 Otsuka,1460Otsuka,N, 1448, Patlak,759(ab)Patt,CS, Phelps, ME, 771(ab), Prato, FS, 880(ab), 1683 O'Connell, RA, 921(ab) 5,901 (ab) NL, 768(ab), 945(ab) 772(ab), 782(ab), 808(ab), Pratt, B, 752(ab) O'Connell, W, 840(ab) Otsuki, H, 939(ab) Patt, YZ, 833(ab), 834(ab), 809(ab), 818(ab), 821(ab), Preiss, S, 873(ab) O'Connell, WJ, 302 Ott, RJ, 752(ab), 877(ab) 886(ab) 827, 831(ab), 832(ab), Prenant, C, 808(ab), 822(ab) O'Conner,765(ab),980(ab)W, Ott, SM, 1853 Patterson,;, 132 837(ab), 839(ab), 853(ab), Preslar, J, 771(ab) Otto,932(ab),933(ab)CA, 768(ab), Patterson,91Patterson,R, 862(ab), 865(ab), 866(ab), Press, O, 757(ab) Press, OW, 835(ab) O'Connor, MJ, 830(ab) O'Tuama, L. 784(ab) RE, 756(ab), 867(ab), 937(ab), 941(ab), O'Connor,1747,t MK, 466, 938(ab), 945(ab), 1901 942(ab), 950(ab), 983(ab) Preston, DF, 763(ab), Outwater,1871Overall,E, 1122, 853(ab), 942(ab), 971(ab), Q

Author Index Â«1988 2041 Rademacher

Rademacher. P. 764(ab) 951(ab) Rosen. ST, 174. 757(ab), Saenger. EL, 753(ab) Sazaki, S, 883(ab) Raff. U, 907(ab), 1656 Reynolds, JC. 39, 751(ab). 901(ab) Saffitz, JE, 1223 Scartato, G, 1507 Raffel. DM, 808(ab). 758(ab). 833(ab), 897(ab), Rosenbaum. EM. 473 Saga. T, 766(ab). 837(ab), Schabe!. SI, 571 822(ab), 939(ab) 901(ab), 1022 Rosenberg. SA, 181 889(ab). 890(ab), 1436 Schaerf, F. 742(ab) Ragazzini, A, 907(ab) Rezai, K, 348, 771(ab), Rosenbloom, M, 1223 Sagoh,C. 801(ab) Schaible, T, 806(ab) Rahier, J. 1826 779(ab). 953(ab). 1876 Rosenblum. M. 834(ab) Saha, GB. 913(ab) Schaible, TF. 746(ab) Raichle. ME, 747(ab). Rhine. JK, 779(ab) Rosen-Levin, E, 795(ab), Sahweil. A. 814(ab). 985(ab) Schauwecker. DS, 23, 773(ab), 831(ab) Ricard, S, 919(ab) 883(ab) Sahweil, AM, 750(ab) 788(ab), 813(ab). 1246, Raiszadeh, M, 799(ab) Rice, DE, 927(ab) Rosenspire, KC, 783(ab). Saiga. A. 922(ab) 1651 Ramanna, L, 753(ab), Rice, K, 796(ab) 784(ab), 807(ab), 938(ab) Saito. S, 741(ab) Schechtmann, NM, 302 854(ab) Richalet. JP, 841(ab), Rosenthal. MS. 865(ab), Saito, T, 825(ab), 843(ab), Scheffel, U, 73, 789(ab), Ramirez, JAF, 805(ab) 842(ab) 1848 851(ab), 905(ab) 809(ab), 1465, 2019 Ramos, M, 1776 Richard, MD, 788(ab), 1817 Rosenthall. L. 1498 Saji, H, 778(ab). 801(ab), Scheiber. C, 837(ab) Ramos-Gabatin, A. 885(ab) Richelle. F. 770(ab) Roskopf. M, 509. 1577 8l7(ab), 826(ab). 827(ab). Scheinman. ED. 941(ab) Rancure!. G, 919(ab) Richman, P. 899(ab) Ross. C, 809(ab), 820(ab) 828(ab), 843(ab), 844(ab). Scheinman. M, 744(ab) Ranganath, MV, 774(ab) Richter. JE. 857(ab) Ross. FK, 923(ab) 877(ab), 886(ab), 918(ab). Scheinman. MM, 941(ab) Rango. M, 830(ab) Richter. P, 818(ab). 946(ab) Rossen. J, 953(ab) 922(ab), 928(ab), 1181 ScheibeÂ«,H, 241 Rao, DV, 375 Riddell, R. 975(ab) Rossing. N, 904(ab). 905(ab) Sakahara, H, 235. 758(ab). Scheiben. HR. 77l(ab), Rao, SA. 776(ab), 1302. Riege. WH. 853(ab) Rossler, H, 1382 889(ab), 890(ab), 897(ab), 782(ab). 783(ab). 808(ab). 1761 Riesen, A. 924(ab) Rosso. J, 824(ab) 901(ab), 1436 818(ab). 827(ab), 828(ab). Rao, TN, 800(ab), 815(ab) Riggs, B. 855(ab) Rota, E, 877(ab) Sakai. K, 918(ab) 837(ab). 867(ab), 937(ab), Rapoport, SI, 392, 867(ab) Rigo, P, 134, 747(ab). Roth. JC. 1462 Sakata. H, 1066 940(ab). 941(ab). 942(ab), Rasciti. L, 762(ab) 758(ab) Roth, SC, 898(ab) Sakharov, IY, 1951 950(ab) Rasey, J, 807(ab) Rimanic. AL, 979(ab) Rothley.JM, 807(ab). Sakuma. S, 919(ab). 985(ab) Schicha, H, 426 Rashid. F. 975(ab) Rimkus. DS, 765(ab) 915(ab) Sakurai, T. 801(ab) SchiÃ©pers.CWJ. 869(ab) Raskob. G, 824(ab) Rippin, R. 110 Rotman, M, 833(ab) Salama. A, 809(ab) Schiff. ER, 712 Rasmussen. JW, 479 Ritchie, JL, 1393 Rotmensch, J, 858(ab) Salgado, A, 913(ab) Schiller, NB, 943(ab) Ratib, O, 771(ab), 782(ab), Ritter, W, 924(ab) Rottenberg. DA. 839(ab) Salimi, Z, 779(ab) Schittek. M, 832(ab) 818(ab). 827(ab). 837(ab), Ritter-Hrncirik. CA, 1212 Roubin. G. 939(ab) Salvatore, M, 1786 Schlag, P. 751(ab), 776(ab) 867(ab). 937(ab) Riva. P. 762(ab) Rowe. B, 822(ab) Samejima. N. 900(ab) Schlom. J, 1022 Rauws. EAJ. 790(ab) Robbins. MS, 801(ab). Rowe, BR, 980(ab) Sampathkumaran. KS. Schlumberger, M, 1790 Ravert, H. 784(ab). 820(ab). 906(ab), 908(ab) Rowe, RK, 760(ab) 864(ab) Schlyer. DJ, 767(ab) 853(ab). 921(ab) Robbins. W, 909(ab). Rowe, RW, 774(ab). 951(ab) Sampson. C, 33, 1747 Schmelter. RF, 111206 Ravert, HT, 796(ab). 852(ab) 951(ab) Rowell. KL, 255 Samson, DS. 911(ab) Schmid. A. 877(ab) Ravich, W, 789(ab) Robbins, WL. 793(ab). 1479 Rowlinson, G, 762(ab) Samson. Y. 822(ab), 919(ab) Schmid. P. 900(ab) Raymond, PA, 854(ab) Robert, A, 1826 Roy, A, 1050 Samuels, LD, 779(ab), Schmidbauer, M, 920(ab) Raynaud, C. 743(ab), Robert, G. 906(ab) Roy, L, 793(ab) 971(ab), 976(ab), 978(ab) Schmidlin, P, 751(ab), 792(ab), 842(ab), 869(ab), Robert, J, 663 Royal, HD, 1157 Sanders, L, 1050 776(ab) 872(ab). 919(ab) Roberts. JW, 1451 Rozanski, A, 741(ab), Sanderson. RA. 2001 Schmidt, A, 818(ab). 946(ab) Raynaud. D, 892(ab) Roberts, R, 293. 755(ab). 770(ab) Sandler, CM. 270, 1279 Schmidt, DH, 745(ab) Razzak, SA, 814(ab) 1526 Rubens, RD, 1045. 1354 Sandler. M, 750(ab) Schmidt, E. 827(ab) Reba, RC, 753(ab), 766(ab), Robeson, W, 898(ab) Rubin. RH, 651, 830(ab). Sandler, MP, 763(ab), 1347, Schmidt. K. 862(ab) 889(ab), 901(ab). 922(ab), Robilotta, CC, 805(ab) 887(ab) 1454, 1457 Schmidt. KG. 479 927(ab) Robin, B, 819(ab) Rubinstein. M, 893(ab) Sandrock, D. 860(ab) Schmidt. RP. 895(ab) Recht. A, 473 Robinson. K, 939(ab) Ruhlmann, J, 891(ab) Sands. H. 823(ab) Schmidt. WP. 780(ab), Rumancik. W, 974(ab) Reddy, KR. 712 Robinson. PJ, 1747 Sanger. J. 785(ab) 943(ab) Ruotsi. A. 873(ab) Redies. C, 866(ab) Robinson. RG. 763(ab), Sanger. JJ, 829(ab) Schmoliner. R. 794(ab) Rusckowski. M, 762(ab). RedotÃ©,R. 841(ab) 853(ab), 942(ab),971(ab), Sanken, U. 833(ab) Schneider, P. 1748 846(ab). 889(ab) RÃ©Ã©d.BR, 743(ab) 979(ab), 982(ab), 983(ab), Sano. M. 840(ab) Schneider, RF. 800(ab) Rushton, HG. 778(ab) RÃ©Ã©d.NS, 1746 984(ab). 986(ab) Sargent, T, III. 784(ab). Schneider, V, 816(ab) Rusinek, H, 785(ab) Reese, L, 880(ab) Robles, RM, 812(ab) 916(ab) Schnobrich, KE, 924(ab) Ruskin, JN, 769(ab) Rehm, PK, 913(ab), 946(ab) Rocco, T, 769(ab) Sargent, TS, III, 773(ab) Schnur, W, 855(ab) Russell, CD, 255, 908(ab). Rehr. RB, 801(ab) Rocco, TP, 769(ab). 945(ab) Sarkar, S, 908(ab) Schober, O, 426, 853(ab) 1189, 1730, 1931 Rehr. RR, 1283 Rodes. J, 1916 Sarno. RC, 118, 1871 Schoelmerich, J, 827(ab) Russell. JAG. 774(ab) Reichman, OH, 927(ab) Roelants. V, 770(ab) Sarti. G, 762(ab) Schoeps. K-O. 754(ab) RÃ¼ther.M. 813(ab), 829(ab) Reichmann. K, 911(ab), Rogere. LW, 917(ab) Sasaki. H, 783(ab). 802(ab). Scholz, A, 977(ab) Ryan. JW, 803(ab) 936(ab) Rogers. PE. 824(ab), 924(ab) 894(ab). 915(ab), 919(ab) Schorlemmer. HU, 925(ab) Ryman, JC. 859(ab) Reid, RH, 572, 902(ab), Rogers, WL, 195. 760(ab). Sasaki. Y.. 982(ab). 986(ab) Schrader. J. 755(ab) Ryo, UY, 765(ab), 877(ab). 919(ab). 978(ab), 984(ab), 785(ab), 797(ab) Sastry, KSR, 375, 858(ab) Schray. KJ. 873(ab) 882(ab), 903(ab), 904(ab). 985(ab), 1998 Roland. W, 898(ab) Satoh. K. 880(ab) SchrÃ¶der.LE. 776(ab) 905(ab), 980(ab) Reilley, J, 758(ab). 759(ab) Romhilt. DW, 1283 Satoyoshi. E. 921(ab) Schroff. RW, 39, 834(ab) Rzecznik. JA, 900(ab) Reilly. RM, 1303 Romyn. A, 977(ab) Satter. MR. 810(ab). 932(ab) Schteingart. DE, 1644 Reiners, C, 854(ab) Roney. TJ, 760(ab) Satyamurthy. N, 809(ab). Schubert, SF. 867(ab). Reisman, S, 782(ab), 953(ab) Rooholamini, M, 771(ab) Saari. M. 804(ab) 866(ab) 871(ab) Reisner, T, 920(ab) Roos.JP, 85l(ab), 1934 Saccavini. JC, 847(ab) Sauris. E, 780(ab) Schubiger. A, 759(ab), 1088 Reivich. M. 747(ab), Roos, MS, 785(ab) Sacchi, T, 782(ab) Savage, S, 746(ab), 819(ab), Schuemichen. C, 827(ab), 830(ab), 836(ab). 852(ab), Roosjen, HN, 1302 Sachs, S, 971(ab) 972(ab) 949(ab) 910(ab). 915(ab) Ropchan. J, 831(ab) Sacker. DF. 843(ab), 886(ab) Savory, CG, 764(ab), 780(ab) Schwaiger, M, 770(ab), Remley, K, 130 Rosebrough, SF, 1212 SackeÂ«.JF, 822(ab) Sawada, Y. 759(ab) 782(ab). 783(ab), 807(ab), Renkin. J, 770(ab) Roseman, H, 805(ab) Sada, M, 802(ab) Sax. FL, 772(ab) 818(ab). 827(ab). 837(ab). Renooij, W, 1259 Rosen, BR. 836(ab) Sadek. S, 752(ab), 980(ab), Saxton, RE, 1200 938. 950(ab) Reske. SN, 756(ab), 842(ab) Rosen. G, 749(ab), 854(ab) 986(ab) Sayama. I, 915(ab) Schwartskopff. B, 832(ab) Resnick, S. 830(ab) Rosen, JM, 925(ab) Sadzot, B, 796(ab) Sayle, B, 813(ab) Schwartz, AN, 812(ab) Resser, K, 770(ab). 793(ab). Rosen. M. 852(ab) Sadzot, BL, 796(ab). 809(ab) Sayle. BA, 763(ab). 883(ab) Schwartz, JA. 917(ab),

2042 The Journal of Nuclear Medicine Sumiya

918(ab) 898(ab) Simoen. JP, 847(ab) Sournac, M, 129 923(ab) Schwartz, RG, 973(ab) Sharma, HL, 485 Simon, EJ, 933(ab) Sowton, E, 952(ab) St. George Hyslop, P, Schwarz, A, 823(ab), Sharp, JG, 90l(ab).979(ab) Simon, HJ. 756(ab) Soya, T. 780(ab) 853(ab) 834(ab). 875(ab), 925(ab) Shaw, LE, 783(ab) Simon. J, 903(ab) Spaccavento, LJ. 770(ab), Stirner, H, 756(ab) Schweighardt, SA, 812(ab), Shaw, SM, 986(ab) Simon, JD, 1470 838(ab) Stiteler, W, 83 893(ab) Shealy, D, 923(ab) Simonetti, I. 953(ab) Spaulding, M, 898(ab) StÃ¶cklin,G, 754(ab), Schwendner, SW, 503 Shealy, DJ, 494 Simonovic. I, 1152 Spaventi, S, 753(ab) 755(ab), 821(ab), 911(ab) Scofield, AK, 984(ab) Shearer, DR, 695 Simonson. RB, 815(ab) Specht, HD, 909(ab), 1154 Stoddort, HF. 876(ab) Scott, EA, 972(ab) Sheffield. C. 772(ab), 775(ab) Simpson, DE, 1022 Speed, NM. 917(ab), 918(ab) Stokely, EM, 1875 Scab, JP, 743(ab). 773(ab), Sheldon, PE, 943(ab) Simpson, N, 796(ab) Spence, AM, 773(ab), Stomper, P, 799(ab) 916(ab) Shelton. ME, 807(ab), Singer, FR. 1083 920(ab) Stomper, PC, 324 Seabold, JE, 813(ab), 1169 848(ab) Singer, H. 820(ab) Spencer. RP. 1463 Stone, CK, 973(ab) Seacat. RH, III, 760(ab) Shepard, JH, 599 Singhaniyom. W. 759(ab) Sperling. M, 910(ab) Stone, G, 741(ab) Sease, D. 951(ab) Sherman, D, 893(ab) Sinn, H-J, 208 Sperling, MI, 766(ab) Stone-Elander, S, 754(ab), Sebag, C, 744(ab) Sherman, DL, 932(ab) Sinusas, AJ. 819(ab), Sperling, MR, 830(ab) 767(ab). 931(ab) Secchi, V, 885(ab) Sherman, PS, 768(ab), 850(ab), 955(ab) Spicer, JA, 763(ab), 853(ab), Storch-Becker, A, 851(ab) Sedvall, G, 754(ab), 767(ab), 932(ab), 933(ab) Sisson, J, 859(ab) 971(ab), 979(ab), 982(ab). Storey, AE, 789(ab) 931(ab) Shewmon, DA, 831(ab) Sisson, JC. 542, 1605 986(ab) Stowe, NT, 849(ab) See. WA, 978(ab) Shiba, K, 922(ab) Sitzmann, J. 799(ab) Spicer, KM, 955(ab) Stowe. S, 846(ab) Segal, B, 742(ab), 943(ab) Shibata, N, 1738 Skarlos, D, 1910 Spielman, G, 910(ab) Stowens, DW, 892(ab) Segal, BL, 742(ab) Shibata, T, 826(ab), 844(ab). Skarzynski, JJ, 905(ab) Spies, SM, 174, 757(ab), Strand, S-E, 1719 Segall, GM, 953(ab), 1662 886(ab), 918(ab) Skelton, JP. 810(ab) 810(ab), 811(ab), 865(ab), Strane, TR, 981(ab) Seki, H, 844(ab), 895(ab), Shields, WD, 83l(ab) Skinner, RWS, 503 870(ab), 884(ab), 901(ab) Strashun, AM, 561 917(ab), 1724 Shih. WJ, 765(ab), 905(ab), Sklar. J, 267, 1466 Spies. WG, 810(ab), 811(ab), Stratbucker, RA, 901(ab), Seidin, DW, 168, 806(ab). 980(ab) Slade, S, 834(ab) 865(ab), 870(ab), 884(ab) 979(ab) 841(ab), 855(ab), 942(ab), Shiire, Y, 827(ab) Slater, JL, 981(ab) Spinks, TJ. 878(ab), 1833 Stratton, H, 1842 1710, 1748 Shimabukuro, K, 1066 Slater, JM, 799(ab) Spire. JP. 839(ab) StrÃ¤ub,RF, 787(ab) Seihorst. J, 978(ab) Shimonishi, Y, 883(ab) Slauson, M, 825(ab) Sporn. V, 942(ab), 950(ab) Strauss, A, 803(ab), 845(ab) Sell, TL, 1492 Shinohara, M, 1621 Sledge, G, 896(ab) Squicciarini, SA. 1368 Strauss, HW, 68, 651, Senda, M, 801(ab), 817(ab), Shinohara, S, 1066 Siegers, G, 1107 Sramek, JJ, 980(ab) 746(ab), 769(ab), 805(ab), 821(ab), 827(ab), 828(ab), Shinotoh, H, 809(ab) Slevin. ML, 599 Srinivasan. A, 815(ab), 825(ab). 830(ab), 832(ab), 877(ab), 920(ab), 1181 Shiomi, S, 460, 2021 Slinkin, MA, 1951 847(ab) 843(ab), 851(ab), 872(ab), Senekowitsch, R. 900(ab) Shirono, K, 1066 Slusarcick, A, 853(ab) Srivastava, PC, 835(ab), 887(ab), 902(ab), 905(ab), Serafini, A, 1675 Shishido, F, 783(ab), Smart, HL, 791(ab) 929(ab) 935(ab), 939(ab), 945(ab). Serafini, AN, 712, 887(ab), 915(ab), 919(ab), 920(ab) Smergel, EM. 689 Srivastava, SC, 787(ab), 947(ab), 1714 897(ab) Shiue. CY, 767(ab), 933(ab) Smimov, MD, 1951 849(ab), 924(ab) Strauss, J, 909(ab) Servano, P, 742(ab) Shively.JE, 103, 926(ab) Smith, AJ. 882(ab) Stabin. M, 874(ab), 1526, Strauss, L, 784(ab) Servis, K.L, 579, 837(ab) Shochat, D, 898(ab) Smith, AP, 786(ab) 1961 Strauss, LG, 75l(ab), Sessler. MJ, 761(ab) ShonkofT, D, 1901 Smith, GE, 725 Stabin, MG, 803(ab), 776(ab) Seto, H, 780(ab) Shreeve, WW. 787(ab) Smith, GT, 940(ab) 859(ab). 874(ab), 875(ab) Strauss, W, 862(ab) Seto, K, 827(ab) Shreve, P. 1304 Smith. JW. 833(ab) Stacy, TM, 135 Strimbu, LM, 760(ab) Seto, M, 940(ab) Shryock, M, 765(ab) Smith, K.F, 806(ab), 841(ab) Stadalnik, RC, 790(ab), Stringham, L, 903(ab) Sette, G, 822(ab) Shuke. N, 750(ab), 827(ab), Smith, WH, 850(ab), 955(ab) 933(ab), 936(ab) Stritzke, P, 862(ab). 921(ab), Severson, AR, 856(ab). 895(ab) Snook, D, 762(ab), 1910 Stafford-Schuck, KA, 1878 882(ab) Shuler, S, 766(ab) Snyder, D, 758(ab), 890(ab) 743(ab), 854(ab), 918(ab) Strnat. MAP. 889(ab) Sfakianaki, ED, 1287 Shulkin, BL, 542, 892(ab) Snyder, M, 971(ab), 975(ab), Stamos, JA, 760(ab) Strother, SC, 631,839(ab), Sfakianakis. G, 794(ab), Shusterman, N, 817(ab) 983(ab) Stanford. W, 771(ab) 876(ab), 878(ab) 1287 Shutter, B. 780(ab) Soares, J, Jr, 805(ab) Stanisavljevic, S, 887(ab) Stubbs, J, 886(ab) Sfakianakis. GN, 829(ab), Sia, BST, 851(ab) Sobel. BE, 818(ab), 1223, Stanton, MS, 840(ab) Studer, A. 811(ab) 909(ab), 986(ab), 1675 Siccardi, A, 762(ab) 2018 Stapleton, J. 903(ab) Stump. DA. 880(ab) Sgammini, H, 950(ab) Siddon, RL, 473, 1745 Sobnack, R, 899(ab) Stark, C, 771(ab) Stumpf, M, 852(ab) Sgouros, G. 803(ab), Sidney Yu, WK, 986(ab) Sokal. G, 1633 Stark, V, 828(ab) Stunkard, A, 857(ab) 845(ab), 858(ab), 874(ab) Sidtis, JS, 839(ab) Sokoloff, L, 862(ab) Stark, VJ, 803(ab) Stuttle, AWJ, 940(ab) Sgoutas. S, 859(ab) Siebecker. D, 762(ab), Solanki, K, 147, 1031 Starling, MR, 744(ab), 1368 Stutzman, M, 908(ab), 1189, Shafer, RB. 751(ab), 897(ab) 846(ab) Soldano, M, 776(ab) Starren, JB, 530 1931 Shafer, RE, 856(ab), 882(ab) Siebecker, DA, 1428 Sole. MJ, 1697 Stauch, M, 946(ab) Sty.JR,1750 Shaff, MI. 1454 Siegel. J. 846(ab) Solin, O, 767(ab) Staudinger, K, 780(ab) Subramanian,G, 800(ab), Shafique, I, 756(ab) Siegel, JA, 689, 803(ab), Solis. E, 794(ab) Steele, PP, 267, 1466 1212,1577 Shah, A, 884(ab) 844(ab), 858(ab), 862(ab), Solomon, H, 852(ab) Stegen. M, 954(ab) Subramanian, K, 908(ab) Shah, P, 768(ab) 874(ab) Solomon, RW, 764(ab) Stein, S, 772(ab) Subramanian, R, 889(ab) Shah, SA, 823(ab) Siegel, ME, 869(ab) Solot. G, 819(ab), 938(ab) Stein. SD, 772(ab) Sudora, EJ, 893(ab). 895(ab), Shah, VO, 886(ab) Siegel, R, 802(ab) Som, P, 843(ab), 886(ab), Steinberg. H, 657 925(ab) Shanes. J, 771(ab) Sigler, CJ, 769(ab) 1697 Steinberg, KK, 859(ab) Suess, E, 920(ab) Shanken, U, 834(ab), Sila,C, 913(ab) Sonnemaker, R, 766(ab) Steinbrenner. L, 898(ab) Sugai, Y, 1621 886(ab) Silberstein, EB. 776(ab), Sonoda, T, 1066 SteinstrÃ¤ÃŸer,A, 823(ab), Sugarbaker, P, 1022 Shao, L, 760(ab), 785(ab) 855(ab) Soper, NJ, 856(ab) 875(ab), 925(ab) Suggs, JA, 929(ab) Shapiro, B, 542, 859(ab), Silbiger, ML, 876(ab) Sorby, P, 762(ab), 815(ab) Steis, RG, 833(ab) Sugimoto, T, 741(ab) 1644 Silver, BB, 883(ab). 973(ab) Sordillo, PP, 903(ab), Stephens, FO, 593 Suh. JH, 799(ab) Shapiro. BJ. 914(ab) Silverberg, SJ, 855(ab) 904(ab) Steplewski. Z, 847(ab), Sukalac, R, 760(ab) Shapiro. T, 977(ab) Silverstein, EA, 174, 810(ab), Sos, T, 908(ab) 924(ab), 925(ab) Suki, W, 816(ab) Sharkey. CA, 881(ab) 811(ab), 865(ab), 870(ab). Soucy, JP, 743(ab), 843(ab), Stepniak-Biniakiewicz, D, Sullivan, M, 846(ab) Sharkey, RM, 757(ab), 884(ab), 901(ab) 919(ab) 801(ab) Sullivan, P. 729 758(ab), 761(ab), 846(ab), Simchon, S, 1710 Soufer, R, 954(ab) Steves, A, 909(ab) Sumida, R, 821(ab), 832(ab) 858(ab), 874(ab), 890(ab), Simmons, G. 877(ab) Sourkes, TL, 784(ab) Stewart, R, 744(ab), 770(ab), Sumiya, H, 844(ab), 917(ab),

Author Index â€¢1988 2043 Summerfeit

1724Summerfeit, 812(ab),895(ab), Tonami, N. 750(ab), Underwood. R, 891(ab) VanZanten. S, 975(ab) 853(ab)Sun, A, 925(ab)Tateno, 812(ab), 827(ab). 857(ab), Unger. EF, 772(ab), 775(ab) Vaquer. RA. 561 789(ab)Sun,S-Y, 838(ab).866(ab).Y, 809(ab), 895(ab) Unger. M, 329, 896(ab) Varga. D, 846(ab) 925(ab)Sun,TTH, (ab)Tatsch. 941 Toorongian. SA, 931(ab) Unger. MW. 812(ab), Varma. VM, 753(ab) 814

2044 The Journal of Nuclear Medicine Zwas

873(ab),911(ab), 916(ab), Webster. EW. 425 Williams. BA, 941(ab) Woods, SD. 748(ab), 867(ab) Yonekura, Y, 801(ab), 921(ab), 938(ab), 944(ab). Webster, W, 896(ab) Williams, CC, 776(ab) Woodson, M, 872(ab) 817(ab), 826(ab), 827(ab), 1057, 1207, N1329, 1465 Wedebye, IM, 479 Williams, CM, 356, 803(ab). Woolfenden, JM. 878(ab), 828(ab), 843(ab). 844(ab), Wagner, HN Jr, 73, 110 Wedeking, PW, 891(ab) 972(ab), 1668 1101 870(ab), 877(ab), 886(ab), Wagner, JG, 889(ab), Wegst, AV, 763(ab), 853(ab), Williams, H, 936(ab) Woolley, G, 62 918(ab). 922(ab), 1181 900(ab) 971(ab), 979(ab), 986(ab) Williams, JJ, 676, 760(ab) Wooten, WW, 616 Yonezawa. Y, 781(ab). Wagner, Jr, HNâ€ž1539 Wei, Y, 789(ab) Williams, KA, 803(ab), Woroniek, CL, 608 782(ab) WagstafT,J, 485 Weigle, JB, 849(ab) 828(ab) Worsley, K, 920(ab) Yonts, S, 877(ab) Wahl, RL, 812(ab), 889(ab), Weiland, FL, 753(ab), Williams, L, 873(ab) Worsley. KJ, 631 Yoo, HS. 799(ab) 900(ab), 904(ab), 923(ab), 770(ab), 838(ab) Williams, LE. 103. 859(ab), Wortzman, G, 914(ab) Yorke, ED, 1795 1304 Weinberg, I, 782(ab) 875(ab), 926(ab), 1464 Wraight. P, 33, 1747 Yoshida, K, 838(ab), Wahner, H, 855(ab) Weinberg, IN, 832(ab) Williams. S, 747(ab) Wright, GL, 898(ab) 866(ab), 941(ab) Wahner, HW, 881(ab) Weiner, R, 896(ab) Williams. SJ, 747(ab), Wu, CC, 826(ab) Yoshida, S, 781(ab), 782(ab) Wakasugi, S, 1738 Weingarten, M, 810(ab) 788(ab), 814(ab), 934(ab) Wu, F, 329 Yoshii, F, 852(ab) Walker, JV, 1596 Weingerg, IN, 241 Williams, W, 972(ab) Wu, J-L, 122 Yoshikawa, K, 890(ab) Walker, KZ, 815(ab) Weinheimer, CJ, 818(ab) Williams. WH, 947(ab) Wu, JL, 929(ab) Yoshitake, A, 922(ab) Walker, PM, 884(ab) Weir, J, 887(ab) Wilson, A, 784(ab), 820(ab). Wu, LC, 863(ab) Young, AB, 767(ab), Wall, RM, 806(ab), 841(ab), Weise, S, 872(ab), 920(ab) 853(ab). 921(ab) Wyper, DJ, 132 774(ab), 930(ab) 942(ab) Weise, SB, 821(ab) Wilson, AA, 796(ab), Young, J, 832(ab) Waller, DG, 1153 Weiselberg, L, 898(ab) 852(ab) Yabuki. M, 934(ab) Young, KA. 788(ab), 1246 Wallis, JW, 864(ab) Weiss, J, 756(ab) Wilson. B, 900(ab), 1304 Yacoub. T, 752(ab), 980(ab), Young, LS, 651 Walovitch, R, 747(ab) Weiss, R, 771(ab) Wilson, CR, 856(ab) 986(ab) Yu, P, 23 Walovitch, RC, 747(ab), Weiss, W, 423 Wilson, D, 947(ab) Yagi, K, 890(ab) Yuan, J, 810(ab) 758(ab), 788(ab) Welch, MJ, 747(ab), 750(ab), Wilson, E, 898(ab) Yamada, LS. 1200 Yudd. AP. 794(ab) Waiser, M, 1927 754(ab), 768(ab), 776(ab), Wilson, GA, 973(ab) Yamada, N, 802(ab) Yumikura. S. 741(ab) Walsh, MN, 818(ab) 795(ab), 807(ab), 814(ab), Wilson, M, 414 Yamagishi, H, 880(ab) Yutami, C. 802(ab) Walsh, RA, 1368 835(ab), 848(ab), 929(ab). Wilson, MA, 822(ab), Yamaguchi, K, 1621 Walters, GL. 954(ab) 930(ab) 980(ab) Yamamoto. K, 817(ab), Zabel, P, 1683 Wang, SJ, 826(ab), 863(ab), Weller, R, 744(ab), 818(ab), Wilson, MW, 918(ab) 826(ab), 844(ab), 877(ab), Zalutsky, MR, 834(ab), 936(ab) 946(ab) Wilson, R, 953(ab) 886(ab). 918(ab), 922(ab) 835(ab), 897(ab) Wang, TF, 927(ab) Wellman, HN, 23, 840(ab), Wilson, RA, 952(ab), Yamamoto, S, 878(ab) Zamora, PO. 886(ab) Wang, TST, 757(ab), 925(ab) 896(ab), 1246, 1651, 1742 953(ab), 1943 Yamamoto, YL, 422, 631 Zanelli. GD, 62 Wang, X, 195, 542, 797(ab) Wells, TM, 769(ab) Windham, JP, 576 Yamamuro, T, 235, 889(ab) Zangerle, R, 1382 Wang, YL, 936(ab) Wendt, RE, III, 1610 Winge, S, N6 Yamaoka. N, 880(ab) Zanzi, I, 898(ab) Wani, H, 883(ab) Wesolowski, CA, 676 Winkler. K, 882(ab) Yamasaki, T, 809(ab), Zanzonico, PB, 803(ab), Wanjura, D, 744(ab) Wessels, BW, 872(ab), Winniford, M, 953(ab) 838(ab), 941(ab) 845(ab), 858(ab), 874(ab) Warber-Matich, SL, 790(ab) 875(ab), 1795 Winston. MA, 855(ab) Yamashita. K, 801(ab), Zapf-LongoC, 1212 Ware, RW, 753(ab), 885(ab) Wester, D, 800(ab) Wisenberg, G, 1683 817(ab), 827(ab), 828(ab), Zapol, WM. 947(ab) Warmelink, CA, 873(ab) Westermann, J, 728 Witanowski, LS, 1212 1181 Zaret. B, 954(ab) Warnaar, SO, 1078 Wetzel, E, 751(ab) Witherspoon, L, 766(ab) Yamazaki, K, 900(ab) Zaret, BL, 1865 Warner Stevenson, L, Wexler. J, 862(ab) Witte, C, 972(ab) Yanagimoto. S, 1448 Zatorre. RJ, 631 818(ab) Whelchel, JD, 950(ab) Witte, M, 972(ab) Yang, C, 781(ab) Zeeberg, BR, 922(ab), Warren, SD, 835(ab) Whitaker, KB, 1354 Wolber, G, 751(ab) Yang, DJ, 767(ab). 930(ab) 927(ab) Washburn, LC, 578, 925(ab) White, C, 953(ab) Woldring, MG, 524, 1419 Yang, L, 741(ab). 948(ab) Zeller, JA, 766(ab) Watanabe, A, 1460 White, DW, 913(ab) Wolf, AP, 767(ab), 774(ab). Yang, NC, 868(ab) Zhang. CG. 87l(ab). 872(ab) Watanabe, I, 741(ab) White, FW, III, 1817 876(ab), 933(ab) Yano, Y, 942(ab) Zhang, J, 845(ab) Watanabe, K, 1627 White, J, 844(ab) Wolf, BH, 725 Yarchoan, R, 852(ab) Zhang, Z, 937(ab) Watanabe, N, 750(ab), White, JK, 955(ab) Wolf, W, 837(ab). 908(ab) Yardley, J, 789(ab) Zhu, J, 871(ab) 895(ab), 954(ab) White, RD, 943(ab) Wolfe. C, 781(ab) Yasillo, N, 839(ab) Zhu. YY, 781(ab) Watanabe, T, 741(ab), Wichman. A, 852(ab) Wolfson. C. 1498 Yasillo, NJ, 977(ab) Zicot, M, 841(ab) 743(ab), 748(ab), 865(ab), Wickham, JEA, 779(ab) Wolkoff, AW, 928(ab) Yasuda, T, 825(ab), 851(ab), Ziessman, HA, 752(ab), 917(ab) Widen. L, 754(ab) Wolverson, MK, 779(ab) 905(ab), 939(ab) 769(ab). 1364. 1608 Watanabe, Y, 235, 766(ab), Wiebe, U, 1252 Wong. C. 948(ab) Yegelwel, E, 886(ab) Ziffer, J, 909(ab) 837(ab), 889(ab), 890(ab), Wieland, DM, 767(ab), Wong, D, 784(ab) Yeh, SDJ. 846(ab) Ziffer, JA, 825(ab), 910(ab) 895(ab), 1436 807(ab), 930(ab), 932(ab), Wong, DF, N2, 717, Yen, SH, 826(ab), 863(ab), Zimmer, AM, 174, 757(ab), Watkins, GL, 755(ab), 938(ab) 809(ab), 820(ab), 840(ab). 936(ab) 8IO(ab), 811(ab), 865(ab), 931(ab) Wienhard, K, 821(ab) 852(ab), 911(ab) Yester, MV, 908(ab), 1189, 870(ab), 884(ab), 901(ab) Watson, AD, 747(ab), Wierzbinski, B, 905(ab), Wong,JYC. 103. 875(ab), 1931 Zimmer, M, 823(ab) 788(ab) 980(ab) 926(ab) Yim. D, 778(ab) Zimmerman, R, 830(ab), Watson, DD, 804(ab), Wigger, B. 954(ab) Wong. STS. 785(ab) Yip, T-CK. 884(ab) 910(ab) 819(ab), 850(ab), 955(ab) Wijns, W, 770(ab), 866(ab), Wong. W-H, 338 Yoganandan. N. 856(ab) Zimmerman, RA, 836(ab), Watson, EE, 427 1826 Wong, WH, 761(ab), Yohannes, P, 936(ab) 852(ab) Waxman, A, 770(ab) Wilbur, DS, 777(ab), 929(ab) 877(ab), 879(ab) Yokoi. F, 921(ab) Zimmerman, RE. 845(ab). Waxman, AD, 749(ab), Wilbur, S. 901(ab) Wong, X, 195 Yokoyama, A, 778(ab), 874(ab), 1745 753(ab), 854(ab), 1083 Wiles, HB, 1526 Woo. DV, 847(ab), 873(ab) 922(ab), 928(ab), 930(ab), Zimmermann, R, 817(ab) Waxman, S, 854(ab) Wilkening, D, 815(ab) Woodard, HQ, 803(ab) 934(ab) Zipes, DP. 840(ab) Webb, S, 877(ab) Wilkins, K, 880(ab) Woodard, ML, 756(ab) Yokoyama, K, 750(ab), Zivanovic, MA, 549 Webbon, P, 62 Wilkinson, R, 651, 830(ab). Woodbury, MC, 1644 812(ab), 827(ab), 857(ab), Zohgbi, S, 954(ab) Weber, DA, 843(ab), 886(ab) 843(ab), 887(ab), 902(ab) Woodhouse, CS, 39 895(ab), 1022 Zuckier, LS. 707 Weber, K, 887(ab) Williams, AE, 768(ab) Woodle. ES, 936(ab) Yoneda, S, 1264 Zwas, ST, 1150

Author Index â€¢1988 2045 Subject Indexâ€”1988

scans, artificial ventilation, 764(ab) recertification examination for nuclear Aging medicine physicians in 1988, N146 Abscess effects of, Tc-99m MAG3 clearances, kidney, abdominal sepsis, value of SPECT, In-111 Amino acids 906(ab) leukocytes, 794(ab) brain transport studies, new radioiodinated diagnostic pattern of Ga-67 uptake, lymphocytic sensitivity of cerebral glucose metabolism, radiopharmaceutical, 778(ab) cerebrovascular risk factors, 852(ab) imaging studies using C-l 1 AIB, malignant interstitial pneumonitis, 887(ab) experimental, localization with In-111 seventy years old and greater, dipyridamole melanoma, 904(ab) thallium imaging. 953(ab) neutral, accumulation, maturation in brain, neutrophils in rabbits, 733(ab) AIDS dementia complex. See Acquired 784(ab) Fisher immunotype 1 Pseudomonas aeruginose, N-13 glutamine transport, cancer cachexia, 1-125 monoclonal antibody, 651 immunodeficiency syndrome imaging potential, Tc-99m multilamellar Alcohol skeletal muscle, 902(ab) cerebral glucose utilization, relation to brain Aminobisphosphate, osteoporosis treatment, dual- liposomes, 888(ab) structure, polydrug abusers, 91 l(ab) imaging with In-111 biotin, streptavidin- photon absorptiometry, 884(ab) effects on regional cerebral metabolic rate, Aminocarboxylic acid, rareearth complex, skeletal conjugated monoclonal antibodies, 889(ab) normal subjects, 840(ab) In-111 white blood cell scintigraphy, febrile ICU uptake of, 280(ab) intoxication, regional cerebral blood flow, Aminophosphonic acid, rareearth complex, patients, 795(ab) 839(ab) occult infection, accuracy of Ga-67, 608 skeletal uptake of, 280(ab) Algorithms Amyotrophic lateral sclerosis, normal cerebral preparation of Tc-99m SnF2 colloid kit, circular harmonic transform, quantitative glucose utilization, 821(ab) leukocyte labeling, 888(ab) SPECT. 868(ab) Aneurysm quantification of PMN granulocyte infiltration, computer processing, in vitro evaluation, "black hole" sign, Tl-201 SPECT images, gore-tex graft, abdominal aorta, 794(ab) 862(ab) 756(ab) salmonella costochondritis, 2004 direct scatter compensation, photopeak ruptured intracranial, Tc-99m HM-PAO Tc-99m anti-SSEA-l as tracer, human distribution analysis, 797(ab) SPECT, 844(ab) neutrophils, 788(ab) edge detection, emission computed tomography, Angiocardiography, radionuclide, first-pass, Absorptiometry 868(ab) correlation of ejection fraction and volume dual photon: See Dual-photon absorptiometry method for receptor pharmacology, non-linear measurements, 1114 medicare coverage, HFCA, N1620 models, variable radioactivities, 822(ab) Angiography, radionuclide Acquired immunodeficiency syndrome (AIDS) multi-grid maximum likelihood image assessment of renal perfusion, insensitive asymptomatic HIV seropositive persons, SPECT reconstruction, PET, real data, 774(ab) indicator, renal allografts, 779(ab) imaging, 1-123 isopropyl amphetamine, planar Tl-201, quantification, degree of compared to renal scintigraphy, chronic 742(ab) reversibility, 861(ab) biodistribution of 5-fluoro-2',3'- glomerulonephritis, 907(ab) radiopharmaceutical organ uptake, detection of regional wall motion abnormalities dideoxycytidine, NMR spectroscopy, measurement, improved method, 861(ab) biplane contrast, factor analysis. 771(ab) 837(ab) Tl-201 SPECT, estimation, left ventricular improved probabilistic image, 863(ab) dementia complex mass, 945(ab) diastolic function, myocardial infarction, 1786 PET-FDG studies, azidothymidine, 852(ab) Â¡V-Alk)lation, comparison of bromo vs. iodoalkyl factor analysis of, valvular rÃ©gurgitation,159 SPECT in, 1382 triflates, F-18 radiolabeling. secondary first-pass, multiwire gamma camera and diagnostic pattern of GA-67 uptake, amines, 754(ab) tantalum-178, 293 lymphocytic interstitial pneumonitis, Aluminum, systemic, Tc-99m MDP distribution, gating mode effects, analysis of left ventricular 887(ab) 856(ab) function, 1272 Ga-67 renal hyperactivity, 909(ab) Alzheimer's disease hepatic perfusion in cancer patients, parameters, pulmonary Ga-67 uptake, pediatrie patient, 707 cerebral perfusion in, Tc-99m HM-PAO SPECT 894(ab) variable presentation of PCP, Ga-67 scans, study, 1507 1-123 HIPDM metabolic lung imaging, HIV-positive persons, 829(ab) cortical signal abnormalities, MRI study, pulmonary hypertension, 765(ab) Adrenal glands 836(ab) left ventricular maximum time-varying adenoma, benign, Ga-67 uptake. 1451 differential diagnosis of non-vascular dementia, elastance calculation, 1368 imaging update, 2026(ab) SPECT. 743(ab) left ventricular pressure-volume loops, increase in 1-131 NP-59 uptake, adrenalectomy, left hemisphere dysfunction, FDG/PET scans, determination in clinical setting, 1492 859(ab) 912(ab) left ventricular volume calculation, 745(ab) low-density lipoprotein biodistribution, 1237 relationships, SPECT findings, clinical features. new tracer Ir-191m, arterioscintigraphy, 841(ab) NP-59 scintigraphy utility, disease diagonsis, 743(ab) quantitative assessment of blood flow, renal 859(ab) Ambulatory cardiac monitoring device transplants, pediatrics, 791(ab) Adrenal medulla detection of silent myocardial ischemia, 741(ab) removal of Ir-192 from reactor-produced Os- 1-131 MIBG imaging, methodology and dipyradimole SPECT thallium imaging and, 191,927(ab) dosimetry, 1638 chest pain syndrome, normal coronary repeat, stress testing, Tl-201 scintigraphy, tumor, nuclear imaging, 276(ab) arteriograms, 742(ab) 77

Page numbers followed by (ab) indicate abstracts. Page numbers followed by (le) indicate letters. N preceding a page number indicates an article appearing in Newsline.

2046 The Journal of Nuclear Medicine Blood flow

compared value, pulmonary embolism. SPECT quantitation. inhomogeneous media, molecular structure of Cu(PTSM), 927(ab) 824(ab) transmission scan, 797(ab) new method. Tc-99m HM-PAO SPECT, Angioplasty Autoradiography 748(ab) coronary, Tl-201 SPECT, indications for evaluation of PET feasibility studies, study O-15 steady state method, arterial referral, 946(ab) protocol screening, 774(ab) concentration, 821(ab) predictive value of thallium SPECT, myocardial mapping of glutamate receptor channels, O-15 water autoradiography and PET, oxygen infarction, 770(ab) 930(ab) inhalation, 915(ab) stress testing and Tl-201 scintigraphy, patient O-15 water, oxygen inhalation, cerebral blood oxygen and glucose metabolism, stroke, selection, repeat angiography, 770(ab) flow, 9I5(ab) 852(ab) stress Tl-201 imaging, restenoses. recurrent quantitative partial epilepsy, childhood, 892(ab) symptoms, 770(ab) detection of cardiomyopathy, animal model, PET, copper-labeled radiopharmaceuticals, Angiotensin converting enzyme 1697 1549 inhibition in renal artery stenosis tumor antigen concentration, tissue sections, PET, lack of ID for EC/IC bypass, 831(ab) 1-123 hippurate renography, 907(ab) 897(ab) PET agent validation, I-I22 HIPDM, 916(ab) renography and renal scintigraphy. 908(ab) Azidothymidine, AIDS-related dementia, PET- potential imaging agents. Tc-99m NEP- Antibodies FDG studies, 852(ab) DADT, 73 bifunctional, optimization of ligand structure. radioxenon tomography. 1875(le) imaging, 835(ab) B resting and hypercapnic, carotid artery radioimmunotherapy for micrometastases, At- stenosis and. 311 Barium fluoride (Hal ) scintillator, camera 2ll,858(ab) side localization by SPECT, temporal lobe performance design evaluation, PET, 338 utility for labeling, meta vs. para substituted N- epilepsy, 916(ab) B cells, monoclonal anti-B cell antibodies, succinimidyl stannyl benzoates, 834(ab) simultaneous SPECT acquisition, 876(ab) localization, human B-lymphoma Antimyosin single-pass extraction, Tc-99m-D,u-HM-PAO, transplants, 899(ab) first-pass myocardial extraction, effect of 747(ab) Benzodiazepine receptors reperfusion, 746(ab) Tc-99m compounds for measurement, binding of H-3-RO15-4513, 809(ab) In-111-labeled central type, quantitative analysis, steady-state 1464(le) kinetics in septum, necrosis, 941(ab) Tc-99m ECD compared to Tc-99m HM- in living brain, 809(ab) uptake specificity, myocardial infarction, C-l 1 Rol5-1788, PET studies, 931(ab) PAO, 844(ab). 9l2(ab) Tc-99m ECD compared to Xe-133, 913(ab) 746(ab) new radioligands for PET studies, 3-[C-l I] Aortic rÃ©gurgitation Tc-99m ECD imaging, 758(ab), 788(ab) methoxybenzodiazepines. 755(ab) cine NMR quantification, 802(ab) Tc-99m HM-PAO SPECT, during Matas test, SPECT mapping in brain, 759(ab) left ventricular ejection fraction, exercise 1724 Bile acid, malabsorption, 1411 tracers, copper bis(thio-semicarbazones, response, 744(ab) Binding assay, In-111 monoclonal antibodies, Arterioscintigraphy, new tracer Ir-191m, 84l(ab) 848(ab) gastrointestinal tumor, 1436 tumors, Tc-99m HM-PAO uptake, Arthroplasty Biotin hip In-111-labeled, streptavidin-conjugated glutathione content, 920(ab) detection of infection, 887(ab) uptake of 1-125 HIPDM, 1675 antibody, tumor localization studies. infection evaluation, In-111 leukocytes, 762(ab) validation studies by radioxenon tomography, 883(ab) potential tumor imaging agents, 729(le) 348 prostheses evaluation, In-111 granulocytes, Xe-133 SPECT, compared to PET, 9l9(ab) Bismuth germanate (BGO) scintillator, camera 883(ab) performance design evaluation, PET, 338 cerebrovascular disease prosthetic tip, In-111 WBC, 764(ab) early and late 1-123 IMP SPECT, 844(ab) Bladder prosthetic tip, three phase bone scan, 780(ab) artifact correction, SPECT evaluation, hips. rapid sequential SPECT study, 880(ab) Aspartame, effect on human brain C-l 1 ACHC 780(ab), 868(ab) congestive heart failure, peripheral uptake, 784(ab) urinary, model, radiation dosimetry hemodynamics and selection of Astatine-211, radioimmunotherapy for calculations. 875(ab) vasodilators. 451 micrometastases, 858(ab) Blood, distribution of Gd-153 (DTPA)2, CO2 reactivity using 1-122 HIPDM, PET study, Astatine-211 monoclonal antibodies, iodine pharmacokinetic analysis, 891(ab) 773(ab) labeling, A'-succinimidyl-3-(tri-n- Blood flow coronary venous retroperfusion, myocardial butylstannyDbenzoate, 835(ab) Alzheimer's disease, SPECT findings, clinical ischemia, PET, 783(ab) Astrocytoma, human high grade, features, 743(ab) density of capillaries, stroke, living human microautoradiography localization, Tl-201, arterial input function, plasma separation. PET brain, 915(ab) 854iofetamine tomography. hallucination, 917(ab) studies. 752(ab) 892(ab) liver physiology, non-invasive multiparametric detector response and, cardiac SPECT image error analysis in SPECT, children, 869(ab) study, cirrhosis, 791(ab) reconstruction, 870(ab) evaluation, 3-headed SPECT system, 9l2(ab) liver transplant rejection, scintigraphy, direct scatter compensation, photopeak 1-123 IMP SPECT redistribution, ischemie deconvolutional analysis, 790(ab) distribution analysis, 797(ab) cerebral vascular disease, 918(ab) localization of seizure foci, 913(ab) factor determination, absolute quantitation. linearization of values, Tc-99m HM-PAO. medically-treated cerebral ischemia, prognosis, radionuclide. 872(ab) 936(ab) PET, 831(ab) non-uniform, SPECT, photopeak and Compton maturation in infants, SPECT, 743(ab) metabolism of Tc-99m ECD, normal spectral windows, 798(ab) maturation in newborns, 1-123 IMP and volunteers, 747(ab) PET quantitation errors due to headrest, SPECT, 893(ab) mild cerebral ischemia, reverse redistribution, 878(ab) measurement with Tc-99m HM-PAO, 1387 Tc-99m HM-PAO, 914(ab)

Subject Index â€¢1988 2047 Blood pool imaging

monitoring of arterial positron concentration, sampling frequency, 869(ab) scanning gamma detector, 833(ab) condensing osteitis, clavicle, 1122 baseline, breast cancer, 1045 myocardial delayed/non-union fractures. Tc-99m/In-l 11 MRI in, 2026(ab) binding characteristics of imaging agents, 55 leukocyte and Tc-99m/Ga-67 imaging, osteoid osteoma, 272(ab) intra-operative regional monitor, 880(ab) 813(ab) osteosarcoma in Paget's disease, 414 molecular structure of Cu(PTSM), 927(ab) density prediction of successful therapy for N-13 ammonia, noninvasive quantification, comparison from different skeletal sites, 168 mÃ©tastases.1354 940(ab) measurement, different skeletal sites. 1748(le) reflex sympathetic dystrophy of the hand. 26 N-13 ammonia metabolic fate, human blood, premenopausal women, hormonal review of sternal disease. 780(ab) 783(ab) relationship. 859(ab) scintigraphic sternal lesions, patients with N-13 ammonia PET, 838(ab) spine and distal forearm, osteoporosis, 131(le) breast cancer, 324 myocardial ischemia and leg muscle assessment, digitally acquired and displayed radioisotope symmetric photon deficiency in femoral stress testing, dipyridamole and exercise, images, diagnostic consequences. 884(ab) heads, 266(le) 947(ab) dual energy radiography, mineral analysis of trochanteric bursitis, 763(ab) oxygen metabolism and, spinocerebellar lumbar spine. 855(ab) scintigraphy degeneration, PET, 920(ab) dual-photon absorptiometry combined with In-111 leukocyte scans, potential tracers, single-pass studies, copper mineral distribution in skeleton. 881(ab) neuropathic foot disease. 1651 bis(thio-semicarbazones), 848(ab) non-hormonal therapy of osteoporosis, detection of obstructive uropathy, 1781 quantitative assessment 855(ab) emergency use, pediatrie, 736(ab) first-pass tracer fractionation, kidney, 907(ab) osteoporosis, 884(ab) factor analysis, renal osteodystrophy, 883(ab) regional myocardial perfusion, dynamic PET precision of, 880(ab) MRI and, osseous spine mÃ©tastases,763(ab) and N-13 ammonia, 782(ab) ectopie, mineralization, MDP effect, 882(ab) quantitative, 881(ab) renal transplants, pediatrics, 791(ab) frontal and lateral DPA measurements, lumbar stress fractures, 1150(le) rapid generation of blood activity curves, multi- spine, strength of vertebral body. 856(ab) Tl-201. soft tissue sarcoma and, 854(ab) slice gated cardiac PET data, 775(ab) healing, lower limb lengthening by distraction skeletal mÃ©tastases,initial experience, 186- rate constant determination, kinetic model, Tc- epiphysiolysis, 1259 Re(Sn)-HEDP, 776(ab) 99mHM-PAO, 9l7(ab) imaging, symmetric photon deficiency in skeletal muscle necrosis, quantitation, Tc-99m renal, noninvasive assessment, temporal femoral heads, 266(le) PYP. 884(ab) deconvolution. 862(ab) In-111 chloride imaging skeletal radiotherapeutic agent, Ga-72 nitrate, retention of Tc-99m ECD in brain, in vivo diabetic foot. 813(ab) 776(ab) metabolism, 747(ab) treated osteomyelitis. 763(ab) SM-153 EDTMP selection of tracers, experimental procedures. In-111 granulocytes, complicated hip prostheses, disseminated skeletal metastasis, dosimetry, imaging techniques, 862(ab) evaluation. 883(ab) 762(ab) Tc-99m HM-PAO SPECT In-111 leukocytes, role, diagnosis of fracture metastatic cancer, dose tolerance, 775(ab) compared to 1-123 IMP. ischemie lesions. and osteomyelitis, 814(ab) tumors, response to therapy, 903(ab) 9l9(ab) ln-111 white blood cells solitary lesions, Tl-201 role, etiologic ruptured intracranial aneurysm, 844(ab) localization, non-infected surgery site, 788(ab) classification, 814(ab) TI-201 renal imaging, stress cardiac imaging, osteomyelitis evaluation. 813(ab) SPECT 9IO(ab) lower extremity periostitis, secondary to venous comparison with planar scintigraphy. skull, tumor uptake and, I463(le) insufficiency, Tc-99m MDP, 1279 1341 vasoreactivity in cerebral arteriosclerosis. marrow scintigraphy, compared to magnetic in hyperplasia, mandibular condyle, 780(ab) without carotid stenosis, 911(ab) resonance tomography, plasmocytoma, spinal osteoporosis, diagnostic sensitivity, SPA Blood pool imaging 891(ab) and DPA. 882(ab) blood volume measurement with C-11 carbon metabolic disease surgical radiation probes, 881(ab) monoxide, carboxyhemoglobin half-life. early diagnosis, dual tracer method. 780(ab) Tc-99m DTPA-HSA, initial experience in man, systemic hematocrit. 894(ab) hip mineral density measurements, interval 922(ab) cell labeling efficiency and, red cell surface changes. 779(ab) Tc-99m MDP. adverse reactions, 1302(le) charge, 1710 mÃ©tastases,bone scan flare for, 1354 therapy of osseous mÃ©tastases,marrow toxicity, compartmental and non-compartmental mineral content Sr-89, 776(ab) modeling, HIDA studies. 862(ab) hemodialysis effects, 277(ab) three phase scan, porous coated hip Cu-62 HSA, plasma volume measurement, lumbar spine, dual-photon absorptiometry, arthroplasty, prosthetic tip, 780(ab) 930(ab) 248 toddler's fracture. Tc-99m MDP. 2001 human testicular carcinoma xenograft, athymic measurement in cats, 280(ab) total joint arthroplasty, occult infection mice, radioimmunodetection, 896(ab) mineral loss, normal postmenopausal women, following. Tc-99m HDP and In-111 WBC left ventricular maximum time-varying 881(ab) imaging. 1347 elastance calculation, 1368 osteomyelitis, subperiosteal abscess Bone densitometry mechanism of inspiratory reduction, left complicating, In-111 leukocyte mineral content of spine/hip/forearm, primary ventricular stroke volume, function, scintigraphy, 1871 hyperparathyroidism, 855(ab) 949(ab) osteomyelitis complicated by pre-existing osteoporosis in eating disorder patients, 882(ab) protein binding studies, Tc-99m, 62 condition, In-111 WBC in detection, 1015 X-ray scintillation camera, 855(ab) Paget's disease. Ga-67 citrate localization in scintigraphic appearance, torsion of testicular Book reviews appendages. 892(ab) osteoclast nuclei, 1083 Advances in Clinical Cardiology, Vol. Ill: Tc-99m DTPA-HSA, initial experience in man, painful prostate and breast cancer, Sr-89 Regional Myocardial Metabolism by 922(ab) chloride, treatment results, 763(ab) Positron Tomography, 1157 Blood volume, visceral, redistribution in exercise, pelvic studies, digital filtering of the bladder in. Age-Related Factors in Radionuclide 1714 1587 Metbaolism and Dosimetry, 428 Bone radiolabeled monoclonal antibodies. Basics of Magnetic Resonance Imaging, 1750 calcium and mineral changes, hemodialysis, osteosarcoma. 235 Cardiac Nuclear Medicine, 1157 816(ab) radionuclide imaging, calvarÃa!infarction in Clinical Anhrography, 2nd Ed, 2022 cancer-related pain, radionuclide pallitation, sickle cell disease, 411 Diagnostic Imaging of Child Abuse, 135 2027(ab) red marrow dosimetry, radiolabeled monoclonal Diagnostic Ultrasound: Text and Cases, 579 cancer therapy. Sn-117m, high specific activity, antibodies. 858(ab) Gamuts in Nuclear Medicine, 1467 849(ab) salmonella costochondritis, Ga-67 detection, Graft-Scientific Plotting/Data Transformation, clinical SPECT studies, optimization, angular 2004 1307

2048 The Journal of Nuclear Medicine Brain

Magnetic Resonance Annual 1988, 1610 cat. metabolic maturation, 772(ab) imaging agents Magnetic Resonance Imaging, 1882 cerebral infarction 5-iodo-thienylamphetamine synthesis, 777(ab) Mammography, Self Assessment in Radiology MRI, proton self-diffusion coefficient, 836(ab) radioactive iodobenzamide, 777(ab) and Imaging, 1750 Tc-99m HM-PAO scintitomography, 843(ab) imaging characteristics of MUMPI. cylindrical NCRP Report No. 93. Ionizing Radiation cerebral maturation in first 20 months of life, neuro-SPECT system, 832(ab) Exposure of the Population of the United regional cerebral blood flow. SPECT. improved HPLC system, analysis, organic States, 1881 743(ab) amine radiopharmaceuticals, 926(ab) New Approaches to Tumour Identification. cerebral oxygen metabolism, effect. O-15 water In-111 oxime, labeling, hematoporphyrin Cancer Surveys; Advances and Prospects in recirculation, 917(ab) derivative, 927(ab) Clinical, Epidemiological and Laboratory collateral circulation, Tc-99m HM-PAO metabolic rate for glucose, partial correlation Oncology, 731 SPECT, during Matas test, 1724 coefficients, 392 Noninvasive Imaging of Cardiac Metabolism, density of capillaries, stroke, 915(ab) metabolism 270 determination of flow and rate constants alcohol effects, normal subjects, 840(ab) Nuclear Magnetic Resonance Imaging in 1-123 IMP SPECT, 870(ab) hypometabolism, olivopontocerebellar Medicine and Biology, 135 kinetic model, Tc-99m HM-PAO, 917(ab) atrophy, 913(ab) Nuclear Medicine Annual 1987, 731 dopamine receptor binding sites patterns of. acute ischemie aphasia, 915(ab) Nuclear Medicine Applications to Surgery, 2022 kinetic parameters for FESP interactions, patterns of, vegetative subjects, 839(ab) Principles of Nuclear Magnetic Resonance in PET, 865(ab) progressive supranuclear palsy, PET. 914(ab) One and Two Dimensions, 579 SPECT, 848(ab) relationships, condition-dependent changes. Quality Assurance and Image Artifacts in F-18 cyclofoxy 839(ab) Magnetic Resonance Imaging, 1307 evaluation in rat. 796(ab) subcortical alterations, partial epilepsy, Radiation Dose to Patients from PET imaging in man, 796(ab) 830(ab) Radiopharmaceulicals: ICRP Publication F-18 6-L-DOPA imaging, asymptomatic MPTP- MRI 53, 1610 lesioned monkeys, 820(ab) new technique, automated edge detection, Radionuclides in Nephrology, 427 F-18 fluorodeoxyglucose, high resolution, event 865(ab) Radiopharmaceulicals in Nuclear Medicine requirements, 760(ab) normal pressure hydrocephalus, radionuclide Practice, 427 F-18 fluorophenylalanine, tumor imaging agent, cisternography, 836(ab) Rational use of Diagnostic Imaging in 919(ab) multiple region-of-imerest capabilities. Paediatrics: Repon of a WHO Study F-18 2-fluorotyrosine, protein synthesis tracer, monitoring, positron-emitting tracers, Group, 1750 754(ab) 832(ab) Safety and Efficacy of Radiopharmaceuticals, F-18 GBR 13119, synthesis and uptake, multi-slice, SPECT, position-sensitive bar 1881 dopamine uptake blocker, 767(ab) detector system, 760(ab) The Clinician 's Guide to Diagnostic imaging, F-18 sex hormone uptake. F-18 ligands, PET, muscarinic receptors 1467 795(ab) C-l 1 scopolamine, PET, 808(ab) 1988 Year Book of Diagnostic Radiology, 2022 glioma, PET-FDG technique, 421(le) radioligand dissociation kinetics, 927(ab) 1987 Year Book of Diagnostic Radiology, 270 glucose metabolism JVX3-F-18fluoropropyI)MK-801, NMDA Â¡987Year Book of Nuclear Medicine, 270 acute cocaine, human substance abusers, receptors, 932(ab) Boron, -capped Tc-99m oxime, compared to tin- 840(ab) perfusion capped, 935(ab) cerebellar FDG metabolism, brain trauma, quantitative SPECT imaging, improved Brain 822(ab) method, 869(ab) AIDS dementia complex normal, amyotrophic lateral sclerosis, 821(ab) reserve in cerebrovascular disease, Tc-99m PRT-FDG studies, 852(ab) PET measurement of, 631 DTPA-HSA, 1-123 IMP, 918(ab) SPECTin, 1382 rates, PET, 867(ab) Tc-99m ECD imaging, 788(ab) Alzheimer's disease senstivity, age and risk factors, 852(ab) Tc-99m HM-PAO, pediatrie patients, 919(ab) left hemisphere dysfunction, FDG/PET scans, structure, polydrug abusers, 911(ab) Tc-99m HM-PAO and ECD, comparison, 912(ab) grey and white tissue water content, partition 844

Subject Index â€¢1988 2049 Brain death

spinocerebellar degeneration, 920(ab) spectroscopy. 785(ab) Campylobacter pyloridis, C-14 urea breath test. regional correction, atrophy effects, 773(ab) glutathione content, Tc-99m HM-PAO 789(ab), 790(ab) ROI analysis, MRI-based templates, 866(ab) uptake, 920(ab) Cancer role, pediatrie epilepsy surgery, 831(ab) multi-parameter studies, PET, 853(ab) see also specific type visual cortex hypometabolism, head injury primary and metastatic. Tc-99m HM-PAO anti-antibody enhancement, monoclonal patients, 830(ab) uptake, 895(ab) antibody imaging, 757(ab) PET scanner rat model, deoxyglucose and glucose bone, Sn-117m therapy, high specific activity, high resolution, double wobbling mode. transport, 920(ab) 849(ab) 877(ab) unilateral occlusive disease of internal carotid colonie, radiolabeled monoclonal antibodies, performance of machine parameters, artery, resting and hypercapnic rCBF, 311 762(ab) metabolic data, 877(ab) validation studies, radioxenon tomography, 348 SM-153 EDTMP proxy for capillary FDG, limitations, arterial vasoreactivity in cerebral arteriosclerosis. disseminated skeletal metastasis, SPECT, FDG, 822(ab) without carotid stenosis. 911(ab) 762(ab) radiation dosimetry Xe-133 SPECT imaging metastatic bone, dose tolerance, 775(ab) I-123SCH23982, 1668 developmental childhood dysphasia, 792(ab) Captopril radioiodinated SCH23982, biodistribution, Sturge-Weber cerebral angiomatosis, 792(ab) abnormal renogram, Tc-99m hippuran analog, 803(ab) Brain death, diagnostic options. 2026(ab) 1730 radiochemical purity of Tc-99m HM-PAO, Breast quantitative radionuclide studies, renal artery 572(le) AIDS and. I607(le) stenosis, 908(ab) radioiodinated 1-125 HEAT, binding, 356 cancer renal scintigraphic test, angiographie data registration of MRI-PET images, procedure, baseline bone scan, 1045 comparison, glomerulonephritis, 907(ab) validation, 853(ab) ER-positive, I-123 estradiol. 853(ab) renography scan, 1-123 IMP, patient with auditory In-111 anti-CEA imaging, subtraction effects, volume depletion, 849(ab) hallucination, 558 techniques, 899(ab) Goldblatt hypertension. 575(le) seizure foci localization, 913(ab) mucin-like carcinoma-associated antigen. renal artery stenosis, 850(ab) serotonin clinical value, 894(ab) saralasin comparison, hypertension, 849(ab) labeling of uptake sites, 3H-paroxetine. scintigraphic sternal lesions in, 324 renovascular hypertension, comparison of 809(ab) Ga-67 uptake, 1606(le) radioactive agents, rat model. 509 synthesis, plasma tryptophan, 784(ab) patient with hypothalamic granuloma. 118 Tc-99m MAG3. renovascular hypertension, SPECT internal lymph nodes, localization by 849(ab) cerebrovascular reserve, hemodynamic risk radionuclide lymphoscintigraphy, 473 Carbon-11 D.i.-homocysteine thiolactone, potential patients, 91 l(ab) internal mammary lymphoscintigraphy, tracer for myocardial ischemia. PET, future directions, 567 ultrasonic guidance for, 1744(le) 755(ab) 1-123 IMT, 91 l(ab) painful metastasis in bone, Sr-89 chloride, Carbon-11 acetate phantom evaluation of distortion, 877(ab) treatment results, 763(ab) myocardial oxidative metabolism, 808(ab) rapid sequential study, cerebrovascular synthesis and target tissue uptake, progestin clearance, 937(ab) diseases, 880(ab) receptor-based radiotracer, 768(ab) myocardial infarction, PET, 818(ab) ring-geometry instrument for imaging, Breastfeeding, internal and external radiation normal myocardium, 937(ab) dose, nursing child, Tl-201 -exposed mother, 760(ab) stunned myocardium, dynamic PET, 782(ab) temporal lobe epilepsy, side localization, 874(ab) probe for myocardial metabolism, simple and Breast milk 916(ab) excretion of 1-131. lactating patient with Grave's efficient synthesis, 932(ab) three-headed system, initial on-site Carbon-11 ACHC, uptake in human brain, effect, evaluation, 760(ab) disease. 407 dietary aspartame, 784(ab) In-111 in, 1301(le) totally digital annular camera, 786(ab) Carbon-11 AIB, imaging studies, malignant Bromine-77 bromospiperone, no-carrier-added Tc-99m-D,L-HM-PAO melanoma, 904(ab) single-pass extraction, 747(ab) synthesis, nucleophilic bromodeiodination, Carbon-11 buprenorphine, compared to C-l 1 stabilization, gentisic acid, 935(ab) 776(ab) diprenorphine, brain uptake, PET, 933(ab) Tc-99m dithiosemicarbazone complex, Bromoacetylation, synthesis of para-substituted Carbon-11 carbon dioxide, trap for removing condensed ring structure, 934(ab) phenyl glyoxals. 928(ab) oxides of nitrogen, 933(ab) 3-Bromopropyl trillate, compared to iodoalkyl Tc-99m ECD SPECT Carbon-11 carbon monoxide, blood volume Inflates, F-18 radiolabeling, secondary kinetics, biodistribution, 921(ab) measurement, carboxyhemoglobin half-life, amines, 754(ab) metabolism, normal volunteers, 747(ab) systemic hematocrit, 894(ab) Brookhaven National Laboratory retention of, in vivo metabolism, 747(ab) Carbon-11 car fontani!. C-l 1diprenorphine and, contract with USDOE, N292 tomographic imaging, stable perfusion agent, opiate receptor binding, dual detector Esselen Award for PET research, N440 758(ab) Budd-Chiari syndrome, Xe-133 system, 921(ab) Tc-99m HM-PAO SPECT Carbon-11 CGP 12177, halothane-induced splenoportography, 423(le) cerebral perfusion, middle cerebral artery decrease, myocardial beta adrenoceptor, Bursitis, trochanteric, bone scanning, 763(ab) velocities, 914(ab) PET, 940(ab) compared to I-123 IMP, ischemie lesions. Carbon-11 diprenorphine 919(ab) binding to opiate receptors in man, PET, cortical peeling and mapping, 914(ab) CA125, recognition by monoclonal antibodies, in 796(ab) decomposition, aqueous media, 1568 vitro and in vivo use, 766(ab) C-l 1 buprenorphine and, brain uptake, PET, evaluation, cerebral perfusion tracer, 843(ab) Cachexia, cancer. N-13 glutamine transport, 933(ab) evaluation, post-stroke depression, 918(ab) skeletal muscle, 902(ab) C-11 carfentanil and high resolution imaging, SPRINT, 917(ab) Calcitonin, human serum, evaluation, commercial opiate receptor binding, dual detector system, mild cerebral ischemia, reverse redistribution, radioimmunoassay kit, 766(ab) 921(ab) 9l4(ab) Calcium, unique non-invasive measurement opiate receptors in man, PET, 796(ab) ruptured intracranial aneurysm, 844(ab) method, tissues, 883(ab) Carbon-11 DMHDA, synthesis and biologic Tc-99m oxime Calciiim-45, osteoporosis, eating disorder patients. evaluation, 68 complexed with 3 Schiff base ligands, 936(ab) 882(ab) Carbon-II malonate platinum, PET studies. 1107 tin-capped vs. boron-capped, 935(ab) Calcium-47, early diagnosis of metabolic bone Carbon-11 methionine tumors disease, dual tracer method, 780(ab) abnormal oxidation, schizophrenia, 784(ab) Co-57 bleomycin delivery to, SPECT, 187 Campylobacter pylori, gastritis associated with, C- cerebral neutral amino acid accumulation, FDG-PET and image-guided MR 14 urea breath test for. 11 maturation, PET study, 784(ab)

2050 The Journal of Nuclear Medicine Cistemography

kinetics model, human brain, 822(ab) radioimmunodetection, I-123 antibody autoradiography, 1697 Carbon-11 3-methoxybenzodiazepines, new fragments, 898(ab) dilated, myocardial gallium uptake, 274(ab) radioligands for PET studies, radioimmunopharmaceuticals, intact v.v. dilated and ischemie, profile analysis, PET, benzodiazepine receptors, 755(ab) fragments, tumor model. 893(ab) 8l8(ab) Carbon-11 me(hyl-i -tryptophan. no-carrier-added, radiolabeled antibodies, imaging of pancreatic hypertrophie, myocardial glucose metabolism, synthesis, 370 cancer, 833(ab) PET, 828(ab) Carbon-11 nisoxetine, fluoxetine and, syntheses, Tc-99m-labeled monoclonal antibody. hypertrophie obstructive, TI-201 imaging, 1738 932(ab) immunoscintigraphy, colorectal carcinoma, Carotid artery, adherence. In-111 endothelial cells, Carbon-11 nitroalkanes, production, synthesis. i> 834(ab) 939(ab) glucose and 0-phenethylamine, 754(ab) Carcinoma, breast, mucin-like carcinoma- Carotid endarterectomy, prediction of successful Carbon-11 NMPB, synthesis and regional brain associated antigen, monitoring, clinical revascularization, 1-123 IMP, 844(ab) distribution. 768(ab) value. 894(ab) Carotid stenosis, correlation of cerebral perfusion, Carbon-11 prazosin, synthesis of, 930(ab) Carcinoma, colon Tc-99m HM-PAO brain SPECT, 914(ab) Carbon-11 pyruvate, metabolism in brain and imaging. 1-131 16-88 monoclonal antibody, Catecholamines, 1-125 MIBG compared to H-3 muscle, mitochondrial encephalomyopathy. 833(ab) NE uptake and release, different brain PET, 921(ab) imaging by Tc-99m monoclonal antibody, regions, 91 l(ab) Carbon-11 raclopride, kinetic analysis, central D-2 834(ab) Catheter ablation, phase image triangulation of dopamine receptors. 820(ab) multiceli spheroids, radioimmunotherapy, accessory pathways, posteroseptal pathways, Carbon-11 RolS-1788 858(ab) 744(ab) benzodiazepine receptors radiolabeled monoclonal antibodies, 762(ab) Catheterization, cardiac, radionuclide studies and, PET studies, 931(ab) Carcinoma, colorectal clinical indications. 2024(ab) quantitative analysis, living brain. 809(ab) detection of Cat-scratch disease, liver lesion with no Carbon-11 SarCNU, synthesis, 1957 In-111 anti-CEA mAb ZCE 025, 812(ab) lymphadenopathy, 1454 Carbon-11 scopolamine, muscarinic receptor SPECT compared to planar imaging, 886(ab) Central nervous system imaging in brain. PET, 808(ab) known and occult, Tc-99m anti-CEA, F-I8 FDG compared to F-18 FDM, PET, Carbon-11 TRB, synthesis and preliminary immunoscintigraphy. 834(ab) 772(ab) evaluation, ligand. muscarinic receptor. localization. In-111 monoclonal antibody. radiation necrosis, PET and NMR, 785(ab) 932(ab) 898(ab) Cerebrospinal fluid, intracrania!. quantifying using Carbon-11 YM-09151-2, dopamine D-2 specific presurgical screening. anti-CEA monoclonal NMR, 132(le) brain uptake, 931(ab) antibody, 897(ab) Charcot foot, scintigraphy of, 280(ab) Carbon-14 iodoantipyrine, kinetic evaluation of radioimmunoscintigraphy. In-111 antibody, Chelates 3H-cyclofoxy, rat brain, 796(ab) compared to In-111 anti-CEA, 899(ab) bifunctional, radiolabeled antibodies. 8l4(ab) Carbon-14 urea radiolabeling of monoclonal antibodies. influence of denticity, biodistribution. In-111 breath taste, diagnosis of Campylobacter pylori bifunctional chelate. 814(ab) B72.3 immunoconjugates. 824(ab) associated gastritis, 11 recurrent tumors, evaluation. PET, 751(ab) optimization of ligand structure, imaging. breath test tumor targeting of radiolabeled monoclonal bifunctional antibody, 835(ab) Campylobacter pyloridis gastric disorders, antibody, chemical bond modification. potential metabolizable linkers. In-111 789(ab), 790(ab) 889(ab) moonclonal antibody, 922(ab) reproducibility, Campylobaaer pyloridis, unlabeled F(ab')2 fragment, In-111 F(ab')2, sulfur-donating, action. Tc-99m renal agents, 790(ab) biodistribution. 834(ab) 801(ab) Carboxyhemoglobin, correlation with systemic Carcinoma, hepatocellular Tc-99m antibody labeling, NSSand N2S2amide hematocrit, blood volume measurement, C- massive type, application, 1-131 lipiodol, mercaptides. 815(ab) 11 carbon monoxide. 894(ab) 799(ab) Tc-99m complexes Carcinoembryonic antigen (CEA) recurrent. Ga-67 citrate imaging, 712 a,a-disubstituted, or-hydroxy carboxylic acids, circulating antigen levels and molecular size, Te-99m DISIDA, hepatobiliary agent in 934(ab) biodistribution, labeled monoclonal diagnosis. 1916 3 Schiff base/oxime ligands. 936(ab) antibodies. 890(ab) Carcinoma, lung Chemotherapy correlation of radiochemical yield, chelator imaging by Tc-99m monoclonal antibody. how to avoid complications, intrahepatic concentration. In-111 labeled antibody- 834(ab) arterial infusions, 799(ab) chelator conjugates. 924(ab) In-111 monoclonal antibody, imaging and intra-arterial, SPECT evaluation of, 593 1-131-labeled monoclonal antibodies, kinetics, 896(ab) -treated mammary tumor, P-31 NMR IH-MRI radioimmunotherapy, phase III trial. Carcinoma, ovarian, enhanced uptake, study, 837(ab) 846(ab) radiolabeled monoclonal antibody, 900(ab) Chernobyl In-111 anti-CEA, unlabeled F(ab')2 fragment. Carcinoma, pancreatic, imaging with antibodies to I-I31 thyroid uptake, southern Sweden, 1719 colorectal cancer. 834(ab) CEA, 833(ab) plume, biological retention, fission products. In-111 anti-CEA monoclonal antibody ZCE Carcinoma, renal cell, escalating single and 804(ab) 025, detection, colorectal carcinoma, multiple fraction low dose rate, I-I31 travelers after, 1-131 uptake, thyroid, 1152(le) 812(ab) monoclonal antibodies. 875(ab) Cholecystitis, acute, In-111 WBC imaging, false In-111 Fab', compared to In-111 F(ab)'2 Carcinoma, squamous cell, serum TA-4 as marker. positive hepatobiliary scan, 826(ab) derivative, 812(ab) lung and other organs, 765(ab) Cholecystography, DISIDA, prÃ©-and post-CCK In-111-labeled monoclonal antibody Carcinoma, testicular, radioimmunodetection. gallbladder sonography, 826(ab) detection, occult metastatic cancer, 833(ab) human xenograft in athymic mice, 896(ab) Cholescintigraphy, rim sign in, prognostic value, tumor mass as determining factor, Carcinoma, thyroid 16080e) biodistribution. 926(ab) criteria for ablation of normal tissue, after Choletec, newly approved agent, N287 monoclonal antibodies surgery. 885(ab) Cholic acid, In-111-labeled. hepatobiliary imaging cancer imaging, anti-antibody enhancement, medullary. MIBG uptake, animal model, agent. 926(ab) 757(ab) 893(ab) Chromatography effects of uptake, external beam radiation, Tc-99m MIBI and Tl-201 uptake, 854(ab) column, In-111 DTPA protein fractions, 926(ab) value of total body scans, 1-131 therapy, 885(ab) monoclonal antibodies, 925(ab) pancreatic oncofetal antigen and. combined Cardiac output, first-pass radionuclide sizing evaluation, fate of In-111 antibodies, assay, digestive system cancer. 906(ab) determination, gamma camera method. 923(ab) -producing tumors 1154(le) Circulation, portal-systemic, evaluation, TL-201 diagnostic value, immunoscintigraphy, Cardiomyopathy and Tc-99m pertechnetate, 827(ab) 811(ab) detection, animal model, quantitative Cisternography, radionuclide. MRI. normal

Subject Index â€¢1988 2051 Clavicle

pressure hydrocephalus. 836(ab) algorithms, 748(ab) right ventricular ejection fraction, first-pass Clavicle, condensing osteitis, Tc-99m, 1122 compensation for collimator divergence, time-activity curves, 1990 Cobalt-57 bleomycin, delivery to brain tumors, SPECT. maximum likelihood simulation of collimator scatter effects, spatial SPECT. 187 reconstruction, 786(ab) resolution, 845(ab) Cocaine, regional cerebral glucose utilization, constrained least-squares Metz filter, 864(ab) SPECT 3D modulation transfer function, human substance abusers, 840

2052 The Journal of Nuclear Medicine Dosimetry

"false" positive pyrophosphate tomoscintigrams. figure captions switched Dipyridamole 954(ab) residency opening, 577 lung uptake of Tl-201. global left ventricular left bundle branch block with, Tl-201 SPECT, typographical error. 1897(le) dysfunction. 953(ab) 1479 Count rate curves, NEMA scintillation cameras. myocardial perfusion imaging, coronary measurement with 1-125 cholesteryl iopanoate. 538 vasodilation. 781(ab) 503 Creutzfeldt-Jakob disease, differential diagnosis of noninvasive detection of coronary artery myocardial uptake and redistribution, RP-30 non-vascular dementia. SPECT. 743(ab) disease, vasospastic angina, 782(ab) compared to SQ 32014, 8l9(ab) Crohn's disease, assessment of localization and perfusion scintigraphy, coronary event noninvasive detection, vasospastic angina, activity, reliability, Tc-99m HM-PAO- prediction, elderly. 781(ab) 782(ab) labeled leukocytes, 827(ab) regional myocardial blood flow, assessment, N- post-prandial changes in left ventricular Crossmatching, red blood cell compatibility 13 ammonia PET, 838(ab) function, ambulatory nuclear monitoring, testing. In-1 I Iin tropolone RBC. 684 single oral dose, serum drug level following, 742(ab) Cyclofoxy 1662 quantitative methods of myocardial imaging, F-18-labeled PET imaging in man, 796(ab) SPECT Tl-201 perfusion, compared to Tl-201 Tc-99m MIBI, 955(ab) kinetic evaluation in rat brain, 796(ab) exercise SPECT. coronary artery disease, rÃ©gurgitantvalvular disease, angiocardiography. Cycles porine 838(ab) 1114 monitoring, rapid 1-125 radioimmunoassay Tl-201 imaging resting thallium perfusion abnormalities, method. 766(ab) ambulatory ventricular function monitor. coronary stenoses, unstable angina, 768(ab) nephrotoxicity, various renal radioactive agents. chest pain. 742(ab) reversible rest-redistribution thallium-201 1577 complications predictions, non-cardiac defects, unstable angina, 768(ab) Cyclotron, 11 MeV proton model, production. surgery, 838(ab) SQ30217 and Tl-201 planar myocardial other radionuclides, 932(ab) elderly patients. 953(ab) imaging, coronary anatomy comparison. Cytokines, effect of administration on prediction, in-hospital ischemia, 781(ab) 841(ab) biodistribution, radiolabeled murine ST segment depression, myocardium, 782(ab) stress Tl-201 imaging post angioplasty. lymphocytes. 902(ab) Tl-201 tomographic scintigraphy. significance, restenoses, recurrent symptoms, 770(ab) ECG changes. 945(ab) stress Tl-201 myocardial emission assessment. tomographic myocardial perfusion. Tc-99m SQ Kawasaki disease, 791(ab) 30217, 938(ab) Decay, radioactive, energetics of. 1156(le) Tc-99m MIBI and Tl-201 SPECT, 952(ab) Distraction epiphysiolysis, lower limb lengthening. Deconvolution, hepatic blood (low. arterial and Tl-201 SPECT bone healing during. 1259 portal venous components, 466 abnormal clearance, improved assessment, Diuresis Deiodination, comparison of antibody conjugates. 948(ab) iodovinyl, para-iodophenyl, 777(ab) renography acceleration of redistribution, ribose. 953(ab) degree of hydronephrosis. renal function. Dementia blood levels and myocardial reversible defects, 816(ab) AIDS complex fasting or eating, 952(ab) PET-FDG studies, 852(ab) intrapelvic pressure, frusemide. 816(ab) combined with "bullseye" analysis. 756(ab) Dobutamine, thallium imaging, detection, SPECT, 1382 compared to Rb-82 PET, 817(ab) assessment, Xe-133 SPECT, 1621 coronary artery disease. 955(ab) compared to Tc-99m MIBI, 793(ab) asymptomatic HIV seropositive persons, SPECT Donner Laboratory, nuclear medicine innovation. dipyridamole perfusion, compared to exercise, imaging. I-123 isopropyl amphetamine. N431 L-DOPA, use of phenylalanine dehydrogenase for 838(ab) 742(ab) evaluation, pre-renal transplant patients, synthesis, N-13. 931(ab) diamox and HIPDM, 734(ab) 950(ab) Huntington's disease. 1-123 IMP brain imaging. Dopamine, uptake blocker. F-18 GBR 13119. improved detection during exercise, 755(ab) 916(ab) synthesis and brain uptake. 767(ab) patients with LBBB, 279(ab) 1-123 IMP and Tc-99m HM-PAO SPECT Dopamine receptors perfusion studies, delayed 24-hour compared to PET. 916(ab) binding sites in baboon brain, SPECT, 848(ab) D-l redistribution. 769(ab) left hemisphere dysfunction, FDG/PET scans. poor predictive values, inferior wall defects, Alzheimer's disease, 912(ab) I-123-IBZP imaging agent, 758(ab) 944(ab) non-vascular, differential diagnosis. SPECT, radiation dosimetry, SCH 23982, 803(ab) prone vs. supine position, 953(ab) 743(ab) radioiodinated SCH 23982. SPECT. 929(ab) quantitation of, 756(ab) Department of Energy (DOE) D-2 quantitative, community hospital, 943(ab) applicants for research grants. N1760 brain uptake. C-l 1 YM-09151-2, 931(ab) referrals, subsequent coronary angioplasty. appropriation for research in nuclear medicine. dynamic FESP interactions, PET, 865(ab) 946(ab) Ml 167 (ethyl-F-18)fiuororaclopride, PET, 767(ab) results of exercise/rest, 756(ab) workshop, improved availability of research I-I23-IBZM imaging agent, 759(ab) reverse redistribution, 952(ab) isotopes, N1611 imaging by SPECT, 922(ab) unbiased sensitivity, specificity Diabetes kinetic analysis. C-l I raclopride. 820(ab) determinations, 946(ab) autonomie neuropathy, sudden cardiac death in. PET investigation, 3-N-(F-18) wash-in and wash-out, redistribution 1605(le) fluoroethylspiperone. 821(ab) phenomenon, 939(ab) foot, In-111 chloride, 279(ab) quantification by PET. various models. Tl-201 washout, from parametric color coded 1-123 free fatty acid metabolism, ischemie 922(ab) Tourette's syndrome, manic depressive illness, images, 302 myocardium, 842(ab) trapping of I-123 OPPA, myocardium, 851(ab) In-111 chloride imaging in foot. 813(ab) 82(Xab) triple vessel disease, exercise Tl-201 Tc-99m DTPA and 1-125 iothalamate plasma new analogs of radioactive iodobenzamide, scintigraphy, benefit from surgery, 949(ab) clearances. 816(ab) brain imaging agents, 777(ab) utility of septal thallium perfusion pattern, Dialysis, continuous ambulatory peritoneal. Dosimetry discrimination, LAD or PDA disease from utility, Tc-SC intraperitoneal scan, 8l7(ab) absorbed fractions for electrons, beta particles. dual vessel disease, 942(ab) Diamide dilhiolale ligands, stereochemistry of Tc- small spheres, 803(ab) validation of quantitative analysis, execise 99m N2S2complexes, 800(ab) biodistribution of In-111 liposomes, normal thallium tomograms, 871(ab) Diet persons, 873(ab) Corrections effect of caloric content, gastric emptying. biodistribution of Tc-99m MIBI, 874(ab) amendment to author line 751(ab) biological retention of fission products, article corrections by Edward A. Deutsch effect of dietary fiber, gastric emptying, 751(ab) Chernobyl plume. 804(ab) author correction, 1880 labeled chicken liver and egg-white as solid bremsstrahlung. component, Y-90 monoclonal erratum correction, 1879 markers, gastric emptying studies, 752(ab) antibody therapy, 859(ab)

Subject Index Â«1988 2053 DTPA complex

clinical thermoluminescent dosimeter, 872(ab) eating disorder patients. 882(ab) comparisons, CT and MR, 852(ab) extra-articular leakage, radiation synovectomy, non-hormonal therapy, 855(ab) C-l 1 acetate, myocardial oxidative metabolism, dysprosium-165-FHMA, 873(ab) spinal, diagnostic sensitivity, 882(ab) 808(ab) 1-131 monoclonal antibodies precision of, 880(ab) compensation for collimator divergence, estimation, absorbed radiation dose. 900(ab) Dual probe positron detector, duration of SPECT. maximum likelihood fractionation of lym-1, radioimmunotherapy. occupancy of opiate receptors, naltrexone, reconstruction, 786(ab) 847(ab) 1207 design of simulation system. 871(ab) liver and lung tumors, 874(ab) Duodenal bulb, chronic ulcer, scintigraphic study. edge detection, evaluation, various strategies, In-111 oxine, children, 689 17 868(ab) In-111 ZCE-025 anti-CEA monoclonal Fab' Duodenal-gastric reflux, hepatobiliary imaging of. FDG. primary visual cortex hypometaboism. fragments, biodistribution, 896(ab) 17 head injury. 830(ab) internal and external radiation dose, nursing Dysphasia, childhood, Xe-133 brain SPECT F-18 uracil accumulation, liver mÃ©tastases, child, Tl-201 to mother, 874(ab) imaging. 792(ab) 776(ab) method for estimating organ brake radiation Dysprosium-165, activable isotopes of. high resolution PET scanner, double wobbling doses, 875(ab) biodegradeable radiotherapeutic mode, 877(ab) physics protocol for UKCCSG toxicity, 1-131 microspheres, 903(ab) 1-123 free fatty acid metabolism, ischemie MIBG, resistant neuroblastoma, 798(ab) Dysprosium-165 ferric hydroxide myocardium, diabetes, 842(ab) radiation macroaggregates, radiation synovectomy multi-slice brain SPECT, position-sensitive bar absorbed dose of 1-123,1-131, and Tc-99m for, 275(ab) detector system, 760(ab) DTPA, 400 Dysprosium-165-FHMA, extra-articular leakage, optimum Butterworth-Wiener filter, I-123 IMP In-111, human melanoma, 329 radiation synovectomy, 873(ab) brain SPECT, 879(ab) thyroid uptake of 1-131 after Chernobyl, persistent TI-201 defects, significance, metabolic 1152(le) activity, 827(ab) treatment of hepatoma, 1038 position-sensitive bar detector system, multi- Eating disorders, osteoporosis, 882(ab) tumor uptake, as a function of tumor mass. slice brain SPECT, 760(ab) Echocardiography, Doppler techniques and. mathematical model, 103 quantitative bone scintigraphy, 881(ab) 2024(ab) radiation calculations, urinary bladder model, quantitative SPECT, empirical threshold Editorials 875(ab) method, 879(ab) Nuclear hepatology: Where is it heading now?. radioimmunotherapy, patient-specific kinetics regional 1144 and S-values, 2030(ab) correction for brain atrophy effects, PET. radioimmunotherapy for micrometastases, At- Of special note, 125 SPECT of the brain and heartâ€”future 773(ab) 211,858(ab) left ventricular wall motion assessment, bull's directions. 567 radioiodinated SCH 23982, biological eye display, cardiac blood pool SPECT, Education and Research Foundation, student distribution, 803(ab) 745(ab) fellowships, N1338 red marrow, radiolabeled monoclonal antibody reversibility bullseye polar map, myocardial Ejection fraction therapy, sacrum, 858(ab) ischemia, 951(ab) cardiac selection of nuclides, immunoscimigraphy, central circulatory function and. multi-probe selection of tracers and experimental immunotherapy, 875(ab) device, 832(ab) procedures, blood flow and metabolism, theoretical tumor absorbed doses, energy window effects, 385 862(ab) radioimmunotherapy, 858(ab) response to various activities, ischemie heart simple high resolution PET camera detector thermoluminescent, micro. disease patients, VEST. 741(ab) design, 761(ab) stress-induced ischemia. N-13 ammonia, radioimmunotherapy measurement, 1795 cine NMR quantification, aortic rÃ©gurgitation, tissue-equivalent anthropomorphic phantom, 802(ab) coronary bypass surgery. 817(ab) imaging studies, 803(ab) counts-based index. ECG-gated myocardial subcortical metabolic alterations, partial treatment planning, monoclonal antibody perfusion scans, 947(ab) epilepsy. 830(ab) three-dimensional cone beam reconstruction, therapy, 803(ab) in vitro evaluation, computer processing treatment planning for monoclonal antibody algorithms. 862(ab) iterative maximum likelihood method, therapy, quantitative planar imaging, left ventricular 786(ab) anthropomorphic phantom, 845(ab) exercise response, aortic rÃ©gurgitation,744(ab) validation of absolute quantitation, calibration tumor-incorporating mean absorbed dose impaired filling, exercise response, 772(ab) phantom, 871(ab) calculation, 874(ab) inspiratory reduction mechanism, stroke workload and sex-related variability, myocardial DTPA complex, conjugated monoclonal volume :949(ab) fatty acid utilization, normals. 841(ab) antibodies, cellular characterization, measurement, 274(ab) Emphysema hepatocytes, 823(ab) volume calculation, gated radionuclide 1-123 HIPDM Dual-detector probe, surgical tumor staging. 1101 angiography, 745(ab) lung scintigraphy, 905(ab) Dual energy acquisition, correction factors for, quantification of infarcÃ¬size. Tc-99m RP-30A metabolic lung imaging, pulmonary 2028(ab) and SPECT, 946(ab) hypertension, 765(ab) Dual-photon absorptiometry (DPA) right ventricular Endocarditis, bacterial. In I l I leukocyte accuracy, excised femurs, 1853 determination, three scintigraphic methods. scintigraphy, 794(ab) bone density measurements, spine and distal 771(ab) Energy window, cardiac ejection fraction and, 385 forearm, osteoporosis, 131(le) enhanced exercise performance, balloon Epidermal growth factor receptor, glioma bone mineral content valvotomy, 945(ab) radioimmunotherapy, 1-125 monoclonal distribution in skeleton, 881(ab) first-pass time-activity curves, 1990 antibody. 847(ab) lumbar spine, 248 noninvasive method for determination, Epilepsy spine/hip/forearm, primary 2029(ab) children hyperparathyroidism, 855(ab) Electrocardiogram (ECG) gating, gating mode 1-123 iofetamine tomography, 892(ab) bone mineral loss, normal postmenopausal effects, analysis of left ventricular function. interjetai SPECT-HMPAO. 792(ab) women, 881(ab) 1272 surgery, role of PET, 831(ab) frontal and lateral measurements, lumbar spine, Electrolytes, unique non-invasive measurement controlled partial, cerebral blood flow, SPECT, vetebral body strength, 856(ab) method, tissues. 883(ab) 892(ab) hormonal relationship of bone density, Electron microscopy, internal conversion, Tc-99m frontal lobe, F-18 FDG PET scanning, 831(ab) premenopausal women, 859(ab) oxidation state measurement. 789(ab) opiate receptor measurement, C-11 osteoporosis Emission computed tomography diprenorphine and carfentanil. 796(ab) aminobisphosphate treatment, 884(ab) Alzheimer's dementia and normal aging. partial

2054 The Journal of Nuclear Medicine Fluorine-18 GBR 13119

PET compared to MRI, 9lO(ab) myocardium and cardiac cavity, PET, asymptomatic MPTP-lesioned monkeys, subcortical metabolic alterations, 830(ab) 866(ab) 820(ab) registration of MRI-PET images, procedure. dynamic renal studies, urology, s lM.Ihi Fluorine-18 FENP, synthesis and target tissue validation, 853(ab) Fatty acids uptake, breast, 768(ab) seizure disorders, remote hypometabolic effects, C-l 1, synthesis, myocardial, 68 Fluorine-18 FESP, measurement of serotonin S2 92

Subject Index â€¢1988 2055 Fluorine-18 PCP analogs

brain uptake, 767(ab) cell membrane permeability and, 663 quantitative planar imaging, treatment Fluorine-18 PCP analogs, PET study, 767(ab) paramagnetically-labeled low density planning, monoclonal antibody therapy, Fluorine-18 sex hormones, uptake in mammalian lipoproteins, fibrosarcoma, 890(ab) 845(ab) brain, F-18 ligands. PET, 795(ab) pulmonary activity, tobacco smoking, HIV- scatter removal, pre- and post-processing Fluorine-18 uracil, accumulation in liver positive persons, 829(ab) techniques, 798(ab) mÃ©tastases.776(ab) renal hyperactivity, AIDS patients, 909(ab) Tc-99m DTPA clearance, healthy non-smokers, Fluorine-19, NMR spectroscopy, 5-fluoro-2',3'- salmonella costochondritis, 2004 905(ab) dideoxycytidine, AIDS virus, 837(ab) SPECT, chest, 276(ab) Gas, inert. Kr-81 m/Tc-99m MAA ventilation Fluoromisonidazole uptake perfusion ratio, weaning, 764(ab) enhanced binding, hypoxia, myocytes, 807(ab) bilateral breast. 1606(le) Gastric function F-18-labeled, marker, salvageable myocardium, breast, AIDS and, 1607(le) Campylobacter pyloridis, C-14 urea breath test, 807(ab) myocardial, dilated cardiomyopathy, 274(ab) 789(ab), 790(ab) 16-FluoropaImitic acid, labeling of, use, F-18 Gallium-67 citrate emptying fluorotrimethylsilane, 930(ab) biodistribution, tumor stage and metastasis body position, 751(ab) Fluoxetine, C-11-labeled, synthesis of, 932(ab) effects, Lewis lung carcinoma model. 1252 caloric content, 751(ab) Food and Drug Administration (FDA) comparison of planar and SPECT images, chest, dietary fiber, 751(ab) clarification of policies, commentary, N1472 CT in lymphoma patients, 898(ab) distal stomach removal, 752(ab) drugs and biologies in separate centers, N146 detection of intracardiac malignant lymphoma, Garren-Edwards gastric bubble, 857(ab) limiting physician-sponsored INDs, N137 1868 gender-related differences, 573(le) newly approved agents in 1987, N287 diagnosis and follow-up of neuroblastoma, high resolution scintigraphy, 857(ab) Office of Orphan Product Development, funds 750(ab) LAO view, attenuation compensation, underused by nuclear medicine researchers, osteoclast nuclei localization, Paget's disease, 752(ab) NI011 1083 noninvasive determination, antral motility, policies on radiochemicals and PET products, radiation pneumonitis 862(ab) N142 assessment of, lung cancer, 829(ab) small bowel transit and. ileal pouch-anal reclassification of NMR instruments, N592 detection of, lung cancer, 888(ab) anastomosis, 856(ab) software policy proposals, N588 recurrent hepatocellular carcinoma, 712 solid markers, chicken liver and egg white. Foot, surgical radiation probes, 881(ab) response prediction, therapy, diffuse large-cell 752(ab) Fourier mapping, multiharmonic, location of lymphoma, 799(ab) esophageal motility disorders, new parametric onset, ventricular tachycardia, 744(ab) uptake imaging technique, 856(ab) Frusemide benign adrenocortical adenoma, 1451 gastrointestinal transit, 857(ab) diuresis renography breast, patient with hypothalamic granuloma, GI transcan, upper tract motility, 886(ab) degree of hydronephrosis, 816(ab) 118 Tc-99m sulfur colloid sucralfate, ulcer avid intrapelvic pressure, 816(ab) pediatrie AIDS patient, 707 agent, 936(ab) Furosemide, renovascular hypertension, variable presentation of PCP, HIV-positive Gastritis, Campylobacler pylori associated with, C- comparison of radioactive agents, rat persons, 829(ab) 14 urea breath test for, 11 model, 509 Gallium-68 Gastroenteropathy, protein-losing, serial low cost large area positron camera, physical abdominal imaging, In-Ill transferrin, evaluation, 877(ab) 857(ab) Gadolinium-153 macromolecular tracer, vascular permeability. Gastrointestinal tract bone mineral content, dual-photon 939(ab) bleeding Gallium-68 deferoxamine-galactosyl- heparin and, Tc-99m RBC imaging, 725(le) absorptiometry, 248 bone mineral distribution in skeleton, dual- neoglycoalbumin, regional measurement, radionuclide detection and localization. 130(le) Technetium-99m RBC photon absorptiometry, 881(ab) hepatic receptor concentration, 933(ab) Gallium-68 DTPA-LDL, receptor activity with frontal and lateral DPA measurements, lumbar localization of gastrointestinal bleeding. 130(le) spine, vetebral body strength, 856(ab) PET, 848(ab) ultrasonic visualization of tablets. 129(le) Gadolinium-DTPA Gallium-72 nitrate, skeletal radiotherapeutic agent, Gastropathy, primary, scintigraphic study, 17 Gated blood-pool studies gated MRI and, serial assessment, myocardial 776(ab) cardiac and central circulatory function, multi- infarction, 802(ab) Gamma cameras iron compounds as MRI contrast agents, liver, acceptance testing, 267(le) probe device, 832(ab) 837(ab) collimator, new methods of examining, 676 cardiac stressing, esophageal pacing, 942(ab) Gadolinium-153 DTPA determination of weighting coefficients, energy hemodynamic changes, radionuclide comparison with Tc-99m DTPA, weighted acquisition, 845(ab) ventriculograms, cardiac transplant biodistribution, 1683 dual-headed digital, dynamic flow studies, rejection, 742(ab) pharmacokinetic analysis, distribution, dog 272(ab) interactive digital filtering, cine display, 864(ab) blood, 891(ab) estimation of tumor uptake. 1-131 MIBG, 542 mechanism of inspiratory reduction, left Gallbladder, pre- and post-CCK sonography, handheld low power, design considerations. ventricular stroke volume, function, DISIDA cholecystography, 826(ab) 832(ab) 949(ab) Gallium-67 1-123 HIPDM lung scintigraphy, chronic phase image triangulation of accessory accuracy, occult infection, 608 obstructive pulmonary disease. 905(ab) pathways, catheter ablation, posteroseptal detection of infection, delayed/non-union imaging characteristics of MUMPI, cylindrical pathways, 744(ab) fractures, 813(ab) neuro-SPECT system, 832(ab) regional left ventricular wall motion assessment, diagnostic pattern of uptake, lymphocytic multi-probe device, cardiac and central bullseye display, cardiac blood pool interstitial pneumonitis, 887(ab) circulatory function, 832(ab) SPECT, 745(ab) esophageal imaging probe, tumor detection, multiwire regional wall motion abnormalities, left bundle 878(ab) first-pass radionuclide angiography, 293 branch block, quantitative phase analysis, high dose-delayed scintigraphy, sarcoma, high volume clinical applications, 1526 744(ab) compared with CT and MRI, 749(ab) myocardial glucose metabolism, perfusion Gated heart studies HIV+ patients, 281(ab) imaging. F-18 deoxyglucose and Tl-201. ambulatory radionuclide monitoring, left increased delivery to tumors, serum-stable 828(ab) ventricular function, patient outcome, liposomes, 516 performance of high-speed ethemet system, 838(ab) lung index computerization, interstitial image archiving, nuclear medicine, 810(ab) amplitude analysis of Tc-99m RP-30A, pneumonitis, 1154(le) planar, radionuclide content, liver or spleen of coronary artery disease assessment, 805(ab) mechanism of tumor accumulation, 2019(le) abdominal phantom, 845(ab) automatic calculation of LV volumes and EF,

2056 The Journal of Nuclear Medicine Heart

RP-30 tomograms, 805(ab) 920(ab) model, ion-exchange assay, tissue cardiac response to various activities, ischemie utilization and rate constants, partial volume radioactivity, 939(ab) heart disease patients, VEST, 741(ab) effect, ischemie myocardium. 783(ab) gated PET data, rapid generation, blood activity counts-based index, left ventricular "ejection D-Glucose, synthesis, C-11 nitroalkane production, curves, 775(ab) fraction", myocardial perfusion scans, 754(ab) halothane-induced decrease of C-l 1 CGP 947(ab) Glutamate receptors, channel mapping, MK-801 12177, beta adrenoceptor, 940(ab) expert images, cardiac wall motion analogs. 930(ab) 0-hydroxy fatty acids, acylation, "masked" abnormalities, 846(ab) Glutathione malonic ester, 848(ab) gated magnetic resonance, 943(ab) content in brain tumors, Tc-99m HM-PAO imaging, quality control, WHO study of, N440 quantification of infarcÃ¬size, Tc-99m RP-30A uptake, 920(ab) Iniii leukocyte scimigraphy, surgical and SPECT, 946(ab) myocardial detoxification system, assessment. F- complications, bacterial endocarditis, Generators, isotope 18 fluorodinitrobenzene, 808(ab) 794(ab) cerebral and myocardial blood flow tracers, Tc-99m HM-PAO stereoisomer interaction, left ventricular maximum time-varying copper bis(thio-semicarbazones), 848(ab) 1998 elastance, radionuclide angiographie Cu-62 HSA, plasma volume measurement, Granulocytes calculations. 1368 930(ab) In-111-labeled, imaging of infections, 23 left ventricular pressure-volume loops. new tracer Ir-19lm, arterioscintigraphy, 841(ab) novel Tc-99m antibody for targeting, 925(ab) determination in clinical setting, 1492 removal of Ir-192 from reactor-produced Os- Grave's disease, lactating patient, breast milk left ventricular volumes assessment, gated Tc- 191,927(ab) excretion of 1-131,407 99m isonitrile tomography, 771(ab) Tungsten-178/Tantalum-178 system, high low-density lipoprotein biodistribution, 1237 volume clinical applications, 1526 H malignant lymphoma, Ga-67 citrate and Tl-201 Gentisic acid, stabilization of Tc-99m D.L-HM- chloride detection, 1868 HaloperidoL, regional and temporal distribution in PAO, 935(ab) metabolism, assessment with 1-123 HDA, 1088 brain, 767(ab) method for receptor pharmacology, non-linear Glioma 11ulotlune, -induced decrease of C-I I CGP 12177 monoclonal antibody imaging, 897(ab) models, variable radioactivities, 822(ab) binding, myocardial beta adrenoceptor, radioimmunotherapy, 1-125 monoclonal modular scintillation cameras, status and PET, 940(ab) antibody, epidermal growth factor receptor, applications. 760(ab) Hand, reflex sympathetic dystrophy, bone 847(ab) muscarinic acetycholine receptor, hyper- and scanning in, 26 rat transplanted brain tumor model, glucose hypothyroidism, PET, 808(ab) Health Care Financing Administration (111( \ ). transport, 920(ab) myocardial blood flow. N-13 ammonia Medicare coverage for Absorptiometry. therapy-resistant malignant, P-32 therapy, metabolic fate, human blood, 783(ab) N1620 902(ab) myocardial oxidative metabolism, C-l I acetate, Heart Glomenilar nitration rate (GFR) 937(ab) Adriamycin cardiomyopathy. earler detection. measurement with Tc-99m DTPA, plasma myocardial perfusion and wall motion, Tc-99m ventriculography, 949(ab) MIBI vs. Tl-201 perfusion, Chagas' clearance techniques, I I52(le) anatomy, SQ30217 and Tl-201 planar radioisotopic measurement, severe chronic renal myocardial imaging. 841(ab) cardiomyopathy, 950(ab) myocarditis. In-111 antimyosin Fab, 939(ab) failure, 1927 arterial sampling vs. quantitative LV cavity Glomerulonephritis, chronic, renal scintigraphic imaging, PET, 772(ab) new high resolution PET scanner, double test, angiographie data comparison, 907(ab) blood flow, molecular structure of Cu(PTSM), wobbling mode, 877(ab) Glucose 927(ab) new technique for automated edge detection, cerebral blood flow, oxygen metabolism, stroke. blood flow tracers, copper bis(thio- MR images, 865(ab) 852(ab) semicarbazones), 848(ab) NMR spectroscopy, 2030(ab) cerebral utilization, relation to structure, cardiac output, first-pass radionuclide noninvasive delineation of infarcÃ¬size, vessel patency, Tc-99m RP-30A, 819(ab) polydrug abusers, 911(ah) determination, 1154(le) non-neuronal uplake of I-123 MIBG, humans, density of capillaries, stroke, living human changes in myocardial FFA metabolism. brain. 915(ab) exercise, 1-123 HDA, 851(ab) 842(ab) F-18 FDG compared to F-18 FDM, PET, congestive failure onhotopic allograts, detection of rejection with In-1 11 lymphocytes and gamma 772(ab) MIBG myocardial uptake, 841(ab) F-18 2-fluorodeoxyglucose compartmental peripheral hemodynamics and selection of scintigraphy. 1223 model, ion-exchange assay, tissue vasodilators, 451 periloneal fluid radioactivity, 939(ab) V/Q pattern, xenon retention, 905(ab) SPECT inferior attenuation. 941(ab) hexokinase Michaels-Menten kinetics, 773(ab) detection of regional wall abnormalities, factor SPECT Tl-201 imaging in women, 1860 hyperkinetic movement disorders, PET, 839(ab) analysis, biplane contrast angiography, PET studies interaction to hexokinase, 928(ab) 771(ab) acquired input functions for, 241 myocardial metabolism, hypertrophie detection of single vessel disease, quantitative arterial activity concentrations, 941(ab) cardiomyopathy, PET, 828(ab) Tl-201 planar and tomographic imaging. automated quantitative analysis. 867(ab) normal cerebral utilization, amyotrophic lateral 948(ab) three-dimensional display, 530 pharmacokinetic analysis of Gd-153 (DTPA)2, sclerosis, 821(ab) determination of left ventricular mass, cine vs. patterns of regional cerebral metabolism, gated spin NMR imaging. 891(ab) distribution in blood, 891(ab) stimulated/deprived, vegetative subjects, diastolic function, myocardial infarction. 1786 planar Tc-99m isonitrile exercise imaging 839(ab) digital acquisition, radioisotope tomographic detection, coronary artery disease. 804(ab) performance of machine parameters. PET images, 870(ab) new normal database, modified background scanner. 877(ab) effect of metabolic inhibitors, Tc-99m MIBI correction, 804(ab) PET and genetic linkage results, subjects at risk, uptake, 820(ab) prolonged muscle flow physiology, distribution Huntington's disease, 853(ab) effect of nifedipine, myocardial perfusion and behavior, perfusion tracers, 942(ab) PET-FDG studies, AIDS-related dementia. metabolism, systemic sclerosis, 828(ab) protective effect of calcium antagonist, In-111- azidothymidine, 852(ab) ejection fraction, energy window effects, 385 anticardiac myosin antibody, 745(ab) PET studies of motor system, tardive enhanced binding of fluoromisonidazole. protein binding studies. Tc-99m, 62 dyskinesia, 821(ab) hypoxia, myocytes, 807(ab) regional ischemie coronary disease, Tl-201 progressive supranuclear palsy, metabolism, expert images, wall motion abnormalities, imaging, combined with "bullseye" cerebral cortex, 914(ab) 846(ab) analysis, 756(ab) regional cerebral utilization, human substance fatty acid utilization, workload and sex-related regional oxidative metabolism, C-11 acetate, abusers, acute cocaine, 840(ab) variability, SPECT, 841(ab) dynamic PET, 782(ab) transport, transplanted brain tumor model. F-18 2-fluorodeoxyglucose compartmental regional wall motion abnormalities, left bundle

Subject Index â€¢1988 2057 Hematocrit

branch block, quantitative phase analysis, duodenal-gastric reflux, 17 renography, 849(ab) 744(ab) dynamic SPECT. changing radioactivity Hyperthyroidism rÃ©gurgitantvalvular disease, angiocardiography, distribution, 98 postmenopausal woman, 263 1114 false positive, In-111 WBC imaging, acute sensitive TSH assay. 766(ab) rejection, In-111 antimyosin, 1893 cholecystitis, 826(ab) Tl-201 of suppressed thyroid, 1360 right ventricular ejection fraction, first-pass Ga-67 citrate, recurrent hepatocellular Ilypoxemia, utility of Tc-99m DTPA aerosol time-activity curves, 1990 carcinoma, 712 inhalation scans, artificially ventilated SPECT, future directions, 567 non-invasive multiparametric study, liver patients. 764(ab) SPECT image reconstruction, attenuation, physiology, cirrhosis, 791(ab) Hypoxia detector response correction, 870(ab) scintigraphy with deconvolutional analysis, altitude, sympathetic activity index, 1-123 studies with ECATIII, Monte Carlo calculation, diagnosis, liver transplant rejection. 790(ab) MIBG myocardial uptake, 842(ab) spillover corrections, 866(ab) Tc-99m IDA time-activity curves, 623 enhanced binding of fluoromisonidazole, adult Tc-99m DADS-amido-fatty acids, imaging Hepatocytes, uptake of Tc-99m IDAS. 928(ab) rat myocytes. 807(ab) agents, 935(ab) Hepatoma Tc-99m dithiosemicarbazone complex, application of 1-131 lipiodol, 799(ab) condensed ring structure. 934(ab) 1-131 lipiodol, biodistribution via hepatic artery, Tc-99m HEXAMIBI synthesis, 1066 lleum, terminal, high resolution scintigraphy, pharmacokinetics, 934(ab) uptake of positron emitting biomolecules, 857(ab) technetium dioxime complexes, chloro-hydroxy heterotransplants. PET feasibility, 903(ab) Image processing substitution, 800(ab) Herpes simplex, type 1, In-111 monoclonal alternative formulation, Wiener restoration tin-capped vs. boron-capped Tc-99m oxime, antibody binding, 275(ab) filter, 845(ab) constrained least-squares Metz filter, 864(ab) 935(ab) Hevesy Pioneer Award, Seymour S. Kety and determination of weighting coefficients, energy Tl-201, bull's eye program for, 1466(le) Louis Sokoloff, N583 Tl-201 imaging HIDA, compartmental and non-compartmental weighted acquisition, 845(ab) high resolution of F-18 fluorodeoxyglucose, correcting for patient motion, 91 modeling. 862(ab) human brain, 760(ab) elliptical versus circular acquisition, 736(ab) Hip holospectral imaging, scatter correction, energy patient and organ movement in SPECT, 441 arthroplasty. infection detection, 887(ab) information, 864(ab) Tl-201 redistribution, ribose effects, 1943 bladder artifact correction, SPECT evaluation, hypermedia, new method for image analysis, Tl-201 SPECT, intraobserver variability, 780(ab), 868(ab) 863(ab) 944(ab) complicated post-operative prostheses, image spread sheet, manipulation, digital transplant rejection evaluation. In-111 granulocytes, 883(ab) images, 81 l(ab) see also Transplantation porous coated arthroplasty allouait rejection with In-111 lymphocytes, prosthesis, In-111 WBC, 764(ab) MACH as satellite station. 810(ab) optimum filter function, SPECT, 643 20l8(le) three phase bone scan, prosthetic tip, 780(ab) PET camera image quality improvement, early rejection detection, ln-111 monoclonal possibly-infected arthroplasties, evaluation. In- removeable rings, high atomic number antimyosin imaging. 745(ab) 111 leukocytes, 883(ab) material, 877(ab) surgery, deep vein thrombosis. In-111 platelet hemodynamic changes, radionuclide PET resolution nonuniformity. cylindrical imaging. 787(ab) ventriculograms, 742(ab) detectors, panul volume effects, 876(ab) sodium NMR imaging, 802(ab) surgical radiation probes, 881(ab) radioisotope bone images, diagnostic valvular/coronary artery and aortic disease, Holmium-16S, activable isotopes of. consequences, 884(ab) application, cine cardiac MRI. 802(ab) biodegradeable radiotherapeutic restoration of SPECT projections, singular value valvular rÃ©gurgitation,evaluation by factor microsphers, 903(ab) decomposition technique, 749(ab) analysis of first-pass angiography. 159 Holospectral imaging, method for scatter ring-geometry SPECT instrument, brain white blood cell accumulation, reperfusion correction, energy information, 864(ab) imaging, 760(ab) myocardial injury, 954(ab) Human immunodeficiency virus (HIV) scatter removal, pre- and post-processing Hematocrit, correlation with half-life of -positive persons techniques. 798(ab) Ga-67 and In-111 WBC in, 281(ab) carboxyhemoglobin, blood volume suitability of microcomputer systems, numerical measurement, C-11 carbon monoxide, Ga-67 pulmonary activity, tobacco smoking. analysis, medical images. 865(ab) 894(ab) 829(ab) thallium reinjection after delayed imaging, fill- Hematoporphyrin derivative, labeling of, In-111 Huntington's disease in to regions with "fixed" defects, 769(ab) oxine, 927(ab) 1-123 IMP brain imaging, 916(ab) Image reconstruction Hemodialysis, bone calcium and mineral changes, PET and genetic linkage results, subjects at risk, Bayesian reconstruction of SPECT, parallel/fan/ 816(ab) 853(ab) cone beam geometries. 871(ab) Hemodynamics Hyperemia, myocardial oxidative metabolism, C- factors determining noise character, filtered captopril renography, renal artery stenosis, 11 acetate clearance, 937(ab) back-projection SPECT reconstructions, 850(ab) Hyperparathyroidism, primary, bone mineral 870(ab) cerebral, PET, lack of ID for EC/IC bypass, content, spine/hip/forearm, 855(ab) multi-grid maximum likelihood, PET, real data. 831(ab) Hyperplasia, mandibular condyle, bone SPECT. 774(ab) medically-treated cerebral ischemia, prognosis, 780(ab) multiplane SPECT reconstruction, PET, 831(ab) Hypertension compensation, collimator response, 785(ab) patients at risk, SPECT cerebrovascular reserve effects of volume depletion, captopril predicting noise energy, SPECT, 748(ab) measurement, 91 l(ab) renography, 849(ab) Immune complex, formation and clearance, mouse Hemorrhage, subarachnoid, triple mode ejection fraction response to exercise, impaired monoclonal antibody, 758(ab) evaluation, 743(ab) left ventricular filling, 772(ab) Immune response, imaging consequences of Heparin myocardial uptake, 19-iodo-3.3-dimethy-18- human anti-mouse antibody, monoclonal gastrointestinal bleeding. Tc-99m RBC imaging, nonadecenoic acid, verapamil, 843(ab) antibody. 761(ab) 725(le) renovascular ImmunoglobulinG radioimmunoimaging of thrombi, antifibrin and captopril. rat model, 509 ln-111-labeled, compared to Tc-99m WBC, antiplatelet antibodies, 825(ab) captopril renography, 575(le) localizing inflammation, 830(ab) Tl-201 SPECT infarcÃ¬size, myocardial Tc-99m MAG3 clearances, captopril. 849(ab) radiolabeled with In-11 l/Tc-99m/I-125, infarction, 951(ab) sensitivity of renography and renal scintigraphy, compared to albumin, focal sites of Hepatobiliary imaging renal artery stenosis, ACE inhibition, infection. 887(ab) accessory hepatic duct leak, following liver 908(ab) Immunoglobulin M. radioimmunodetection, transplantation, 259 two-kidney/one-clip, saralasin vs. captopril testicular carcinoma xenograft. athymic

2058 The Journal of Nuclear Medicine Indium-111 oxine

mice, 896(ab) patients with ischemie chest pain, 805(ab) evaluation, infected hip arthroplasties. 883(ab) Immunomodulation, I-131 TlOl, chronic Q-wave myocardial infarction Ga-67 and, HIV+ patients, 281(ab) lymphocytic leukemia, 757(ab) comparative imaging, thallium and SPECT, HM-PAO-labeled leukocytes comparison. Tc- ImmunoradiometricTSH assay, clinical 806(ab) 99m-labeled small colloid, osteomyelitis, performance of, 280(ab) size, SPECT, 942(ab) 813(ab) Immunoscintigraphy scintigraphy, prediction, extent of akinesis, importance of whole body studies, diagnostic accuracy, In-111 OC 125 and I-I3I 851(ab) immunosuppressed organ transplantation, OC 125, 81l(ab) uptake specificity, myocardial infarction, 795(ab) diagnostic value, CEA-producing tumors, 746(ab) In-111 in breast milk. I301(le) 811(ab) Indium-Ill antimyosin Fab ischemie myocardium, 1826 effect of circulating antigen, monoclonal myocarditis, 939(ab) localization, noninfected neoplasms, 1921 antibody localization, 762(ab) regional asynergy, myocardial infarction, lung microvascular injury, 657 imaging consequences of human anti-mouse 806(ab) migratory patterns, thymectomized and control antibody, monoclonal antibody, 761(ab) tumor of rhabdomyosarcoma, 791(ab) rats, 83 kinetics and metabolism, labeled monoclonal Indium-Ill antimyosin Fab-DTPA neuropathic foot disease, 1651 photopenic skeletal defect, Paget's disease, 561 antibodies, cellular level, 823(ab) absence of human antimouse antibody native and DTPA conjugated monoclonal response, 851(ab) potential of imaging abscesses. Tc-99m antibodies, cellular characterization, trace metal ion contamination, 923(ab) multilamellar liposomes, 888(ab) hepatocytes, 823(ab) Indium-Ill 9B9, blood clearance, 1951 scintigraphy of heart, surgical complications, selection of nuclides, 875(ab) Indium-Ill benzyl-EDTA monoclonal antibody, bacterial endocarditis, 794(ab) Tc-99m anti-CEA, known and occult colorectal metabolism in mouse liver, 824(ab) specificity of imaging, non-inflammatory soft carcinoma, 834(ab) Indium-Ill bifunctional hapten, pre-targeted tissue lesions, 795(ab) Indium!III) complexes, functionalized immunoscintigraphy, 226 subperiosteal abscess, complicating tetraazamacrocyclic ligands, monoclonal Indium-Ill B72.3 Â¡mmunoconjugates, osteomyelitis, 1871 antibody coupling, 924(ab) biodistribution, influence, chelator value of SPECT, abdominal sepsis, 794(ab) Indium-Ill denticity, 824(ab) Indium-111 liposomes, biodistribution in normal anticardiac myosin antibody, protective effect of Indium-Ill biotin, abscess imaging, streptavidin- persons, 873(ab) calcium antagonist, myocardium, 745(ab) conjugated monoclonal antibodies, 889(ab) Indium-Ill lymphocytes attenuation correction factor, absolute Indium-Ill chelates, optimization of ligand detection of allograft rejection, heart, 2018(le) quantitation, 872(ab) structure, imaging, bifunctional antibody, gamma scintigraphy and. detection of cytotoxicity, mouse testes, 375 835(ab) orthotopic cardiac allograft rejection, 1223 intact vs. fragments, Indium-Ill chloride Indium-111 monoclonal antibodies radioimmunopharmaceuticals, tumor diabetic foot, 279(ab) absence of intrinsically higher tissue uptake. model, 893(ab) imaging in diabetic foot, 813(ab) 924(ab) intracavitary use, 1910 imaging in treated osteomyelitis, 763(ab), anti-CEA ZCE 025, detection, colorectal neutrophil injection, infected wound chambers, 883(ab) carcinoma, 812(ab) 787(ab) Indium-Ill cholic acid, hepatobiliary imaging binding of herpes simplex virus type 1, 275(ab) platelet survival studies, 564 agent, 926(ab) biodistribution differences, 2029(ab) Indium-Ill 9.2.27, anti-melanoma monoclonal Indium-Ill citrate, radiolabeling of monoclonal CITC, protein mass effect, hepatic uptake, antibody, antibody dose effects on, 39 antibodies, bifunctional chelate, 814(ab) 888(ab) Indium-Ill albumin, compared to In-111 non Indium-111 DTPA detection of occult mÃ©tastases.893(ab) specific IgG, other radiolabels, focal sites of imaging of localized bacterial infections, non effect of radiolabeling method, retention, infection, 887(ab) specific antibody fragments, 887(ab) cultured cells, 901(ab) Mulinili 111 antibodies, sizing Chromatographie new approaches to radiosensitization, hypoxic imaging and kinetics, lung carcinoma. 896(ab) evaluation, 923(ab) tumor cells, 873(ab) internally-labeled, biodistribution, 889(ab) Indium-111 antibody-chelator conjugates, separation of protein fractions, column interstially administered, lymphoscintigraphy, correlation of radiochemical yield, chelator chromatography, monoclonal antibodies. I303(le) concentration, 924(ab) 925(ab) kinetics and metabolism, cellular level, 823(ab) Indium-Ill anti-CEA thrombus imaging, radiolabeled Fab' fragments. localization of colorectal carcinoma, 898(ab) compared to In-111 antibody, 940

Subject Index â€¢1988 2059 Indium-111 plastic particles

administration, biodistribution effect. Interleukin 2 early and late SPECT, value and limitation, 902(ab) biodistribution of 1-131 monoclonal antibody. cerebrovascular disease, 844(ab) Indium-111 plastic particles, gastrointestinal 897(ab) in vivo chemistry of, 122 transit, 857(ab) effect on biodistribution, I-131 monoclonal malignant melanoma detection, 1200 Indium-Ill platelets antibody, 901(ab) ocular melanoma. 1448 accuracy of imaging, deep vein thrombosis, hip Intraperitoneal disease, alpha-emitting redistribution patterns, prediction, successful surgery, 787(ab) radiocolloid treatment, 858(ab) revascularization, 844(ab) diagnosis of deep venous thrombophlebitis. Investigational new drug exemptions (I\lK). regional cerebral perfusion, quantitative SPECT 1169 physician-sponsored, FDA limiting of, imaging, improved method, 869(ab) natural history of platelet aggregation, N137 SPECT endothelial injury, angiography, 948(ab) Iodine-122HIPDM assessment, perfusion reserve in CVD, survival and sequestration, patients with cerebral blood flow agent for PET, validation of, 918(ab) neoplasms. 787(ab) 916(ab) blood flow and redistribution, ischemie CVD. Indium-111 porphyrin, tumor imaging. 900(ab) CO2 reactivity, blood flow tracer. PET study, 918(ab) Indium-Ill transferrin 773(ab) clinical application, brain death and coma, macromolecular tracer, vascular permeability, Iodinc-123 917(ab) 939(ab) absorbed fractions for electrons, beta particles, evaluation, major psychosis. 921(ab) serial abdominal imaging, protein-losing small spheres, 803(ab) meningioma. 1627 gastroenteropathy, 857(ab) factors related to parathyroid imaging. 860(ab) Tc-99m HM-PAO SPECT and, compared to Indium-l 11 tropolonate, Tc-99m HM-PAO and. free fatty acid metabolism, ischemie PET, dementia, 916(ab) kinetics of leukocytes labeled with, 1246 myocardium, diabetes, 842(ab) Iodine-123 IMT, brain SPECT, 91 l(ab) Indium-Ill tropolone, migratory patterns, 0-hydroxy fatty acids, acylation. "masked" Iodine-123 iofetamine, tomography in pediatrie thymectomized and control rats, 83 malonic ester, 848(ab) patients, epilepsy, 892(ab) Indium-Ill white blood cells I-124 contamination of, second dose calibrator, Iodine-123IPPA accumulation, reperfusion myocardial injury, 1302(le) preserved uptake, reperfused myocardium. 954(ab) SPECT, thyroid, multinodular goiter, 110 842(ab) closed system, 733(ab) Tc-99m and, comparative imaging, thyroid SPECT imaging, asymptomatic HIV detection of infection nodules, 753(ab) seropositive persons, 742(ab) delayed/non-union fractures, 813(ab) Iodine-123 AMT, cerebral amino acid transport workload and sex-related variability, fatty acid hip arthroplasty, 887(ab) studies, 778(ab) utilization, SPECT, 841(ab) detection of osteomyelitis, complicated by a pre Iodine-123 BGA, glucose derivative, interaction to Iodine-123 ISP, SPECT, dopamine D-2 receptor existing condition, 1015 hexokinase. 928(ab) imaging, 922(ab) evaluation of localization, non-infected surgery Iodine-123 estradici. ER-positive breast cancer Iodine-123 LDL, Tc-99m LDL and. human site, 788(ab) detection, 853(ab) biodistribution. 803(ab) false positive in simple fracture, 571(le) Iodine-123 HDA Iodine-123MIBG identification of acute cholecystitis, false assessment of myocardial metabolism, fatty comparative SPECT and Tl-201 cardiac positive hepatobiliary scan, 826(ab) acid oxidation effects, 1088 imaging, myocardial infarction, 840(ab) imaging following porous coated hip changes in myocardial FFA metabolism, peak myocardial uptake arthroplasty, study, prosthetic tip, 764(ab) exercise. 851(ab) congestive heart failure, 841(ab) osteomyelitis evaluation. 813(ab) lmlini-12.1 IIII'll.M sympathetic activity index, altitude hypoxia, quantification of PMN granulocyte infiltration, brain SPECT, carotid artery occlusion, 913(ab) 842(ab) gore-lex graft, abdominal aorta, 794(ab) clinical evaluation, pancreas scintigraphy, non-neuronal cardiac uptake, humans, 842(ab) scintigraphy, febrile ICU patient, 795(ab) 826

2060 The Journal of Nuclear Medicine Kidney

Indine-125 cholesteryl iopanoate, measuring thyroid uptake, after Chernobyl, 1152(le) lymphoma, retreatment following atherosclerosis. 503 T101 in patients with chronic lymphocytic plasmapheresis, 174 Iodine-125 DHTP, mapping central noradrenergic leukemia, cellular immunomodulation, Iodine-131 NP-59 innervation, 777(ab) 757(ab) compensatory functional increase in uptake, Iodine-125 HEAT, radioiodinated, binding in rat total body scan after, thyroid carcinoma, adrenalectomy, 859(ab) brain, 356 279(ab) scintigraphy. accuracy and utility, disease Iodine-125 HIPDM, uptake, brain, hypercapnia. uptake diagnosis. 859(ab) 1675 from Chernobyl, southern Sweden, 1719 Iodine-131 OIH Iodine-125 iodocyanopindolol, receptor inflammatory lung disease. 701 absorbed radiation dose, 400 pharmacology, non-linear models, variable value of total body scans, thyroid carcinoma. clearance, comparison with Tc-99m MAGj, radioactivities, 822(ab) 885(ab) 1878(le) Iodine-125 iothalamate Iodine-131 anti-CEA clearance and biodistribution, altered clearance and biodistribution, altered enhancement of tumor imaging and therapy, physiologic state effects, 669 physiologic state effects, 669 administration, second antibody, 890(ab) compared to Tc-99m MAG3 kit formulations, plasma clearances, Tc-99m DTPA, diabetic ladini mmunotherapy 909(ab) patients, 816(ab) colon carcinoma multiceli spheroids. 858(ab) evaluation of Tc-99m D-MAGAG Iodine-125 II'M, radiolabeled monoclonal phase I/II trial, 846(ab) diastereomers, primates, 909(ab) antibodies, compared to 1-125 ICI labeling, Iodine-131 ethiodol, dosimetry. treatment of probenecid inhibition of uptake, kidney, tumor uptake, 836(ab) hepatoma, 1038 908(ab) Iodine-125 MilÂ«,, compared to H-3 NE uptake Iodine-131 fibronectin, atherosclerotic lesion and Tc-99m MAGj comparison, patients with renal and release, different brain regions, 91 l(ab) thrombus, 1264 disorders, 147 Iodine-125 monoclonal antibodies Iodine-131 heptadecanoic acid, time-activity Iodine-131 OPPA and PPPA, metabolism in absence of intrinsically higher tissue uptake, In- curves, myocardium, 1934 heart, 938(ab) lll,924(ab) Iodine-131 hippuran Iodine-131 PPPA, metabolism in heart, 938(ab) effect of radiolabeling method, retention, compared to Tc-99m MAG3, dual channel lodo-antipyrine, lung water measurements. cultured cells, 901(ab) technique. 908(ab) 275(ab) epidermal growth factor receptor, glioma effect of saralasin vs. captopril renography. two- 3-Iodopropyl trillate, compared to 3-bromopropyl radioimmunotherapy, 847(ab) kidney/one-clip hypertension. 849(ab) triflate, F-18 radiolabeling. secondary fibrin, uptake by mouse cancer, coagulative measurement of differential renal function, amines, 754(ab) properties, 899(ab) 134(le) lodovinyl antibody conjugate, compared with pai a- Fisher immunotype 1 Pseudomonas aeruginosa Iodine-131 lipiodol iodophenyl conjugate, in vim deiodination, infection, 651 biodistribution via hepatic artery, liver cancer, 777(ab) influence of antibody catabolism, shed antigen, 1066 Iridium-1 Vim. new tracer for arterioscintigraphy. 823(ab) massive type hepatocellular carcinoma, 799(ab) 841(ab) internalization of monoclonal 3G5-IgM, Iodine-131 lun-l. successful radioimmunotherapy, Iron, evaluation as MRI contrast agents, liver, 923(ab) lymphoma, 847(ab) 837(ab) internally-labeled, biodistribution, 889(ab) Iodine-131 MIBG Iron-59, macromolecular tracer, vascular pharmacokinetics. intraperitoneal injection adrenal medullary imaging, methodology and permeability, 939(ab) volume, protein dose, 889(ab) dosimetry, 1638 Isopropyliodoamphelamine, SPECT, comparison, quantitative autoradiography, tumor antigen diagnosis and follow-up of neuroblastoma, O-I5 water cerebral blood flow. 747(ab) concentration, tissue sections, 897(ab) 750(ab) Isotopes, research, DOE workshop on availability, radioimmunoscintigraphy, colon cancer, 1022 1-131 3F8 and. neuroblastoma imaging. 846(ab) NI611 recombinant human-mouse chimeric mAb, nonsecreting paraganglioma mÃ©tastases.2008 K immunoreactivity. lymphocytic leukemia. physics protocol for UKCCSG toxicity, resistant Kawasaki disease, assessment, stress Tl-201 myo- 890(ab) neuroblastoma, 798(ab) cardial emission tomography, 791(ab) Iodine-125 nucleoside, synthesis and side effects, neural crest tumors. 798(ab) Sipple's syndrome, with liver tumors, 1130 Kidney biodistribution. 929(ab) accuracy of Tc-99m DMSA renal cortical scintig Iodine-125 SCH-23982, mapping cerebral thyroid medullary carcinoma, 33 raphy, pyelonephritis, 778(ab) dopamine D-l receptors, 929(ab) tumor uptake, gamma camera estimation of, action of Tc-99m renal agents, sulfur-donating Iodine-131 542 chelates, 801(ab) absorbed fractions for electrons, beta particles, Iodine-131 monoclonal antibodies blood flow, noninvasive assessment, temporal de- small spheres, 803(ab) astatine labeling, /V-succinimidyl-S-ftri-n- convolution, 862(ab) attenuation correction factor, absolute butylstannyl)benzoate. 835(ab) captopril renography quantitation, 872(ab) B-cell lymphoma treatment, 757(ab) effects, volume depletion. 849(ab) breast milk excretion, lactating patient. 407 effect of interleukin-2 on biodistribution. renal artery stenosis, 850(ab) rulli niatni perturbation of image, renal plasma 897(ab) chronic failure, hemodialysis, effects on bone flow measurements, 909(ab) biodistribution. 901(ab) mineral, 277(ab) enhanced uptake of OC 125 (Fab')2, ovarian criteria for ablation of normal thyroid tissue. chronic glomeruloncphritis. renal scintigraphic surgery, thyroid cancer, 885(ab) carcinoma, 900(ab) test, angiographie data comparison, 907(ab) external exposure rates, guidelines, resuming escalating single and multiple fraction low dose collimator perturbation of image, renal plasma close contact, 873(ab) rate, renal cell carcinoma. 875(ab) flow measurements, 909(ab) intracavitary use, 1910 estimation of absorbed radiation dose, tumor disorders. Tc-99m MAGj, I-123 and 1-131 OIH location of ovarian dysfunction. 1644 and major organs, 900(ab) comparison. 147 meta vs. para substituted /V-succinimidyl stannyl imaging of colon cancer, 833(ab) diuresis renography benzoates, utility, antibody labeling, imaging of gliomas, 897(ab) degree of hydronephrosis, 816(ab) 834(ab) kinetics and metabolism, cellular level. 823(ab) intrapelvic pressure, frusemide, 816(ab) mortality in well-differentiated thyroid cancer, OC 125, diagnostic accuracy, diuretic scan, urinary tract obstruction, 133(le) 753(ab) immunoscintigraphy, 81 l(ab) extracellular fluid volume, Tc-99m DTPA, 255 parotid oncocytoma, 1126 organ and tumor dosimetry, liver and lung factor analysis, dynamic renal studies, urology. rationale for Tl thyroglobulin screening, tumors, 874(ab) 816(ab) 753(ab) pharmacokinetics, intraperitoneal injection failure reduction in radioantibody-induced volume, protein dose, 889(ab) severe chronic, glomerular filtration rate in. myelosuppression. recombinant radioimmunoscintigraphy. colon cancer, 1022 1927 interleukin-1, 758(ab) radioimmunotherapy of cutaneous T-cell Tc-99m MAG, kit formulation, 616

Subject Index â€¢1988 2061 Kinetic models

first-pass tracer fractionation, blood (low, 907(ab) spectroscopy, 890(ab) compartmental and non-compartmental model function Krypton-Sim ing, HIDA studies, 862(ab) after extracorporeal shock-wave lithotripsy, Tc-99m MAA ventilation perfusion ratio, inert diagnosis of transplant rejection, scintigraphy, radionuclide evaluation, 906(ab) gas and, weaning. 764(ab) deconvolutional analysis, 790(ab) quantitation of, 2024(ab) texture analysis of lung scans, 86 l(ab) digital acquisition, radioisotope tomographic im quantitation with Tc-99m MAG3, 1931 ages, 870(ab) Ga-67 renal hyperactivity, AIDS patients, fatty, focally abnormal sonograms, scintigraphy 909(ab) in, 1050 Goldblatt hypertension, captopril renography, LÃ¡clate,changes in myocardial FFA metabolism, hepatobiliary diseases, Tc-99m IDA time-activity 1-123 HDA, 851(ab) 575(le) curves, 623 handling of Tc-99m DMSA, 778(ab) Lactation, breast milk excretion of I-131, patient with Grave's disease, 407 hepatoma, dosimetry of 1-131 Ethiodol, 1038 1-123 hippurate and Tc-99m DTPA renography, hepatoma heterotransplants, uptake of positron Lactoperoxidase, radioidinated tyramine-cellobiose Tc-99m DMSA renal scintigraphy, renal ar emitting biomolecules, 903(ab) tery stenosis with ACE inhibition, 908(ab) labeling, monoclonal antibodies, 835(ab) 1-131 lipiodol, biodistribution via hepatic artery, Lead-203, new antibody label, radioimmunoimag- mean parenchymal transit time, detection, renal cancer patients. 1066 artery stenosis, 850(ab) ing, 924(ab) In-111 benzyl-EDTA monoclonal antibody, me measurement of differential function, 134Levothyroxine, effect of post dose sampling time. regional measurement of receptor concentration, Ga-68 deferoxamine-galactosyl-neoglycoal- urinary pH effect. 906(ab) thyroid function indices, 753(ab) Tc-99m MP-600, 735(ab) Ligands bumin, 933(ab) Tl-201 imaging, stress cardiac evaluation, 910(ab) F-18. uptake of sex hormones, mammalian brain, Tc-99m galactosyl-neoglycoalbumin, kinetic sen transplants 795(ab) sitivity, 936(ab) see also Transplantation Tc-99m, synthesis, biodistribution, 788(ab) Tc-99m IDAS, hepatocyte uptake, 928(ab) perfusion after, quantitative measurement of, Lipoproteins Tc-99m NGA test of functional mass. 790(ab) 1656 low density, biodistribution, 1237 Tc-99m sulfur colloid, spleen size, planar and pregnancy and, renal scans in, 1364 paramagnetically-labeled low density, Ga-67. fi transaxial SPECT images, 870(ab) pre-surgical evaluation, Tl-201 cardiac SPECT, brosarcoma, 890(ab) Tc-99m sulfur colloid uptake, microautoradi- 95

2062 The Journal of Nuclear Medicine Monoclonal antibodies

cancer allogenic, Tc-99m MAA, control of allograft re occult, detection of, In-111 monoclonal anti evaluation, TI-201 SPECT, 895(ab) jection. 757(ab) bodies, 833(ab), 893(ab) In-Ill anti-CEA imaging, subtraction tech In-Ill oxine-labeled. cytokine administration, prostate cancer, Sr-89 for palliation, wide field niques, 899(ab) biodistribution effect, 902(ab) radiotherapy. 775(ab) diagnosis of acute pulmonary embolism, angiog- radiolabeled murine, cytokine administration, radioimmunodetection. malignant melanoma. raphy methods, 824(ab) biodistribution effect, 902(ab) 896(ab) emphysema Lymphoid cell malignancy, In-ll4m lymphocyte therapy of osseous mÃ©tastases,marrow toxicity, 1-123 HIPDM lung scintigraphy, emphysema, behavior. 485 Sr-89, 776(ab) 905(ab) I.ymphoma thyroid cancer 1-123 HIPDM metabolic lung imaging, pulmo comparison of GA-67 planar and SPECT images, lung. Tl-201 scans, 895(ab) nary hypertensin, 765(ab) chest, CT, 898(ab) Tl-201 SPECT. 804(ab) increased Ga-67 activity, tobacco smoking, HIV- cutaneous T-cell, radiotherapy using 1-131 mon 3-JC-l l|Metho\ybenzodiazepines, new radioligands positive persons, 829(ab) oclonal antibody, 174 for PET studies, benzodiazepine receptors, increased Tl-201 uptake during exercise, size of diffuse large-cell, Ga-67 citrate therapy, response 755(ab) perfusion deficit, 943(ab) prediction, 799(ab) /V-Meth)l-D-aspartate receptors, iV-(3-F-18 fluoro- initial experience with Technegas, 7G5(ab) non-Hodgkin's, C-ll thymidine uptake, PET, propyl)MK-801,932(ab) interstitial pneumonitis, Ga-67 lung index com 1633 a-Methyl-L-tryptophan, C-ll. synthesis, 370 puterization, 1154(le) Lymphoma, B cell Metz filter, image-dependent, nuclear medicine im Lewis carcinoma model, biodistribution of Ga- localization of transplants, monoclonal anti-B ages, 1980 67 citrate in, 1252 cell antibodies, 899(ab) MIBG, mechanism of uptake in animal model. lymphocytic interstitial pneumonitis, diagnostic successful radioimmunotherapy, I-13I lym-1 medullary thyroid carcinoma, 893(ab) pattern, Ga-67 uptake. 887(ab) monoclonal antibody, 847(ab) Microautoradiography, Tc-99m sulfur colloid up mÃ©tastases treatment, 1-131 murine monoclonal antibodies. take, liver. 1118 differentiated thyroid carcinoma. 1-131 and, 757(ab) Microwave, no-carrier-added synthesis, bromine-77 1790 Lymphoscintigraphy bromospiperone, 776(ab) thyroid carcinoma. 1-131 uptake and, 701 interstially administered In-111 monoclonal anti Migratory patterns, In-Ill leukocytes, thymecto- metastatic large cell carcinoma, Tc-99m MDP bodies, 1303(le) mized and control rats, 83 uptake, 726(le) mammary, Tc-99m antimony colloid, 1744(le) Milk, internal and external radiation dose, nursing microvascular injury, In-Ill leukocytes for de measurement of angle, slant hole collimator, child, Tl-201-exposed mother, 874(ab) tection, 657 1745(le) Misonidazole, new approaches to radiosensitiza- normal perfusion scan, clinical validity, pulmo radionuclide. localization of internal mammary tion. hypoxic tumor cells, 873(ab) nary embolism, 824(ab) lymph nodes. 473 Mitral valvotomy, enhanced right ventricular exer organ and tumor dosimetry, 1131 monoclonal Tc-99m SbSc. cutaneous malignant melanoma, cise performance. 945(ab) antibodies, 874(ab) 893(ab) MK-801 analogs perfusion scanning, diffusing capacity and, 1268 Tc-99m sulfur colloid, surgical management, mapping of glutamate receptor channels, 930(ab) radiation pneumonitis melanoma, 854(ab) A43-F-18 fiuoropropyl)MK-801. NMDA recep cancer. Ga-67 citrate scans, 829(ab) tors, 932(ab) detection of. Ga-67 citrate scans, 888(ab) M Molybdenum-99 early diagnosis, permeability, 894(ab) Magnetic resonance imaging: See Nuclear magnetic enriched uranium embargo risked supply, N1003 radioisotopic lobectomey, P-32 resin micro- resonance radiopharmaceuticals contaminated with, 695 spheres, 799(ab) Mammary tumor, chemotherapy-treated, P-31 Monoclonal antibodies Radon reduction, cost-effectiveness, 268(le) NMR and IH-MRI study, 837(ab) 19-24, improved sarcoma imaging and reduced regional ventilation, compartmental modeling, Mandible, hyperplasia. bone SPECT. 780(ab) hepatic activity, 1810 861(ab) Manic-depressive illness, Tourette's syndrome and. absorbed fractions for electrons, beta particles. scans, texture analysis, 861(ab) D-2 dopamine receptors. 820(ab) small spheres, 803(ab) squamous cell carcinoma, serum TA-4 as marker, anti-antibody enhancement of cancer imaging. Medicare, coverage for absorptiometry. HFCA, 765(ab) N1620 757(ab) anti-B cell, localization, human B-lymphoma Tc-99m carbon particles, ventilation scanning, Melanoma 765(ab) cutaneous malignant transplants, 899(ab) Tc-99m DTPA aerosol In-Ill 9.2.27 anti-melanoma monoclonal anti anti-CEA, presurgical screening, colorectal carci position effect, ventilation scintigraphy, body, antibody dose effects on, 39 noma. 897(ab) 764(ab) malignant antifibrin towards normal values for clearance, 904(ab) 1-123 IMP detection, 1200 detection, pulmonary emboli and venous Tc-99m DTPA clearance, gamma camera, non- imaging studies, C-l 1 AIB. 904(ab) thrombi, 905(ab) smokers, 905(ab) radioimmunodetection. 896(ab) detection, venous thrombosis, 825(ab) Tc-99m HEXAMIBI synthesis, pharmacokinet- metastatic. detection of, Tc-99m monoclonal Tc-99m imaging, venous thrombi, 745(ab) ics, 934(ab) antibodies, 897(ab) antifibrin and antiplatelet. radioimmunoimag- Tc-99m MIBI uptake, extent of coronary artery ocular, 1-123 IMP visualization of. 1448 ing, pulmonary emboli. 825(ab) disease, 952(ab) ocular radioimmunoscintigraphy, 1031 anti-melanoma, In-111 9.2.27, antibody dose ef thyroid cancer mÃ©tastases,quantitative analysis, Tc-99m SbSC lymphoscintigraphy, 893(ab) fects on. 39 Tl-201 scans, 895(ab) surgical management, 854(ab) antimyosin radiolabeled fragments, tumor imag Tl-201 uptake, dipyridamole. global left ventric Meningioma, I-123 SPECT, 1627 ing, rhabdomyosarcoma. 791(ab) ular dysfunction. 953(ab) Metaiodobenzylguanidine, expanding role of, 1457 B72.3 and B6.2. antibody catabolism. human tumor uptake, two dose levels, In-111 anti-CEA Metal-induced artifacts, MRI and, 279(ab) tumors. 823(ab) monoclonal antibody, 825(ab) Metals comparison of antibody conjugates, iodovinyl, water measurements, iodo-antipyrine, 275(ab) catalytic effect, radioiodination. W-isopropyl-p- para-iodophenyl, 777(ab) Xe-133 retention, V/Q pattern, congestive heart iodoamphetamine, 929(ab) correlation of m vivodistribution, tissue sampling failure, 905(ab) trace ion contamination, In-111 antimyosin Fab- in viiro, metastatic colon carcinoma, 901(ab) Lymph nodes DTPA, 923(ab) Cu-67, cancer therapy, 217 detection of tumor involvement, F-18 FDG, Metastasis direct radiorhenium labeling, model studies, 904(ab) disseminated skeletal, SM-153 EDTMP therapy 847(ab) mammary, measurement of angle in slant hole dosimetry, SPECT, 762(ab) distinct routes of administration, radioimmunod collimator, 1745(le) lung carcinoma, In-1 II monoclonal antibody, etection of tumor deposits, 761(ab) Lymphocytes imaging and kinetics, 896(ab) examination of classes and fragments, absorp-

Subject Index â€¢1988 2063 Moynihan's disease

lion, peritoneal cavity, 900(ab) radioimmunodetection, testicular carcinoma skeletal. N-13 glutamine transport, cancer cach- fibrin, uptake by mouse cancer, coagulative prop xenograft, athymic mice, 896(ab) exia, 902(ab) erties, 899(ab) radioimmunopharmaceuticals, intact vs. frag M>Â«cardinicells, Tl-201 chloride and Tc-99m human anti-mouse antibody ments, tumor models. 893(ab) MIBI uptake and release, 48 imaging consequences, 761(ab) radioiodinated tyramine-cellobiose labeling, Myocardial infarction radioimmunotherapy clinical trial, 761(ab) compared to lactoperoxidase, 835(ab) absence of human antimouse antibody response, response absence, antimyosin Fab-DTPA, radiolabeled antimyosin Fab-DTPA monoclonal anti 851(ab) bifunctional chelate, 814(ab) body, 851(ab) IgM, distribution in murine models, 1688 enhanced uptake, ovarian carcinoma, 900(ab) accumulation of polymorphonuclear leukocytes, I-131-labeled intraperitoneal administration, colon cancer. 1826 anti-CEA and anti-AFP, radioimmunotherapy, 762(ab) accumulation of white blood cells, reperfusion 846(ab) red marrow dosimetry, 858(ab) myocardial injury, 954(ab) B-cell lymphoma treatment, 757(ab) tumor accumulation of, bone, 235 acute coronary reperfusion, reverse redistribu biodistribution, interleukin-2 effect, 897(ab) tumor targeting, chemical bond modification. tion, poor early prognosis. 948(ab) escalating single fraction low dose rate, renal 889(ab) acute Q-wave infarcÃ¬size, In-111 antimyosin cell carcinoma, 875(ab) radiolabeled with IPM, compared to 1-125 ICI SPECT, 942(ab) 3F8 and MIBG, neuroblastoma imaging, labeling, tumor uptake, 836(ab) ambulatory radionuclide monitoring, left ventric 846(ab) recognition of CA125, in vilro and in vivo use, ular function, patient outcome. 838(ab) interleukin-2 effect, biodistribution, 90l(ab) 766(ab) apical, electrocardiographic correlation, 2029(ab) organ and tumor dosimetry, lung and liver, recombinant human-mouse chimeric, immuno- "black hole" sign of left ventricular aneurysm, 874(ab) reactivity, lymphocytic leukemia, 890(ab) Tl-201 SPECT images, 756(ab) radioimmunotherapy, chronic lymphocytic reduction in radioantibody-induced myelo- comparative SPECT imaging, thallium and anti leukemia, 901(ab) suppression, recombinant interleukin-1. myosin, acute Q-wave, 806(ab) radioimmunotherapy of cutaneous T-cell lym 758(ab) complications predictions of non-cardiac surgery, phoma with, 174 selective radiolabeling, neutrophils, 1817 dipyridamole thallium tomography, 838(ab) imaging of gliomas, 897(ab) sensitive TSH assay, 766(ab) defect size, TL-201 SPECT measurement, 1486 imaging with Tc-99m separation of In-111 DTPA protein fractions, diastolic function in, 1786 lung and colon carcinoma. 834(ab) column chromatography. 925(ab) differentiation from ischemia, Tl-201 bullseye tumor xenografts, carbohydrate residue label, Sm-153, production, radioimmunoconjugates, display, 938(ab) 815(ab) 815(ab) exercise Tl-201 scintigraphy, assessment of prog In(III)complexes, functionalized tetraazamacro- streptavidin-conjugated, abscess imaging, In-111 nosis, 951(ab) cyclic ligands, 924(ab) biotin, 889(ab) "false" positive pyrophosphate tomoscintigrams, In-111 and 1-131, thrombus imaging, 1212 Tc-99m and In-111 labeled antifibrin antibodies, 954(ab) In-111 anti-CEA thrombus model, 746(ab) glucose metabolism and perfusion imaging, is two dose levels, lung tumor uptake, 825(ab) Tc-99m anti-CEA. known and occult colorectal chemia detection, planar scintigraphy, unlabeled F(ab')2 fragment, colorectal cancer, carcinoma, 834(ab) 828(ab) 834(ab) Tc-99m antiplatelet, diagonsis, mesenteric 1-123 MIBG SPECT compared to Tl-201 cardiac In-111 antifibrin, imaging venous thrombi, thrombosis, 886(ab) imaging, 840(ab) 806(ab) Tc-99m anti-SSEA-1 as tracer, human neutro In-111 antimyosin Fab scintigraphy, regional In-Ill bifunctional hapten, pre-targeted immu- phils, 788(ab) asynergy, 806(ab) noscintigraphy. 226 Tc-99m-labeled, detection, metastatic mela inferior left ventricle, right ventricular involve In-Ill CITC, protein mass, hepatic uptake, noma, 897(ab) ment, antimyosin. 806(ab) 888(ab) tissue biodistribution, tumor mass, determining intravenous dipyridamole-Tl-201 imaging, pre In-Ill fab, studies using serum from patients, factor, 926(ab) diction, in-hospital ischemia, 781(ab) 895(ab) treatment planning for therapy left ventricular function, gated planar Tc-99m In-111 -labeled, subcellular kinetics, liver. 812(ab) 3D dosimetry, 803(ab) RP-30. contraction fraction, 818(ab) In-Ill OC 125, biodistribution, ovarian cancer, quantitative planar imaging, anthropomorphic noninvasive delineation of size, vessel patency, 847(ab) phantom, 845(ab) Tc-99m RP-30A, 819(ab) internally-labeled, biodistribution. 889(ab) uptake of radiolabel in liver cells, F(ab')2 frag non-invasive detection of reperfusion, Tl-201/ labeled ment, 823(ab) Tc-99m PPI uptake pattern, 949(ab) biodistribution, antigen levels and molecular Y-90 patients with ischemie chest pain, antimyosin size, 890(ab) therapy, bremsstrahlung dosimetry, 859(ab) imaging, 805(ab) kinetics and metabolism, cellular level, 823(ab) therapy, human cancer xenografts, 901(ab) post-, PET evaluation, F-18 uptake. 783(ab) labeling with iodine and astatine, A'-succinimidyl- Moynihan's disease, duodenal-gastric reflux in, posterolateral, Tl-201 SPECT, 954(ab) 3-(tri-n-butylstannyl)benzoate, 835(ab) scintigraphic study, 17 prediction of extent of akinesis, acute antimyosin localization, effect, circulating antigen, 762(ab) Mucin, -like carcinoma-associated antigen, moni scintigraphy, 851(ab) method of labeling, effect on retention, cultured toring, breast cancer patients. 894(ab) predictive value, thallium SPECT, 770(ab) cells. 901(ab) Muscarinic receptors regional oxidative metabolism, PET, C-11 ace mixture of. optimization, tumor targeting, C-l 1 TRB as ligand. synthesis, preliminary eval tate, 818(ab) 750(ab) uation, 932(ab) reperfusion after thrombolysis, Tc-99m isonitrile, mouse, complex formation and clearance, evaluation of potential PET agents. 933(ab) 1865 758(ab) hyper- and hypothyroidism. PET investigation. reperfusion effects, Tc-99m RP-30 and Tl-201, native and DTPA conjugated, cellular character 808(ab) 819(ab) ization, hepatocytes, 823(ab) imaging in brain. C-li scopolamine, PET. serial assessment, gated MRI and Gd-DTPA, novel Tc-99m antibody, targeting of granulo- 808(ab) 802(ab) cytes, 925(ab) regional quantitation, radioligand dissociation ki tissue glucose metabolism, PET, persistent Tl- OC 125, In-Ill- and I-131-labeled, diagnostic netics, 927(ab) 201 defects, 827(ab) accuracy, 811(ab) synthesis and regional brain distribution, C-11 Tl-201 SPECT infarcÃ¬size, heparin, fibrinolytic pharmacokinetics, intraperitoneal injection vol NMPB. 768(ab) agent, 951(ab) ume, protein dose, 889(ab) Muscle uptake specificity. In-111 antimyosin, 746(ab) platelets, thrombus imaging, radiolabeled Fab' atrophy in knee-joint disorders, P-31 MR spec- Myocardial ischemia fragments, 940(ab) troscopy, 890(ab) abnormal clearance of TL-201 during SPECT, prostate tumor localization, mouse subrenal cap C-11 1-pyruvate metabolism, mitochondria! en- assessment, coronary artery disease, 948(ab) sule model, 898(ab) cephalomyopathy, PET, 92l(ab) after attempted reperfusion, Tl-201/Tc099m RP-

2064 The Journal of Nuclear Medicine Myocardium

30A disparity, 1283 fects, unstable angina. 768(ab) altitude hypoxia. 842(ab) ambulatory ventricular function monitor, vali ribose effects on Tl-201. 1943 improved accuracy of imaging, elliptical regions dation, exercise left ventricular ejection frac role of 24-hour tomographic TI-201 myocardial of interest, 944(ab) tion, 741(ab) imaging, revascularization, 769(ab) intra-operative blood flow monitor, 880(ab) comparison of Tl-201 and Tc-99m RP-30A, scintigraphic assessment, sympathetic nerves, jeopardized, ischemia assessment, exercise quantitative cardiac SPECT, 793(ab) 840(ab) SPECT TI-201.943(ab) coronary bypass surgery, N-13 ammonia, PET, significance of regional wall thickening, cardiac left ventricular maximum time-varying elastance, 817(ab) MRI imaging, perfusion and PET. 801(ab) radionuclide angiographie calculations. 1368 coronary venous retroperfusion, PET. 783(ab) silent, detection of, ambulatory left ventricular mechanism of Tl-201 uptake in tumors, 750(ab) counts-based index, left ventricular "ejection function monitor, 741(ab) metabolism fraction", ECG-gated perfusion scans. simultaneous assessment of leg muscle, stress test 1-131 OPPA and PPPA, 938(ab) 947(ab) ing, dipyridamole and exercise, 947(ab) radioiodinated methyl-branched fatty acids, defect detection, Tc-99m MIBI vs. Tl-201, stress-redistribution Tl-201 scintigraphy, left 1230 gStXab) bundle branch block. 946(ab) Tc-99m fatty acid analogs, 935(ab) delayed 24-hour redistribtuion, SPECT Tl-201 thallium dobutamine imaging, detection, coro tracers, fatty acid derivatives of PnAO, 934(ab) myocardial perfusion studies, 769(ab) nary artery disease. 955(ab) MRI. computer analysis of, 277(ab) detection of coronary artery stenoses, exercise, Tl-201 perfusion defects, weaning, mechanical multicenter trial of Cedars-Sinai method, quan PET, 837(ab) ventilator-dependent patients, 947(ab) titative analysis, Tl-201 myocardial tomog differentiation from infarction, Tl-201 bullseye Tl-201 redistribution, ribose, coronary artery dis raphy, 755(ab) display, 938(ab) ease, 9S3(ab) neutral tris oxime complexes, technetium(III), dipyridamole perfusion scintigraphy. known or Tl-201 SPECT chemistry, 800(ab) suspected angina, 781(ab) bullseye. applying standard deviation, 954(ab) N-13 glutamate uptake, rest and exercise, PET, distribution of perfusion, patients surviving sud value and limitations, 1181 950(ab) den death, 769(ab) transient, one and two day protocol, Tc-99m normal and ischemie, fatty acid influx, biochem early Tl-201 redistribution, effect, SPECT imag MIBI, 851(ab) ical characteristics, 940(ab) ing, 947(ab) uptake of Tc-99m MIBI and Tl-201, 819(ab) novel diaminodithiol-fatty acid complex, synthe effect of nifedipine. perfusion and metabolism, validation of quantitative analysis, exercise thal sis, imaging agent, 935(ab) systemic sclerosis, 828(ab) lium tomograms, 871(ab) oxidative metabolism effect of reperfusion, first-pass extraction, pyro- Myocarditis C-11 acetate. 808(ab), 937(ab) phosphate and antimyosin, 746(ab) In-111 antimyosin Fab, 939(ab) C-11 acetate clearance, 937(ab) enhanced binding of fluoromisonidazole, hy- myocardial damage in. In-Ill antimyosin, 1893 perfusion distribution, 3D visualization, coro poxia, 807(ab) Myocardium nary arterial tree. 810(ab) extent of coronary disease in unstable angina, assessment of metabolism and function, multi- perfusion images, end-diastolic versus conven exercise thallium scintigraphy, 94S(ab) gated PET, 771(ab) tional, 2030(ab) glucose metabolism assessment of regional blood flow, N-13 ammo planar Tl-201, quantification, degree of reversi hypertrophie cardiomyopathy, PET, 828(ab) nia PET, 838(ab) bility, 861(ab) rate constants, partial volume effect, 783(ab) blood flow, noninvasi ve quantification. N-13 am potential imaging agents, Tc-99m complexes of 1-123 free fatty acid metabolism, diabetes, monia, 940(ab) aromatic isocyanides. 800(ab) 842(ab) C-11 acetate probe of metabolism, simple and prediction of coronary events, Tl-201 qunatita- improved detection of coronary artery disease, efficient synthesis, 932(ab) tion, 770(ab) exercise, Tl-201 SPECT tomography, cardiac cavity and, correction, activity cross-con quantitative assessment of regional perfusion, N- 755(ab) tamination, 866(ab) 13 ammonia, dynamic PET, 782(ab) injections of Tc-99m MIBI, myocardial tomo- C-11 fatty acid synthesis and biologic evaluation. rest and exercise SPECT studies, TI-201 thallous graphic imaging, 804(ab) 68 chloride, Tc-99m isonitrile, 944(ab) nitroglycerin response prediction, radionuclide congestive heart failure. MIBG myocardial up salvageable, marker, F-18 fluoromisonidazole, monitoring, left ventricular function, take, 841(ab) 807(ab) 838(ab) correction for partial volume effects, PET, sarcoid heart disease, magnetic resonance imag oxidative metabolism. C-ll acetate clerance. 774(ab) ing. 891(ab) 937(ab) damage, myocarditis and cardiac rejection. In- scar size, quanification in SPECT, 872(ab) persistent Tl-201 defects, significance, metabolic 111 antimyosin, 1893 serial biopsies, time-activity curves, 1934 activity, 827(ab) determination of left ventricular mass, cine vi. SPECT imaging planar Tc-99m isonitrile exercise imaging gated spin NMR imaging, 891(ab) poor predictive values, inferior wall defects, detection, coronary artery disease, 804(ab) differentiation by P-31 NMR, reperfused viable 944(ab) new normal database, modified background from reperfused infarcted, 801(ab) reconstruction, attenuation, detector response correction, 804(ab) dipyridamole-induced coronary vasodilation. correction, 749(ab) potential tracer using PET, 1-[C-11 ]-D,L-homo- quantitative assessment. PET and N-13 am ST segment depression, intravenous dipyrida cysteine thiolactone, 755(ab) monia, 818(ab) mole thallium infusion, 782(ab) protective effect of calcium antagonist. In-111- dipyridamole tomographic myocardial perfusion, "stunned", F-18 fluorometaraminol, neuronal in anticardiac myosin antibody, 745(ab) Tc-99mSQ30217,938(ab) jury, 938(ab) quantification of infarcÃ¬size, Tc-99m RP-30A emission tomography, bull's eye plot for, 267(le) Tc-99m MIBI and SPECT. 946(ab) estimation of right ventricular pressure overload compared to Tc-99m MPIN, imaging in man, quantitation of ischemie zone at risk, coronary ing, Tl-201 myocardial SPECT, 950(ab) 794(ab) occlusion, PET, 951(ab) evaluation of F-18 6-fluorometaraminol kinetics. compared to Tl-201, coronary artery disease, regional oxidative metabolism. C-11 acetate, dy PET, 807(ab) 793(ab) namic PET, 782(ab) experimentally-induced necrosis. In-Ill anti dosimetry and biodistribution, 874(ab) regional wall motion, perfusion and metabolism, myosin kinetics, septum, 941(ab) effect on uptake, metabolic inhibitors, 820(ab) PET, 828(ab) glutathione detoxification system, assessment, F- perfusion and wall motion assessment, Chagas' reperfusion and 18 fluorodinitrobenzene. 808(ab) cardiomyopathy, 950(ab) preserved 1-123 IPPA uptake, 842(ab) 0-hydroxy fatty acids, acylation, "masked" ma- slow infusion, rest and stress studies. 942(ab) Tc-99m RP-30, 1539 Ionic ester, 848(ab) Tc-99m RP-30. kinetics, flow and work con resting thallium perfusion abnormalities, coro hypertrophie obstructive cardiomyopathy, Tl- trolled conditions, 792(ab) nary stenoses, unstable angina, 768(ab) 201 imaging, 1738 thallium reinjection after delayed imaging, fill-in reversibility bullseye polar map, 951(ab) imaging agent, binding characteristics, 55 to regions with "fixed" defects, 769(ab) reversible rest-redistribution thallium-201 de 1-123 MIBG uptake, sympathetic activity index. Tl-201

Subject Index â€¢1988 2065 Naltrexone

diffuse decreased wash-out, quality of stress. myocardial blood flow muscle atrophy, knee joint disorders. 890(ab) 945(ab) metabolic fate in human blood. PET, 783(ab) PET late redistribution, viability. 948(ab) noninvasive quantification, PET, 940(ab) coordinate system, localization of neuro- reverse redistribution, coronary artery disease, PET and first-pass flow model, 838(ab) anatomy. 918(ab) 952(ab) quantitation of ischemie zone at risk, coronary radiation necrosis, canine CNS, 785(ab) wash-in and wash-out, redistribution phenom occlusion, PET, 951(ab) radionuclide cisternography and, evaluation, nor enon, 939(ab) stress-induced ischemia, coronary bypass surgery. mal pressure hydrocephalus, 836(ab) trapping ofl-123 OPPA, 85l(ab) 817(ab) registration of MRI-PET images, procedure, val uptake and redistribution, RP-30 compared to Nitrogen-13 glutamate idation, 853(ab) SQ32014, 8l9(ab) delayed recovery of myocardial metabolism, suc sarcoid heart disease, 891(ab) uptake of 19-iodo-3.3-dimethyl-18-nonadecenoic cessful angioplasty. 817(ab) significance of regional wall thickening, cardiac acid, hypertension, verapamil, 843(ab) methotrexate effects, Walker-256 carcinosar- MRI imaging, 80l(ab) N coma, 208 sodium, cardiac rejection, heterotopic heart myocardial uptake, rest and exercise. PET, Naltrexone, opiate receptors, duration of occu transplantation, 802(ab) 95

2066 The Journal of Nuclear Medicine Positron emission tomography (PET)

phine binding. PET, 796(ab) therapy, 2027(ab) Orphan products development, funds underused by Phosphonis-31 NMR, myocardium differentiation, PACS reperfused viable from reperfused infarcted. nuclear medicine researchers, N1011 high-speed ethemet system, image archiving, nu Os-191, reactor-produced, removal of Ir-192, 801(ab) clear medicine, 810(ab) 927(ab) Phosphorus-32 resin microspheres, radioisotopic image spread sheet, manipulation, digital images. lobectomy. vicinal and systemic safety, Osteoid osteoma, bone scan, 272(ab) 811(ab) Osteomyelitis Paget's disease 799(ab) Physician training, NRC, medical use of byproduct comparison of HM-PAO-labeled leukocytes, Tc- osteoclast nuclei. Ga-67 citrate localization. 1083 99m small colloid. 813(ab) materials. N1159 osteosarcoma in calvarium, 414 Pick disease, differential diagnosis of non-vascular diagnosis of fracture and. role. In-111 leukocytes, photopenic skeletal defect. In-Ill leukocytes. 561 dementia. SPECT, 743(ab) 8l4(ab) Pancreas hematogeneous. failure of Tc-99m MDP bone Planar imaging oncofetal antigen, combined assay, digestive sys compared to Ga-67 SPECT, chest, CT in lym- scintigraphy in. 274(ab) tem. 906(ab) phoma patients, 898(ab) In-111 chloride imaging scintigraphy, evaluation. 1-123 HIPDM, 826(ab) compared to SPECT, detection, metastatic colo- -spleen transplantation, graft perfusion, serial diabetic foot, 813(ab) rectal cancer, 886(ab) treated, 763(ab), 883(ab) radionuclide determinations. 885(ab) F-18 deoxyglucose and TI-201, ischemia detec In-Ill leukocytes, possibly-infected hip arthro- Pancreatic cancer, imaging with antibodies to CEA. tion, post-myocardial infarction. 828(ab) plasties. 883(ab) 833(ab) gamma camera, radionuclide content, liver or Paraganglioma, nonsecreting. mÃ©tastases.I-131 In-Ill WBC spleen of abdominal phantom. 845(ab) evaluation. 8l3(ab) MIBG effectiveness, 2008 SQ302I7 and Tl-201. comparison with coronary Parathyroid localization, non-infected surgery site, 788(ab) anatomy. 841(ab) neuropathic foot disease, In-111 leukocyte scans adenoma and paraganglioma. radionuclide scin Plasmapheresis, retreatment of cutaneous T-cell and bone scintigraphy. 16SI tigraphy and MRI. 277(ab) lymphoma following, 1-131 monoclonal factors related to imaging, 860(ab) Osteoporosis antibody, 174 failure of scintigraphy. 860(ab) bone mineral loss, normal postmenopausal Parkinson's disease, metabolites of F-18 fluoro-L- Plasminogen activator, radioiodinated recombinant women, 881(ab) tissue, localization of malignant tumors, dopa. human blood. 363 eating disorder patients. 882(ab) Parotid, oncocytoma, I-I31 therapy. 1126 1194 non-hormonal therapy of. dual-photon absorp- 3H-Paroxetine, labeling of serotonin uptake sites. Plasmocytoma, bone marrow scintigraphy, com pared to magnetic resonance tomography, tiometry, 855(ab) 809(ab) 891(ab) spinal, diagnostic sensitivity, SPA and DPA, Partial correlation coefficient, interregional rela Platelets 882(ab) tions, cerebral metabolic activity. 392 improved kit method for labeling with Tc-99m, spine and distal forearm, bone density measure Paul C. Aebersold Award, achievement in basic ments in. I31(le) science. William C. Eckelman, N586 787(ab) In-111 endothelial cells, adherence, carotid arter Osteosarcoma Pediatrie patients calvarium. Paget's disease, 414 emergency use of bone scintigraphy. 736(ab) ies, 939(ab) monoclonal antibody, thrombus imaging, radio- neoadjuvant chemotherapy, scintigraphic evalu In-111 oxine, dosimetry, 689 labeled Fab' fragments, 940(ab) ation. Tc-99m MDP, 882(ab) lymphocytic interstitial pneumonitis, Ga-67 up natural history of aggregation, endothelial injury, Ovarian cancer take in AIDS. 707 angiography, 948(ab) biodistribuiton, In-111 OC 125 monoclonal anti nuclear medicine in. 1287 survival and sequestration of In-111 donor plate body, 847(ab) osteomyelitis, subperiosteal abscess complicating. In-Ill leukocyte scintigraphy. 1871 lets, patients with neoplasms. 787(ab) radioimmunoscintigraphy. 599 Peptic ulcer, Campylobacter pylori, C-14 urea survival in thrombocytopenic children, In-111 recognition of CAI 25 by monoclonal antibodies, breath test for, 11 oxine. 892(ab) in vitro and in vivo use, 766(ab) survival studies. In-111, 564 Ovarian dysfunction, I-I31 scintigraphic localiza Periostitis, lower extremity, secondary to venous insufficiency, 1279 Pneumocystis carinii pneumonia, variable presen tion. 1644 tation, Ga-67 scans, HIV-positive persons, Peristalsis, renal antegrade perfusion scintigraphy. Oxygen study, ureteric function. 779(ab) 829(ab) cerebral blood flow, glucose metabolism, stroke, Peritoneal cavity, examination of antibody classes Pneumonitis 852(ab) and fragments, absorption. 900(ab) lymphocytic interstitial, Ga-67 uptake in pediat metabolism and blood flow, spinocerebellar de Peritoneal fluid, SPECT inferior attenuation, rie AIDS patient, 707 generation. PET, 920(ab) 941(ab) radiation metabolism in cerebrovascular disease, early and PET: See Positron emission tomography (PET) early detection, Ga-67 citrate scans, 888(ab) late 1-123 IMP SPECT, 844(ab) Phantom, tissue-equivalent anthropomorphic, early diagnosis, lung permeability, 894(ab) Oxygen-15 radionuclide dosimetry. imaging studies. Positron, energetics of decay, 1156(le) absorbed dose estimates, newborn, 1961 803(ab) Positron emission tomography (PET) dynamic PET studies, arterial input function. Pharmacokinetics, monitoring of positron-emitting acceptance testing of CTI 933/04 ECAT scanner, plasma separation, 832(ab) tracers, multiple region-of-imerest capabili 880(ab) radiation absorbed dose estimate, newborn in ties, 832(ab) accuracy of neuroreceptor quantification, various Phencyclidine, F-18 PCP analogs for PET, 767(ab) models, 922(ab) fants. 874(ab) f3-Phenethylamine,synthesis, C-11 nitroalkane pro acquired input functions, cardiac studies, 241 steady state method, correction, arterial concen Alzheimer's dementia and normal aging, com tration. 821(ab) duction. 754(ab) Phenylalanine dehydrogenase, synthesis of L-phen- Oxygen-IS water parisons, CT and MR, 852(ab) ylalanine, L-tyrosine and l.-dopa, N-13, arterial sampling v.v.quantitative LV cavity im autoradiography and PET. oxygen inhalation, 931(ab) aging. 772(ab) cerebral blood flow, 915(ab) Phenylalkylamines, 5-iodo-thienylamphetamine assessment of regional wall motion, perfusion, direct measurement of distribution volume. PET, synthesis, brain imaging agents. 777(ab) metabolism, 828(ab) 822(ab) Phenylalkyloxirane carboxy acid, metabolism of I brain image analysis, metabolic centroid method. effect of recirculation, estimation, cerebral oxy 131 OPPA and PPPA, heart, 938(ab) 774(ab) gen metabolism. 917(ab) Philips and Picker Medical Systems, joint venture brain metabolic relationships, condition-depend evaluation of dispersion, input function, dynamic plan, N292. N440 ent changes, 839(ab) PET, 867(ab) Phosphorus-32, therapy for therapy-resistantmalig C-ll acetate high resolution PE, cache memory system, real nant glioma. 902(ab) clearance, myocardial oxidative metabolism, time operation, 878(ab) Phosphorus-32 chromic phosphate, intracavitary 937(ab)

Subject Index â€¢1988 2067 Positron emission tomography (PET)

myocardial oxidative metabolism, 937(ab) Cu-62 HSA, plasma volume measurement, centration, 933(ab) regional oxidative metabolism, myocardial in 930(ab) Ga-68 DTPA-LDL, receptor activity, 848(ab) farction, 818(ab) current generation scanner, performance evalua genetic linkage results and, subjects at risk, Hun- regional oxidative metabolism, stunned myo tion, 878(ab) tington's disease, 853(ab) cardium, 782(ab) cyclotron-produced radiopharmaceutical for D-glucose and /3-phenethylamine synthesis, pro simple and efficient synthesis, myocardial me clinical use, 2030(ab) duction, C-l 1 nitroalkanes, 754(ab) tabolism, 932(ab) delayed recovery of myocardial metabolism, suc glucose metabolism, cerebral, 631 C-l I diprenorphine compared to carfentanil cessful angioplasty, 817(ab) glucose utilization and rate constants, partial vol binding to opiate receptors, man, 796(ab) design of simulation system, 871(ab) ume effect, ischemie myocardium, 783(ab) brain uptake, 933(ab) detection of coronary artery disease, Rb-82 PET grey and white tissue water content, partition C-l I malonate platinum, 1107 compared to Tl-201 SPECT, 817(ab) coefficient, labeled water, 773(ab) C-l I 1-pyruvate, brain and muscle metabolism, detection of coronary artery stenoses, exercise, halothane-induced decrease of C-l 1 CGP 12177, mitochondria! encephalomyopathy, 921(ab) 837(ab) myocardial beta adrenoceptor, 940(ab) C-11 Rol5-1788, benzodiazepine receptors, detector design, crystal masking analog position hepatoma heterotransplant uptake, 903(ab) 931(ab) ing, 761(ab) high resolution, cache memory system, realtime C-I I scopolamine, muscarinic receptor imaging, development of PET workstation, personal com operation, 878(ab) brain, 808(ab) puter, 867(ab) high speed automated discrete blood sampling, C-11 thymidine uptake, non-Hodgkin's lym- dilated and ischemie cardiomyopathy, visual, cir 879(ab) phoma, 1633 cumferential profile analysis, 818(ab) hyperkinetic movement disorders, 839(ab) C-11 TRB, ligand, muscarinic receptor, 932(ab) dipyridamole-induced coronary vasodilation, I-122 HIPDM, cerebral blood flow agent, 916(ab) C-l l YM-09151-2, brain uptake, dopamine D-2 quantitative assessment, N-13 ammonia, imaging agent for prostate tumors, 750(ab) receptors, 931(ab) 818(ab) improved HPLC system, analysis, organic amine camera image quality improvement, removeable direct measurement of distribution volume, radiopharmaceuticals, 926(ab) rings, high atomic number material, 877(ab) water, PET, 822(ab) influence of finite resolution, rate constant esti camera performance design evaluation, BGO and dopaminergic system, 3-N-(F- mates, ligand-neuroreceptor binding, BaF2 scintillators, 338 I8)fluoroethylspiperone, 821(ab) 866(ab) canine stroke model, 920(ab) dual detector system, opiate receptor binding. C- kinetic parameters cardiac 11 diprenorphine and carfentanil, 921(ab) FESP-D2 receptor interactions, 865(ab) arterial activity concentrations, 941(ab) dynamic and static, i|Â»Â¡imitationof uncertainties, selection criteria, neuroreceptor binding li- automated quantitative analysis, 867(ab) 912(ab) gands, 86S(ab) correction, partial volume effects, 774(ab) dynamic technique, cerebral blood flow evalua lack of ID for EC/IC bypass, cerebral hemody- cerebellar metabolism of FÃœG,brain trauma, tion, 775(ab) namics, 831(ab) 822(ab) enhanced binding of fluoromisonidazole, hy- low cost large area camera, physical evaluation, cerebral blood flow, oxygen and glucose metab poxia, myocytes, 807(ab) 877(ab) olism, stroke, 852(ab) evaluation of dispersion, peripherally sampled maturation of cerebral neutral amino acid accu cerebral glucose utilization, relation to brain input function, 867(ab) mulation, C-l 1 methionine, 784(ab) structure, polydrug abusers, 91 l(ab) evaluation of feasibility studies, other modalities, measurement of protein synthesis rates, tyrosine, cerebral metabolic rate, glucose, 392 study protocol screening, 774(ab) 524 cerebral oxygen metabolism, effect, O-15 water evaluation of F-18 6-fluoromeetaraminol kinet medically-treated cerebral ischemia, prognosis of, recirculation, 917(ab) ics, 807(ab) 831(ab) clinical, N1751 evaluation of F-18 uptake, post-infarct myocar metabolic imaging, extremity musculoskeletal tu clinical center, manpower requirement and work dium, 783(ab) mors, 181 flow organization, 2028(ab) evaluation of potential agents, mAChR, 933(ab) metabolic maturation in cat brain, 772(ab) clinical status in U. S. in 1987, 1136 evaluation of recurrent colorectal tumors, metabolites of F-18 fluoro-L-dopa, human blood, compared to CT and MRI brain imaging, acute 751(ab) 363 head injury, 910(ab) evaluation of Tc-99m HM-PAO SPECT, cerebral 3-[C-11]methoxybenzodiazepines, new radiolig- compared to early and late 1-123 IMP SPECT, perfusion tracer, 843(ab) ands, benzodiazepine receptors, 755(ab) cerebrovascular disease, 844(ab) FDG 11 MeV proton cyclotron, production, other compared to 1-123 IMP and Tc-99m HM-PAO AIDS-related dementia, azidothymidine, radionuclides, 932(ab) SPECT, dementia, 916(ab) 852(ab) MK-801 analogs, mapping, glutamate receptor compared to MRI, partial epilepsy, 910(ab) compared to image-guided MR spectroscopy, channels. 930(ab) compared to Xe-133 SPECT, cerebral blood flow, brain tumors, 785(ab) model of C-l 1-L-methionine kinetics, human 919(ab) left hemisphere dysfunction, Alzheimer's dis brain, 822(ab) comparison of bromo vs. iodoalkyl triflates, F-18 ease, 912(ab) monitoring of arterial positron concentration, radiolabeling, secondary amines, 754(ab) primary visual cortex hypometabolism, head gamma detector, 833(ab) comparison of macromolecular tracers, vascular injury, 830(ab) monitoring of positron-emitting tracers, multiple permeability, 939(ab) rate constants, degenerative brain disorders, region-of-interest capabilities, 832(ab) coordinate system, localization, neuroanatomy, 915(ab) Monte Carlo calculation, spillover corrections, 918(ab) F-18 cyclofoxy imaging in man, 796(ab) cardiac studies, 866(ab) copper-labeled radiopharmaceuticals, cerebral F-18 FDG MRI of proton self-diffusion coefficient, cerebral and myocardial blood flow evaluation, l S49 compared to F-18 FDM, 772(ab) infarction, 836(ab) CO2 reactivity using 1-122 HIPDM, quantitative frontal lobe epilepsy, 831(ab) multigated. assessment, myocardial metabolism, blood flow tracer, 773(ab) hexokinase reaction, 1443 771(ab) coronary artery disease, neurological disorders initial clinical experience, 2028(ab) multi-grid expectation maximation algorithm, and, 2028(ab) therapeutic effects, transarteria] embolization 278(ab) coronary venous retroperfusion, myocardial is to liver tumors, 886(ab) multi-grid maximum likelihood image recon chemia, 783(ab) F-18 fluoromisonidazole, marker, salvageable struction algorithm, real data, 774(ab) correction for arterial concentration variation, O- myocardium, 807(ab) multi-parameter studies, brain tumors, 853(ab) 15 steady state method, cerebral blood flow. F-18 fluorophenylalanine, brain tumors, 919(ab) myocardial glucose metabolism, hypertrophie 821(ab) F-18 PCP analogs, 767(ab) cardiomyopathy, 828(ab) correction of activity cross-contamination, myo 6-F-18-L-DOPA brain imaging, asymptomatic myocardial muscarinic acetylcholine receptor, cardium and cardiac cavity, factor analysis, MPTP-lesioned monkeys, 820(ab) hyper- and hypothyroidism, 808(ab) 866(ab) Ga-68 deferoxamine-galactosyl-neoglycoalbu- myocardial perfusion and metabolism, nifedipine correlation with MRS, CNS disorders, 910(ab) min, regional measurement, receptor con effect, systemic sclerosis, 828(ab)

2068 The Journal of Nuclear Medicine Radiocolloid

N-13 ammonia evaluation and operation. 880(ab) Pyrophosphate, first-pass myocardial extraction, ef assessment, myocardial blood flow, 838(ab) optimization, data acquisition, 876(ab) fect of reperfusion. 746(ab) metabolic fate, human blood, 783(ab) stress-induced ischemia. N-13 ammonia, coro noninvasive quantincation, myocardial blood nary bypass surgery, 817(ab) flow, 940(ab) studies of motor system, tardive dyskinesia, Quality assurance quantitative assessment, regional myocardial 821(ab) cardiac imaging, WHO study of, N440 perfusion, 782(ab) subcortical indices of hypometabolism, olivopon- proposed regulations new high resolution scanner, double wobbling tocerebellar atrophy, 913(ab) NRC, N283, N1008 mode, 877(ab) subcortical metabolic alterations, partial epilepsy. NRC commissioners meet, N592 /VX3-F-18 fluoropropyl)MK-801, NMDA recep 830(ab) Quality control, fluorine-18 FDG. hexokinase re tors, 932(ab) synthesis and regional brain distribution. C-11 action. 1443 NMR and. radiation necrosis, canine CNS, NMPB, 768(ab) Quinuclidinyl benzilate, analysis of receptor-ligand 785(ab) synthesis of para-substituted phenyl glyoxals, bro- binding, time-activity data, 759(ab) normal cerebral glucose utilization, amyotrophic moacetylation, 928(ab) lateral sclerosis, 821(ab) three-dimensional display, heart, 530 O-15 water autoradiography and, oxygen inhala tissue glucose metabolism, persistent Tl-201 de Radiation dose tion, cerebral blood flow, 915(ab) fects, 827(ab) application of count-dependent Metz filter, oxygen metabolism and blood flow, spinocere- tracer for cerebral protein synthesis, F-18 2-fluo- bremsstrahlung imaging, 863(ab) bellar degeneration, 920(ab) rotyrosine, 754(ab) biological retention of fission products, Cherno oxygen-15 radiopharmaceuticals, absorbed dose tracer for myocardial ischemia. 1-[C-1I]-D,L- byl plume, 804(ab) estimates, newborn, 1961 homocysteine thiolactone, 755(ab) estimates for O-15 tracers, newborn infants, oxygen studies, arterial input function, plasma uptake of F-18 sex hormones, mammalian brain, 874

Subject Index â€¢1988 2069 RadiofluorÃnation

Radiofluorination, polymer-supported NCA nu- para-iodophenyl, 777(ab) tion, multigated PET, 771(ab) cleophilic, 754(ab) 5-iodo-2-thienylamphetamine synthesis, evalua cardiac abnormalities, expert images, 846(ab) Radiography, dual energy, bone mineral analysis. tion, brain imaging agents. 777(ab) detection of abnormalities lumbar spine. 855(ab) radiopharmaceutical for cerebral amino acid factor analysis, biplane contrast angiography, Radiohalogenation, no-carrÃer-addedsynthesis, bro- transport, 778(ab) 771(ab) mine-77 bromospiperone, 776(ab) study in 100 hyper-/hypo-/euthyroid patients, improved probabilistic image, 863(ab) Radioimmunoassay Tc-99m pertechnetate uptake and imaging, gated myocardial positron tomography, 828(ab) commercial kit evaluation, human serum calci- 753(ab) interactive digital filtering, gated cardiac studies, tonin, 766(ab) therapy controversies, 2026(ab) cine display. 864(ab) fibrinopeptide-A measurement, single urine sam Radioisotopes, production LINAC. commentary. left ventricular, hull's eye display, cardiac blood ple. 766(ab) N1758 pool SPECT, 745(ab) new monoclonal antibodies, recognition, CA125. Radioligands, analysis of receptor-ligand binding. myocardial perfusion. Tc-99m MIBI vs. Tl-201 766(ab) time-activity data, quinuclidinyl benzilate. perfusion, 950(ab) pancreatic oncofetal antigen/CAI9-9/CEA, can 759(ab) phase image triangulation of accessory pathways, cer of digestive system. 906(ab) Radionuclides catheter ablation, posteroseptal pathways, rapid I-125 method, cyclosporine monitoring, dosimetry and imaging studies, tissue-equivalent 744(ab) 766

2070 The Journal of Nuclear Medicine Single photon emission computed tomography (SPECT)

Tl-201 SPECT and. detection, coronary artery thyroid, thallium, 860(ab) Bayesian reconstruction, in parallel/fan/cone disease, 817(ab) Tl-201, bone and soft tissue sarcoma. 854(ab) beam geometries, 871(ab) ultrasound and, assessment, renal transplant pa bone, hyperplasia. mandibular condyle, 780(ab) thology, 779(ab) bone studies of pelvis, digital filtering of the blad Scintillation camera der in, 1587 Saline, washing effects, platelet function, 735(ab) accumulation of ln-111 granulocytes. malignant brain and heart, future directions, 567 Samarium-153, production of radioimmunoconju- tumors. 479 brain tomographic imaging with Tc-99m ECD, gates, 81Mab i BGO and BaF2, PET. 338 stable perfusion agent. 758(ab) Samarium-153 EDTMP cardiac imaging, patient and organ movement in bremmstrahlung radiation, energy window, col- bone tumor response, 903(ab) SPECT. 441 limation, 876(ab) dose tolerance in metastatic bone cancer, 775(ab) Compton-scatter photons, three boundary detec cardiac, bull's eye plot, 267(le) therapy dosimetry and SPECT, disseminated tion methods, 203 cardiac data skeletal metastasis, cancer, 762(ab) design and manufacturing defects, nonisotropic computer simulation, 2027(ab) Saralasin. vs. captopril renography, two-kidney/ point spread function, 1096 evaluation, reconstruction algorithms, 748(ab) one-clip hypertension, 849(ab) diagnosis of deep venous thrombophlebitis, 1169 cardiac image reconstruction, attenuation, detec Sarcoidosis, heart disease, magnetic resonance im 1-123 HIPDM metabolic lung imaging, pulmo tor response correction, 749(ab), 870(ab) aging, 891(ab) nary hypertension. 765(ab) center of rotation measurement, collimators in. Sarcoma 1-125 monoclonal antibody. Fisher immunotype 1393 high dose-delayed Ga-67 scintigraphy, compared 1 Pseiidomonas aeruginasa infection, 651 clinical studies, optimization, angular sampling with CT and MRI, 749(ab) 1-131, location of ovarian dysfunction. 1644 frequency. 869(ab) improved imaging, reduced hepatic activity and, In-111 and 1-131, thrombus, 1212 Co-57 bleomycin. delivery to brain tumors. 187 1810 In-111 lymphocytes and, detection of orthotopic compared to planar imaging, detection, meta tumor mass and viability, bone. Tl-201 scintig cardiac allograft rejection, 1223 static colorectal cancer, 886(ab) raphy, 854(ab) In-Ill WBC. detection of osteomyelitis. 1015 comparision of Ga-67 planar images, chest, CT Scaner left ventricular maximum time-varying elastance in lymphoma patients, 898(ab) Compton estimation calculation, 1368 comparison of 360Â°and 180Â°sections, 868(ab) Monte Carlo simulation, distributed sources, line resolution pattern, 1856 comparison of Tl-201 and Tc-99m RP-30A, car 865(ab) modular, status and applications, 760(ab) diac data, 793(ab) spectral fitting. Monte Carlo simulation. NEMA, count rate curve determination, 538 comparison of three scatter correction tech 797(ab) position-sensitive bar detector system, multi-slice niques, 1971 direct copensation. photopeak distribution analy brain SPECT, 760(ab) compensation for collimator divergence, maxi sis, 797(ab) method for correction, energy information, ho- routine lung perfusion scanning, diffusing capac mum likelihood reconstruction. 786(ab) ity and, 1268 Compton-scatter correction lospectral imaging, 864(ab) X-ray, bone mineral densiometry. 855(ab) removal by pre- and post-processing techniques, analysis of energy spectra, 195 Scintitomography, Tc-99m HM-PAO, acute cere spectral fitting. Monte Carlo simulation. 798(ab) bral infarction, 843(ab) 797(ab) SCH 23982, radioiodinated, biological distribution. Sclerosis, systemic, nifedipine effect, myocardial three boundary detection methods, 203 radiation dosimetry, 803(ab) Schizophrenia, C-l 1 and C-14 5-methyl-methio- perfusion, 828(ab) cone beam Selena-25-homocholic acid, tauro-23, biologic sta nine, abnormal oxidation. 784(ab) collimator, 1398 maximum-likelihood reconstruction. 869(ab) Scientific fraud. Congressional investigation, bility of. 1411 Selenium-75, internally-labeled monoclonal anti correction for patient and organ movement, Tl- N1469 Scintigraphy bodies, biodistribution. 889(ab) 201 cardiac imaging, 441 Selenium-75 bile acids, biologic stability. 1411 cylindrical neuro-SPECT system, imaging char antimyosin, prediction, extent of akinesis. 851(ab) Serotonin acteristics of MUMPI, 832(ab) labeling of uptake sites, 3H-paroxetine, 809(ab) bone, factor analysis, renal osteodystrophy, design of simulation system, 871(ab) differential diagnosis, non-vascular dementia, 883(ab) synthesis in brain, plasma tryptophan, PET. bone marrow, compared to magnetic resonance 784(ab) 743(ab) tomography, plasmocytoma, 891(ab) Serotonin receptor digital acquisition, radioisotope tomographic im exercise Tl-201 blockade, equilibrium binding kinetic analysis, ages, 870(ab) detection, single vessel disease. 948(ab) 809(ab) dipyridamole Tl-201 perfusion, exercise, coro prognosis assessment, prior myocardial infarc S2 neuroreceptor density measurement, PET, nary artery disease, 838(ab) double-injection method, 809(ab) tion, 951(ab) 3D modulation transfer function, stationarity, high dose-delayed Ga-67, compared with CT and Serum averaging opposing projections, 749(ab) MRI, sarcoma, 749(ab) in vitro complex formation and clearance, mouse dopamine receptor binding sites, baboon brain, high resolution, human terminal ileal emptying, monoclonal antibody, 758(ab) 848(ab) 857(ab) TA-4 as marker of squamous cell carcinoma, lung dual-energy-window Compton correction, k myocardial sympathetic nerves, ischemia. and other organs. 765(ab) value object, 797(ab) 840(ab) Sex hormones, uptake in mammalian brain, I -is early and late I-123 IMP-labeled. value and lim NP-59, accuracy and utility, disease diagnosis. ligands, PET, 795(ab) itation, cerebrovascular disease, 844(ab) 859(ab) Sex steroids, hormonal relationship of bone den emission and transmission data, three-dimen pancreas, evaluation, I-123 HIPDM, 826(ab) sity, premenopausal women, 859(ab) sional display, 786(ab) parathyroid, failure, 180 patient studies. 860(ab) Sickle cell disease, calvarÃa)infarction, radio- evaluation of hips, bladder artifact correction, radioisotope bone images, diagnostic conse nuclide bone imaging findings. 411 780(ab) quences, 884(ab) Single-photon absorptiometry (SPA) evaluation of strategies for edge detection, renal, compared to angiographie data, chronic DPA and, diagnostic sensitivity, spinal osteopo 868(ab) glomerulonephritis, 907(ab) rosis. 882(ab) exercise Tl-201 imaging renal antegrade perfusion, study, ureteric func osteoporosis, eating disorder patients. 882(ab) ischemia assessment, jeopardized myocar tion, 779(ab) Single photon emission computed tomography dium. 943(ab) Tc-99m MDP, neoadjuvant chemotherapy, os- (SPECT) size of perfusion deficit, increased lung uptake, teosarcoma, 882(ab) AIDS dementia complex, 1382 943(ab) Tc-99m pertechnetate, evaluation, Barrett's aperture design, 785(ab) "false" positive pyrophosphate tomoscintigrams, esophagus. 886(ab) application of count-dependent Metz filter, 954(ab) three methods, right ventricular ejection fraction bremsstrahlung imaging. 863(ab) filtered back-projection reconstructions, factors determination, 771(ab) arterial perfusion, regional chemotherapy, 593 determining noise character, 870(ab)

Subject Index â€¢1988 2071 Single photon emission computed tomography (SPECT)

Ga-67, chest, 276(ab) limatore, 676 localization, seizure foci, 913(ab) Ga-68 deferoxamine-galactosyl-neoglycoalbu- new radioiodinated radiopharmaceutical, cere preparation considerations, 928(ab) min, regional measurement, receptor con bral amino acid transport studies. 778(ab) ruptured intracrania! aneurysm, 844(ab) centration. 933(ab) noise power, 1704 uptake, primary and metastatic brain tumors, hepatobiliary, changing radioactivity distribu nonisotropic point spread function, collimator 895(ab) tion, 98 design defects, 1096 Tc-99m HM-PAO compared to Tc-99m ECD, high-resolution 3-headed system, evaluation, cer non-uniform attenuation correction, photopeak, brain perfusion imaging agents, 844(ab) ebral blood flow. 912(ab) Compton spectral windows, 798(ab) Tc-99m HM-PAO compared to 1-123 IMP, hip, correction, bladder artifact. 868(ab) novel diaminodithiol-fatty acid complex, synthe brain, ischemie lesions, 919(ab) -123, thyroid, multinodular goiter, 110 sis, myocardial imaging, 935(ab) Tc-99m MIBI, one and two day protocol, tran -123 estradiol, ER-positive breast cancer detec optimum filter function, determination. 643 sient ischemia, 85 l(ab) tion, 8S3(ab) phantom, new design, 2030(ab) Tc-99m MIBI compared to Tl-201, assessment. -123 HIPDM, carotid artery occlusion. 913(ab) persistent Tl-201 defects, tissue glucose metabo coronary disease, 793(ab) -123 IBZM, D-2 dopamine receptors. 759(ab) lism, myocardium, 827(ab) Tc-99m pyrophosphate and DTPA comparison, -123 IMP phantom evaluation of distortion, brain, 877(ab) ventilation studies, 1761 blood flow and redistribution, ischemie CVD, planar and transaxial images. Tc-99m sulfur col Tc-99m PYP. quantitation, skeletal muscle ne 918(ab) loid, liver and spleen size, 870(ab) crosis. 884(ab) brain, after cerebral radiation therapy. 914(ab) quantification, myocardial scar size, 872(ab) Tc-99m RP-30. myocardial ischemia and reper- brain, auditory hallucination, 917(ab) quantitation, attenuation correction, inhomoge- fusion, 1539 brain, Huntington's disease, 916(ab) neous media, 797(ab) Tc-99m sulfur colloid, volume determination in brain maturation, human newborns. 893(ab) quantitative liver and spleen, 1768 clinical application, brain death and coma, bone scintigraphy. 881(ab) thallium and antimyosin, acute Q-wave myocar 917(ab) circular harmonic transform algorithm. dial infarction, 806(ab) evaluation, major psychosis, 921(ab) 868(ab) thallium imaging with oral dipyridamole. ambu flow and back difTusion rate images, brain, empirical threshold method. 879(ab) latory ventricular function monitor, chest 870(ab) imaging, improved method, cerebral perfusion, pain, 742(ab) revascularization prediction, carotid endarter- 869(ab) three-dimensional cone beam reconstruction, it ectomy, 844(ab) radioiodinated glucose derivative, interaction to erative maximum likelihood method. 1-123 IMP and Tc-99m HM-PAO, compared to hexokinase. 928(ab) 786(ab) PET, dementia, 916(ab) radioiodinated SCH-23982, dopamine D-1 recep three-headed system/Prism, initial on-site evalu I-123 IMT, brain tumors, 91 l(ab) tors, 929(ab) ation, 760(ab) 1-123 ISP, dopamine D-2 receptor imaging, radiopharmaceutical uptake, cerebral blood flow, Tl-201 922(ab) neocortex, 927(ab) abnormal clearance, assessment of coronary 1-123 MIBG compared to Tl-201 cardiac imag radioxenon tomography, cerebral blood flow, artery disease. 948(ab) ing, myocardial infarction. 840(ab) 1875(le) "black hole" sign, left ventricular aneurysm, image data by presentation as stereo pairs, 3D rapid sequential study, cerebral vascular diseases, 756(ab) visualization, 810(ab) 880(ab) bull's eye. applying standard deviation, 954(ab) image restoration, singular value decomposition reconstructions, predicting noise energy. 748(ab) bull's eye display. 1901 technique, 749(ab) regional cerebral blood flow measurements bull's eye display, correcting for patient mo imaging using Tc-99m HM-PAO, stroke prog maturation, first 20 months of life, 743(ab) tion, 91 nosis. 743(ab) partial epilepsy, childhood, 892(ab) bull's eye display, ischemia and infarction. relationship to clinical features. Alzheimer's dis imaging with 1-123 isopropyl amphetamine, 938(ab) asymptomatic HIV seropositive persons, ease, 743(ab) comparison with N-13 ammonia, 1181 742(ab) RP-30 tomograms, automatic calculation, LV coronary artery disease patients. 1479 instrumentation, 2026(ab) volumes and EF, 805(ab) detection, single vessel disease, 948(ab) In-Ill antimyosin, acute Q-wave infarcÃ¬size, simultaneous acquisition, cerebral blood flow, dipyridamole scintigraphy, ECG changes, 942(ab) metabolism, 876(ab) 945(ab) In-Ill leukocytes, value in abdominal sepsis, skull, comparison with planar scintigraphy, 1341 effect, early myocardial redistribution. 947(ab) 794(ab) SM-153 EDTMP therapy dosimetry, dissemi estimation, left ventricular mass. 945(ab) interictal, HMPAO, epilepsy in children, 792(ab) nated skeletal metastasis, cancer, 762(ab) evaluation, suspected lung cancer. 895(ab) isopropyliodoamphetamine, comparison, O-I5 Sprint II, ring-geometry instrument, brain imag exercise, coronary artery disease detection, water cerebral blood flow, 747(ab) ing, 760(ab) 755(ab) mapping of human brain benzodiazepine recep stress Tl-201 imaging post angioplasty, resten- exercise/rest, coronary artery disease, 756(ab) tors, 759(ab) oses, recurrent symptoms, 770(ab) heart, intraobserver variability. 944(ab) measurement of cerebrovascular reserve, hemo- stress Tl-201 myocardial emission tomography, infarcÃ¬size, myocardial infarction, 951(ab) dynamic risk patients, 91 l(ab) assessment. Kawasaki disease, 791(ab) inferior attenuation, peritoneal fluid, 941(ab) modular scintillation cameras, status and appli Tc-99m anti-melanoma fragments and. clinical interpretation, 272(ab) cations, 760(ab) experience, 812(ab) late redistribution, myocardial viability, Monte Carlo simulation, Compton scatter, dis Tc-99m DISIDA, detection, intrahepatic lithiasis. 948(ab) tributed sources. 865(ab) 826{ab) measurement of myocardial defect size, 1486 multicenter trial of Cedars-Sinai method, quan Tc-99m DTPA-HSA. initial experience in man. patients with LBBB, 279(ab) titative analysis, Tl-201 myocardial tomog 922(ab) peritoneal fluid effects, myocardial imaging in raphy, 755(ab) Tc-99m DTPA-HSA and I-123 IMP, assessment, women. 1860 multiplane reconstruction, compensation, colli- perfusion reserve in CVD, 918(ab) posterolateral myocardial infarction, 954(ab) mator response, 785(ab) Tc-99m ECD, new brain agent, kinetics, 921(ab) predictive value, myocardial infarction, multi-slice brain SPECT, position-sensitive bar Tc-99m HM-PAO 770(ab) detector system, 760(ab) Alzheimer's disease. 1507 prone vs. supine position, 953(ab) myocardial imaging, poor predictive values, in brain, cerebral perfusion correlation. 914(ab) quantitation. community hospital. 943(ab) ferior wall defects, 944(ab) brain, cortical peeling and mapping. 914(ab) referrals, subsequent coronary angioplasty, myocardial infarction, after attempted reperfu- brain, post-stroke depression. 918(ab) 946(ab) sion, 1283 evaluation, cerebral perfusion tracer, 843(ab) septal perfusion pattern, discrimination of new method for brain functional study, Tc-99m flow and rate constants, kinetic model. 917(ab) heart diseases. 942(ab) HM-PAO. 748(ab) glutathione content, brain tumors, 920(ab) simultaneous assessment, leg muscle and myo new methods of examining gamma camera col high resolution imaging, SPRINT, 917(ab) cardial ischemia. 947(ab)

2072 The Journal of Nuclear Medicine Technetium-99m

specificity determinations, coronary artery dis technologists offered liability plan, N292 Sympathetic nerves, myocardial, scintigraphic as ease, 946(ab) Sodium, NMR imaging of acute cardiac rejection. sessment, 840(ab) Tc-99m MIBI and angiography, coronary ar heterotopic heart transplantation. 802(ab) Synovitis, radiation synovectomy. dysprosium-165 tery disease, 952(ab) SPECTamine, newly approved agent. N287 ferric hydroxide macroaggregates for, thyroid cancer. 884(ab) SPECT. See Single photon emission computed to 275(ab) Tl-201 cardiac, evaluation, pre-renal transplant mography patients, 950(ab) Spleen Tl-201 compared to Rb-82 PET. detection, cor liver size and. Tc-99m sulfur colloid, planar and onary artery disease. 817(ab) transaxial SPECT images. 870(ab) Tachycardia, ventricular, location of onset, multi- Tl-201 myocardial. estimation, right ventricular -pancreas transplantation, graft perfusion, serial harmonic Fourier mapping, 744(ab) overloading, 950(ab) radionuclide determinations. 885(ab) Tantalum-178 Tl-201 myocardial imaging, 24-hour delay, re- planar gamma camera methods, quantitation, generator system, high volume clinical applica vascularization, 769(ab) radionuclide content, 845(ab) Tl-201 thallous chloride and Tc-99m isonitrile, tions, 1526 platelet survival in thrombocytopenic children, multiwire gamma camera and. first-pass radio rest and exercise studies. 944(ab) In-111 oxine, 892(ab) nuclide angiography, 293 totally digital annular brain camera. 786(ab) radionuclide imaging, heat denatured Tc-99m Tardive dyskinesia, PET studies of motor system, trapping of I-123 OPPA, myocardium. 851(ab) RBC. 320 821(ab) tumor imaging with In-111 synthetic porphyrin. volume determination. Tc-99m sulfur colloid Technegas 900(ab) SPECT, 1768 initial experience with new ventilation agent, use of resampling methods, precision estimation. Splenic reticuloendothelial system, radionuclide 765(ab) imaging, heat denatured Tc-99m RBC. 320 emission tomography images. 748(ab) lung ventilation scanning, 765(ab) Splenoportography, Xe-133, Budd-Chiari syn validation of absolute quantitation. calibration Technetium compounds, structure-stability relation phantom, 871(ab) drome, 423(le) ship, 789(ab) validation of quantitative analysis, exercise thal Sports medicine, bone scintigraphy, stress fractures. Technetium(III), neutral tris oxime complexes, lium tomograms. 871(ab) 1150(le) chemistry, biodistribution. 800(ab) vasoreactivity in cerebral arteriosclerosis, without SQ 30217 Technelium-99m carotid stenosis. 911(ab) Tc-99m-labeled. dipyridamole tomographic action of renal agents, sulfur-donating chelates. workload and sex-related variability, fatty acid myocardial perfusion. 938(ab) 801(ab) utilization. 841(ab) Tl-201 planar myocardial imaging, compared to 10- and 11-membered N2S2 ligands, synthesis, Xe-133 and Tc-99m HM-PAO. side localization, coronary anatomy. 841(ab) biodistribution, 788(ab) temporal lobe epilepsy, 9l6(ab) Sternal lesions, scintigraphic. patients with breast antifibrin antibody Xe-133 brain imaging cancer. 324 imaging, venous thrombi. 745(ab) developmental childhood dysphasia, 792(ab) Sternum, review of disease on bone scans. 780(ab) thrombus model. 746(ab) error analysis, cerebral blood flow in children. Stomach, distal, removal of, gastric emptying. carbohydrate residue label, tumor xenograft im 869(ab) 752(ab) aging, monoclonal antibodies. 815(ab) Sturge-Weber cerebral angiomatosis. 792(ab) Streptavidin comparative study of labeled chicken liver, egg- Skeletal mÃ©tastases,absorbed dose. Sr-89, 549 -conjugated antibody, labeled biotin. tumor lo white as solid markers, gastric emptying. Smoking, increased Ga-67 pulmonary activity. calization studies, 762(ab) 752(ab) HIV-positive persons, 829(ab) -conjugated monoclonal antibodies, abscess im comparison of 360' and 180' sections, SPECT Sn-M7ni, high specific activity, bone cancer ther aging, In-111 biotin, 889(ab) imaging, 868(ab) apy, 849(ab) potential tumor imaging agents. 729(le) comparison of MRI and bone scintigraphy. eval Society of Digital Imaging, Management and Com radiolabeled biotin derivative, facile preparation. uation, osseous spine mÃ©tastases.763(ab) munication, first meeting in June, N10 923(ab) complexed with 3 Schiff base/oxime ligands, Society of Nuclear Medicineâ€”Europe (SNME), Stress testing, thallium scintigraphy and. patient 936(ab) ENMS and. formation of European Associ selection, repeat angiography. 770(ab) Compton-scatter estimation, spectral fitting, ation of Nuclear Medicine. N7 Stroke, prognosis using Technetium-99m HM- Monte Carlo simulation. 797(ab) Society of Nuclear Medicine (SNM) PAO, 743(ab) condensing osteitis, clavicle. 1122 archives seeks material, N1005 Strontium-89 dioxime complexes, chloro-hydroxy substitution, Board of Trustees, scientific, educational services absorbed dose, skeletal mÃ©tastases.549 800(ab) abroad. N429 marrow toxicity, therapy, osseous mÃ©tastases. effect of body position, gastric emptying, 75 l(ab) commentary 776(ab) effect of caloric content, gastric emptying. FDA clarification of policies. N1472 metastatic prostate cancer, palliation, wide field 751(ab) FDA/SNM/ACNP recruitment venture. radiotherapy. 775(ab) enriched uranium embargo risked supply. N1003 N1477 Strontium-89 chloride, treatment results and kinet factors related to parathyroid imaging. 860(ab) lines from the president ics, painful prostate & breast cancer in bone. fatly acid derivatives of PnAO. tracers, myocar a vintage year. N1006 763(ab) dial metabolism. 934(ab) getting paid in America-DRGs. RAPs. Struma ovarii, postmenopausal woman. 263 how to avoid complications, intrahepatic arterial RVSs. N289 Sturge-Weber cerebral angiomatosis, Xe-133 brain infusions, chemotherapeutic agents. 799(ab) moving into fall, N1475 SPECT imaging, 792(ab) 1-123and. comparative imaging, thyroid nodules, RVSs. regional compacts, and other national /V-Suceinimidyl stannyl benzoates, meta v.v.para 753(ab) issues, N1891 substituted, utility, antibody labeling. instant kit, N586 need for radioisotope production LINAC, 834(ab) labeled phosphine and isocyanide cationic com N1758 W-Succinimidyl-3-(tri-n-butylstannyl)benzoate, la plexes, protein binding studies, 62 1988 election results, N1478 beling of monoclonal antibody, iodine and labeling of human platelets, improved kit E&R Foundation approves research grant, astatine. 835(ab) method. 787(ab) N587 Super-Collider, superconducting, impact on nu measurement of cerebral blood flow. 1464(le) self-study program. N590 neutral alkyl-DADT-technetium complexes, pul clear medicine. 576(le) SNM annual meeting. San Francisco. N581 monary accumulation. 789(ab) SNM Education and Research Foundation. Swyer-James syndrome, unilateral hyperlucent noninvasive determination, gastric emptying, an- lung, ventilation-perfusion scan in. 114 student fellowships, N1338 tral motility, 862(ab) SNM 35th Annual meeting, scientific highlights. Sympathetic activity oxidation state measurement, internal conversion N1329 non-neuronal cardiac uptake. I-123 M1BG. hu electron microscopy, 789(ab) SNM 7th Annual Winter Meeting, instrumenta mans. 842(ab) perfusion of tumor-bearing kidneys, model for tion and computer seminars, N6 response to altitude hypoxia. I-123 MIBG myo scintigraphic screening for monoclonal anti structural change, N1014 cardial uptake. 842(ab) bodies, 1078

Subject Index â€¢1988 2073 Technetium-99m D, L-HM-PAO

radiolabeled patÃ©,esophageal function study. era, 905(ab) determination of flow and rate constants, kinetic 885(ab) comparison with Gd-153 DTPA, biodistribution. model, human brain, 917(ab) tablets, ultrasonic visualization in gastrointestinal 1683 I-123 IMP SPECT and, compared to PET, de tract, 129(le) effect of saralasin vs. captopril rcnography, two- mentia. 916(ab) validation of absolute quantitation. SPECT, cal kidney/one-clip hypertension. 849(ab) In-111 tropolonate and, kinetics of leukocytes ibration phantom, 871(ab) first-pass camera study, renal blood flow. GFR. labeled with, 1246 Technetium-99m D,L-HM-PAO, stabilization using and filtration fraction. 733(ab) labeled leukocytes, reliability, Crohn's disease, gentisic acid, 935(ab) glomerular filtration rate, plasma clearance tech 827(ab) Technetium-99in albumin niques. Il52(le) linearization of rCBF values, 936(ab) compared to Tc-99m non-specific IgG, other I-125 iothalamate plasma clearances, diabetic pa local cerebral blood flow, quantitative measure radiolabels, focal sites of infection, 887(ab) tients, 816(ab) ments, 1387 labeled leukocytes, evaluation, 903(ab) lack of breakdown, ultrasound nebulization. localization of seizure foci. 913(ab) Technetium-99m antibody 905(ab) radiochemical purity, 572(le) labeling with N,S and N2S2amide mercaptides. measurement of differential renal function, reverse redistribution, mild cerebral ischemia, 8IS(ab) 134(le) 9l4(ab) Re N2S? complexes per antibody Fab fragment, radioaerosol inhalation, effect of position, venti scintitomography, acute cerebral infarction, immunoreactivity, tumor uptake, 815(ab) lation scintigraphy, 764(ab) 843(ab) Technetium-99m anti-CEA, immunoscintigraphy. renography and Tc-99m DMSA renal scintigra serial radionuclide determinations, graft perfu known and occult colorectal carcinoma, phy, renal artery stenosis, ACE inhibition, sion, pancreas-spleen transplantation. 834(ab) 908(ab) 885(ab) Technetium-99m anti-granulocyte antibody, detec single-injection, two-sample method, extracellu SPECT tion of inflammatory diseases, 829(ab) lar fluid volume from plasma clearance, 255 cerebral collateral circulation during Matas Technetium-99m anti-melanoma, SPECT and, clin Technetium-99m DTPA-HSA test, 1724 ical experience, 812(ab) initial experience in man, 922(ab) cerebral perfusion tracer, evaluation. 843(ab) Technetium-99m antimony colloid, mammary lym- SPECT. assessment, perfusion reserve in CVD, high resolution imaging. SPRINT. 917(ab) phoscintigraphy, I744(le) 918(ab) new method, brain functional study, 748(ab) Technetium-99m anti-SSEA-1, tracer for human Technetium-99m ICH ruptured intracranial aneurysm, 844(ab) neutrophils, 788(ab) brain perfusion imaging. 788(ab) side localization, temporal lobe epilepsy. Technetium-99m aromatic isocyanides, potential brain tomographic imaging, stable perfusion 916(ab) myocardial imaging agents. 800(ab) agent. 758(ab) stereoisomers. interaction with glutathione, 1998 Technetium-99m carboxylic acids, a.a-disubsti- compared to Tc-99m HM-PAO, 9l2(ab) stroke prognosis, 743(ab) tuted. a-hydroxy-, 934(ab) brain perfusion imaging agents. 844(ab) technical considerations for preparation, assess Technetium-99m cellulose Tiber, gastrointestinal compared to Xe-133, SPECT, cerebral blood ment, cerebral blood flow, 928(ab) transit, 857(ab) How, 913(ab) triple mode evaluation, subarachnoid hemor Technetium-99m colloids, compared to HM-PAO- compared with Tc-99m HM-PAO. first human rhage, vasospasm, 743(ab) labeled leukocytes, 813(ab) results. 747(ab) uptake in brain, primary and metastatic tumors, Technetium-99m CPI, binding characteristics, cul metabolism in normal volunteers, 747(ab) 895(ab) tured chick heart cells, 55 new brain agent, kinetics and biodistribution. Technetium-99m IDA, time-activity curves, hepa- Technetium-99m DADS-amido-fatty acid, myocar 921(ab) tocyte versus biliary disease, 623 dial imaging, 935

2074 The Journal of Nuclear Medicine Thallium-201

sion, 849(ab) quantitative methods, myocardial imaging, reperfusion effects, myocardial extraction, compared to I-131 hippuran, dual channel tech 955(ab) 819(ab) nique. 908(ab) renal imaging. 2027(ab) Technetium-99m RP-30A compared to I-131 OIH kit formulations. 909(ab) same-day injections, myocardial tomographic compared to Tl-201, quantitative cardiac SPECT, comparison with I-131 hippuran, renal imaging, imaging, 804(ab) 793(ab) 1I89 slow infusion, increased myocardial uptake, rest noninvasive delineation of infarcÃ¬size, vessel pat effect of urinary pH, 906(ab) and stress studies, 942(ab) ency, 819(ab) evaluation of Tc-99m D-MAGAG diastereomers, Tl-201 and, uptake in thyroid carcinoma, 854(ab) quantification of infarcÃ¬size, compared to CPK primates, 909(ab) Tl-201 SPECT and, coronary angiography, cor and LVEF, 946(ab) I-123 and I-131 comparison, patients with renal onary artery disease, 952(ab) uptake, skeletal muscle, 275(ab) disorders, 147 uptake and release, cultured myocardial cells, 48 Technetium-99m SbSC, lymphoscintigraphy, cuta kit formulation, renal failure patients, 616 vs. Tl-201 perfusion imaging, myocardium, wall neous malignant melanoma, 893(ab) pharmacokinetics and metabolism. 906(ab) motion assessment. 950(ab) Technetium-99ni-Sn-pyrophosphate, localization, probenecid inhibition of uptake, kidney, 908(ab) Technetium-99m microcolloids, hepatic blood flow, m-iMiophiK. 1406 quantitation, renal function. 1931 graft rejection and, 1776 Technetium-99m SQ 30217, dipyridamole tomo renal radiopharmaceutical, 2027(ab) Technetium-99m monoclonal antibodies graphic myocardial perfusion, 938(ab) Technetium-99m MDP antiplatelet, diagnosis, mesenteric thrombosis, Technetium-99m stannous fluoride colloid, prepa alteration of distribution, systemic aluminum, 886(ab) ration of kit, leukocyte labeling. 888(ab) 856(ab) detection of metastatic melanoma. 897(ab) Technetium-99m sulfur colloid bone formation, metastatic transitional cell car kinetics and metabolism, cellular level, 823(ab) detection of infected hip arthroplasty, 887(ab) cinoma, 1462(le) ocular radioimmunoscintigraphy. 1031 fine aerosol distribution, human airway, 1057 bone imaging successful imaging, lung and colon carcinoma, hepatic uptake, microautoradiographic study, adverse reactions, 1302(le) 834(ab) 1118 symmetric photon deficiency in femoral heads, targeting of granulocytes, 925(ab) liver and spleen size, planar and transaxial 2660e) Technetium-99m MP-600, renal imaging, 735(ab) SPECT images, 870(ab) bone scanning, trochanteric bursitis, 763(ab) Technetium-99m NÃ‚, Tc-99m antibody labeling, lymphoscintigraphy, surgical management, mel detection of infection, delayed/non-union frac active ester complex, side chain length, anoma, 854(ab) tures, 813(ab) 8IS(ab) radionuclide lymphoscintigraphy, localization of diagnosis and follow-up of neuroblastoma, Technetium-99m NiS2 complexes, stereochemistry, internal mammary lymph nodes, 473 750(ab) 8

Subject Index â€¢1988 2075 Thallium-201 chloride

elliptical versus circular acquisition, 736(ab) myocardial emission assessment, Kawasaki dis stress testing, patient selection for repeat an- evaluation, pre-renal transplant patients, ease, 791(ab) giography. 770(ab) 950(ab) myocardial infarction, after attempted reperfu- single-photon emission tomography, exercise, 1-123 MIBG comparison, myocardial infarc sion, 1283 coronary artery disease detection, 755(ab) tion, 840(ab) myocardial perfusion defects, weaning, mechan SPECT patient and organ movement in SPECT, 441 ical ventilator-dependent patients, 947(ab) abnormal clearance, assessment of coronary cardiac stressing, esophageal pacing, 942(ab) myocardial perfusion imaging, coronary vasodi- artery disease, 948(ab) compared to Rb-82 PET, detection, coronary lation, 781(ab) bullseye, applying standard deviation, 954(ab) artery disease, 817(ab) myocardial redistribution, ribose effects, 1943 bull's eye display, 1901 compared to Tc-99m MIBI myocardial scans, reverse redistribution, coro cardiac studies, intraobserver variability, assessment, coronary disease. 793(ab) nary artery disease marker, 952(ab) 944(ab) detection, coronary artery disease, 793(ab) myocardial SPECT, estimation, right ventricular combined with "bullseye" analysis, ischemie myocardial defect detection, 850(ab) overloading, 950(ab) coronary disease, 756(ab) compared to Tc-99m RP-30A, quantitative car myocardial tomography, multicenter trial, Ce comparison of bullseye display, 3D surface im diac SPECT, 793(ab) dars-Sinai method, 755(ab) ages, 756(ab) computer-simulated cardiac SPECT data, evalu noninvasive detection of coronary artery disease, dipyridamole, compared to exercise SPECT, ation, reconstruction algorithms, 748(ab) vasospastic angina, 782(ab) coronary artery disease, 838(ab) dipyridamole and exercise, simultaneous assess normal and ischemie myocardium, fatty acid in dipyridamole scintigraphy, ECG changes, ment, leg muscle and myocardial ischemia, flux, biochemical characteristics. 940(ab) 945(ab) 947(ab) perfusion defects, detection and quantification, effect, early myocardial redistribution, 947(ab) dipyridamole imaging, prediction, in-hospital is 273(ab) estimation, left ventricular mass, 945(ab) chemia, 78 l(ab) persistent defects evaluation, suspected lung cancer, 895(ab) dipyridamole perfusion scintigraphy, known or significance, metabolic activity, 827(ab) infarcÃ¬size, myocardial infarction, 951(ab) suspected angina, 781(ab) tissue glucose metabolism, myocardium, inferior attenuation, peritoneal fluid. 941(ab) dipyridamole tomography, complications predic 827(ab) interpretation, 272(ab) tions, non-cardiac surgery, 838(ab) pharmacokinetics, routine myocardial scintigra myocardial perfusion defect size. 278(ab) dipyridamole with, serum drug level following, phy, 1582 myocardial perfusion studies, utility, delayed 1662 planar, quantification, degree of reversibility. 24-hour redistribution. 769(ab) distribution behavior, prolonged heart muscle 861(ab) patients with LBBB, 279(ab) flow physiology, 942(ab) planar myocardial imaging, SQ30217, compared peritoneal fluid effects, myocardial imaging in distribution of myocardial perfusion, patients to coronary anatomy, 841(ab) women, 1860 surviving sudden death. 769(ab) planar scintigraphy. myocardial glucose metabo posterolateral myocardial infarction, 954(ab) dobutamine imaging, detection, coronary artery lism, 828(ab) predictive value, myocardial infarction, disease, 955(ab) planar Tc-99m isonitrile exercise imaging 77

2076 The Journal of Nuclear Medicine Tumors

Thallium-201 SQ 32014, compared to RP-30, myo- phy, 1169 See also specific organ cardial uptake and redistribution, 819(ab) detection of, comparison, monoclonal antifibrin control of allograft rejection. Tc-99m MAA, al- Thallium-201 thallous chloride, Tc-99m isonitrile antibodies, 905(ab) logenic lymphocytes, 757(ab) and, rest and exercise SPECT studies. 1-131 fibronectin imaging. 1264 heart: See Heart 944

Subject Index â€¢1988 2077 Tumor-seeking agents

monoclonal antibodies. 900(ab) mate uptake. 208 internalization of monoclonal 3G5-lgM, 923(ab) evaluation of commercial radioimmunoassay kit. primary and metastatic brain. Tc-99m HM-PAO internally-labeled monoclonal antibodies, biod- human serum calcitonin. 766(ab) uptake. 895(ab) istribution. 889(ab) experimental. Lewis lung carcinoma model. 1252 prostate, localization, monoclonal antibody. I-125 nucleoside. synthesis and biodistribution. extremity musculoskeletal. metabolic imaging by 898(ab) 929(ab) PET, 181 protein labeling. I-123 PIP conjugate. 929(ab) In-l 11ZCE-025 anti-CEA monoclonal Fab' frag fibrosarcoma, paramagnetically-labeled LDL. radioimmunodetection of deposits, monoclonal ments, biodistribution. 896(ab) GA-67. 890(ab) antibody administration. 761(ab) location of ovarian dysfunction. 1644 Ga-67 accumulation in. 20l9)le) radioimmunopharmaceuticals, intact v.v. frag metabolism of In-l 11 benzyl-EDTA monoclonal gastrointestinal. In-Ill monoclonal antibodies, ments. 893(ab) antibody, mouse liver, 824(ab) binding assay. 1436 registration of MR1-PET images, procedure, val mucin-like carcinoma-associated antigen, moni hepatic perfusion in cancer patients, parameters. idation, 853(ab) toring, breast cancer patients. 894(ab) 894(ab) review of sternal disease, bone scans. 780(ab) optimization of ligand structure, imaging, bifunc hepatic perfusion index. I747(le) squamous cell carcinoma, serum TA-4 as marker, tional antibody. 835(ab) hexokinase Michaels-Menten kinetics. 773(ab) lung and other organs. 765(ab) radioimmunodetection of human melanoma. human cancer xenografts. therapy. Y-90 mono studies using serum from patients. In-l II fab. 329 clonal antibodies. 901(ab) 895(ab) radiolabeled, intracavitary use of, 1910 hypoxic. new approaches, radiosensitization. surgical radiation probes. 881(ab) serum-stable liposomes, 516 873(ab) surgical staging, dual-detector probe. 1101 streptavidin and biotin, 729(le) I-123 IMP brain SPECT. after cerebral radiation survival and sequestration of In-l 11 donor plate synthesis of para-substituted phenyl glyoxals. bro- therapy. 914(ab) lets. 787(ab) moacetylation. 928(ab) I-125 nucleoside. synthesis and biodistribution, thyroid, differentiated. TI-201 follow-up. 1515 Tc-99m HM-PAO uptake, primary and meta 929(ab) thyroid carcinoma. Tc-99m MIBI and TL-201 static brain tumors. 895(ab) increased delivery of Ga-67. serum-stable lipo uptake. 854(ab) theoretical tumor absorbed doses, radioimmu- somes. 516 treatment of painful skeletal mÃ©tastases,initial notherapy, radionuclides. 858(ab) In-l 11 Fab' compared to F(ab)'2 derivative, experience. !86-Re(Sn>-HEDP. 776(ab) tumor-bearing kidneys, model for scintigraphic 8l2(ab) uptake screening for monoclonal antibodies. 1078 internalizaron of monoclonal 3G5-IgM, 923(ab) I-I25 IPM compared to I-I25 ICI labeling. tumor uptake intra-arterial chemotherapy. SPECT evaluation monoclonal antibodies. 836(ab) as a function of tumor mass, mathematical of. 593 ni I Ml MIBG. gamma camera estimation of. model. 103 liver, Sipple's syndrome. Tc-99m (V)-DMSA and 542 blood How and. I463(le) 1-131 MIBG. 1130 Yt-90 anti-tumor antibodies, therapy trials. uptake, non-Hodgkin's lymphoma. 1633 uptake of radiolabel in liver cells. F(ab')2 frag liver mÃ©tastases. F-18 urani accumulation, 846(ab) 776(ab) Yttrium-90 antibody biodistribution, intraperi- ment, 823(ab) localization studies, streptavidin-conjugated anti toneally. 1428 value of l-l31-MlBG/Tc-99m-MDP/Ga-67-cit- body, labeled biotin. 762(ab) Tumor-seeking agents rate, diagnosis and follow-up, neuroblas lung and colon carcinoma, imaging. Tc-99m colon cancer. 1022 toma, 750(ab) monoclonal antibody. 834(ab) correlation of radiochemical yield. In-Ill anti- Tungsten-178, generator system, high volume clin lung uptake, two dose levels. In-Ill anti-CEA body-chelator conjugates. 924(ab) ical applications. 1526 Tungsten-188, W-l88/Re-188 gel generator. monoclonal antibody. 825(ab) Cu-67 monoclonal antibody, cancer therapy. 217 malignant detection of intracardiac malignant lymphoma. 923(ab) Tyramine-cellobiose antibody accumulation of In-l 11 granulocytes. 479 1868 localization with radioiodinated recombinanl effect of radiolabeling method, retention of mon compared to lactoperoxidase, 835(ab) tissue plasminogen activator. 1194 oclonal antibody, cultured cells. 901(ab) evaluation of. 835(ab) L-Tyrosine, use of phenylalanine dehydrogenase for mammary effects of external beam radiation, tumor uptake, synthesis. N-13. 931(ab) chemotherapy. P-31 NMRand IH-MRlstudy. external beam radiation. 926(ab) 837(ab) estimation of uptake from images, metastatic co lymphoscintigraphy, I744(le) lon carcinoma. 901(ab) U mass as determining factor, tissue biodistribution, evaluation of treatment response to radiotherapy, Ulcer, Tc-99m sulfur colloid sucralfate. 936(ab) monoclonal antibodies. 926(ab) head and neck cancer. 1521 Ultrasound massive type hepatocellular carcinoma, applica Ga-67. cell membrane permeability and. 663 ln-1 II WBC scimigraphy. febrile ICU patient. tion. 1-131 lipiodol. 799(ab) 1-123 IMP 795(ab) mechanism of Ga-67 accumulation, cell mem malignant melanoma detection. 1200 nebulization, Tc-99m DTPA breakdown, brane permeability and. 663 visualization of ocular melanoma. 1448 905(ab) mechanism of TI-201 uptake. 750(ab) I-13I anti-CEA and anti-AFP antibodies, ra- scintigraphy and. assessment, renal transplant pa melanoma, radioimmunodetection with In-l 11 dioimmunotherapy. 846(ab) thology. 779(ab) monoclonal antibody, 329 imaging of rhabdomyosarcoma. radiolabeled United States Council for Energy Awareness, edu metastatic colon carcinoma, uptake estimation fragments, monoclonal anti-myosin anti cation plan. NI 168 from images. 901(ab) body. 791(ab) United States Department of Energy (USDOE), metastatic transitional cell carcinoma, bone for imaging with 1-131 16-88 monoclonal antibody, Brookhaven National Laboratory contract, mation. Tc-99m MDP and. I462(le) colon cancer. 833(ab) N292 neural crest, side effects. 1-131 MIBG. 798(ab) imaging with In-l 11synthetic porphyrin. 900(ab) Uranium, embargo, supply of Mo-99 and. N1003 neuroblastoma imaging. I-I31 3F8 and MIBG. ln-111 anti-CEA monoclonal antibody ZCE 025. Ureter 846(ab) detection, colorectal carcinoma. 8l2(ab) renal antegrade perfusion scintigraphy. 779(ab) ocular melanoma. 1-123 IMP visualization of. ln-1 II bifunctional hapten. pre-targeted imrriu- segmental resection of. radionuclides. radiologi 1448 noscintigraphy. 226 cal renal function study, 778(ab) optimization of targeting, mixture, monoclonal In-l II fab. studies using serum from patients. Urinary tract, obstruction, diuretic renal scan. antibodies, 750(ab) 895(ab) 133(le) parotid concocytoma. 1-131 therapy. 1126 In-l 11 monoclonal antibody, localization, colo Urine, single sample, fibrinopeptide-A measure Pb-203 as new antibody label, radioimmunoim- rectal carcinoma, 898(ab) ment, 766(ab) aging. 924(ab) influence of antibody catabolism and shed anti Urology PET for evaluation, recurrent colorÃ©ela!tumors, gen, monoclonal antibody uptake. 823(ab) factor analysis, dynamic renal studies. 816(ab) 751(ab) influence of chelator denticity. biodistribution. pediatrie, nuclear medicine in, 1287 physiology, methotrexate effects on N-13 gluta In-l 11 B72.3 immunoconjugates, 824(ab) Uropathy, obstructive, bone scintigraphy, 1781

2078 The Journal of Nuclear Medicine Yttrium-90

monitoring. 838(ab) regional pulmonary ventilation, compartmental modeling, 861(ab) Valvular rÃ©gurgitation,factor analysis, first-passan- radionuclide monitoring, nitroglycerin re sponse in ischemia. 838(ab) texture analysis of lung scans. 861(ab) giography, 159 Tc-99m isonitrile dynamic imaging. 805(ab) Xenon-133 Venography left ventricular ejection fraction, exercise re brain SPECT imaging In-11 platelet, diagnosis of deep venous throm sponse, aortic rÃ©gurgitation.744(ab) developmental childhood dysphasia. 792(ab) bophlebitis, 1169 post-prandial changes, coronary artery disease. Sturge-Weber cerebral angiomatosis. 792(ab) in vitro evaluation, computer processing algo ambulatory nuclear monitoring, 742(ab) cerebral maturation in first 20 months of life, rithms, 862(ab) right regional cerebral blood flow, SPECT, radionuclide exercise performance, balloon valvotomy. 743(ab) evaluation, deep venous thrombosis. 825(ab) 945(ab) compared to Tc-99m ECD SPECT. cerebral upper extremity and superio vena cavai, inferior left ventricular infarction, amimyosin, blood flow. 913(ab) 737(ab) 806(ab) distribution behavior, prolonged heart muscle Tc-99m RBC. deep vein thrombosis. 1498 pressure overloading. Tl-201 myocardial flow physiology. 942(ab) Venous insufficiency, lower extremity periostitis SPECT, 95(Xab) focal abnormalities, fatty liver. 1050 secondary to, Tc-99m MDP. 1279 radioactivity concentrations of Radon-222, fol Ventricular volume Ventilation-perfusion calculation from radionuclide angiography, no lowing ingestion. 872(ab) routine lung scanning, diffusing capacity and, blood sampling or distance measurement. radioxenon tomography, validation studies for brain blood flow. 348 1268 745(ab) unilateral hyperlucem lung patient. 114 left,, assessment, gated Tc-99m isonitrile tomog regional cerebral blood flow by SPECT. partial epilepsy, childhood. 892(ab) Ventilation studies raphy, 771(ab) effect of position on ventilation scintigraphy. Tc- Y'entriculography retention, V/Q pattern, congestive heart failure. 99m DTPA radioaerosol inhalation. 764(ab) exercise-equilibrium-radionuclide, earlier detec 905(ab) SPECT initial experience with Technegas. 765(ab) tion, Adriamycin cardiomyopathy. 949(ab) cerebral blood flow, 1875(le) Kr-81m/Tc-99m MAA ventilation perfusion ra multi-probe device, cardiac and central circula tio, inert gas and, weaning, 764(ab) tory1function. 832(ab) compared to PET, cerebral blood flow. 919(ab) lung scanning, Tc-99m carbon particles, 765(ab) error analysis, cerebral blood flow in children. radionuclide 869(ab) parameter estimation gating models, 1842 hemodynamic changes, cardiac transplant re Tc-99m DTPA and Tc-99m pyrophosphate aer side localization, temporal lobe epilepsy. jection. 742(ab) 9l6(ab) osols in. 1761 location of tachycardia, multiharmonic Four splenoportography. Budd-Chiari syndrome. utility of Tc-99m DTPA aerosol inhalation scans. ier mapping. 744(ab) 423(le) artificially ventilated patients, 764(ab) removal of Ir-192 from reactor-produced Os-191, vasoreactivity in cerebral arteriosclerosis, without Xe-133 retention. V/Q pattern, congestive heart 927(ab) carotid stenosis. 911(ab) failure, 905(ab) scintigraphic phase maps, fast CT. 941(ab) Xenon-133 gas, SPECT. assessment of dementia, Ventricular function Verapamil, 19-iodo-3,3-dimethyl-18-nonadecenoic 1621 ambulatory ventricular function monitor acid uptake, myocardium, hypertension. X-ray detection, silent myocardial ischemia. 741(ab) 843(ab) scintillation camera, bone mineral densitometry, validation, exercise left ventricular ejection VEST: See Ambulatory cardiac monitoring device 855(ab) fraction. 741(ab) unique non-invasive method, measurement of cine NMR quantification, aortic rÃ©gurgitation. W calcium and electrolytes, tissues, 883(ab) 802(ab) Water, labeled, partition coefficient, grey and white elliptical regions of interest, improved accuracy, myocardial imaging. 944(ab) tissue, 773(ab) Weaning, K.r-81m/Tc-99m MAA ventilation per yttrium-90 impaired left ventricular filling, ejection fraction fusion ratio, inert gas and. 764(ab) absorbed fractions for electrons, beta particles, response to exercise, hypertension, 772(ab) Wiener restoration filter, alternative formulation. small spheres, 803(ab) left 845(ab) anti-tumor antibodies, therapy trials. 846(ab) arterial activity concentrations, PET. 941(ab) method for estimating organ brake radiation dispersion evaluation, O-15 water, 867(ab) World Health Organization (WHO), quality con trol of cardiac imaging. N440 doses, 875(ab) gated planar Tc-99m RP-30, contraction frac monoclonal antibodies, radioimmunotherapy. tion, 8l8(ab) WR-2721 adjunct, 925(ab) inspiratory reduction, stroke volume, 949(ab) monoclonal antibody therapy lung uptake of TI-201, 953(ab) Xenografts, tumor imaging with monoclonal anti bremsstrahlung dosimetry, 859(ab) mass determination, cine vs. gated spin NMR bodies, carbohydrate residue label, Tc-99m. human cancer xenografts. 901(ab) imaging. 891(ab) 81S(ab) antibodies, biodistribution, intraperitoneally, patient outcome, ambulatory radionuclide Xenon-127 1428

Subject Index â€¢1988 2079 Information for Authors ABSTRACT AND KEY WORDS An abstract of no more than 150 words should state the purpose of the study or investigation, basic procedures (study subjects or experimental animals and observational and analytic methods), major findings (spe EDITORIAL POLICY cific data and their statistical significance, if not too lengthy), and the principal conclusions. Emphasize new and important aspects of the study The Journal of Nuclear Medicine publishes original articles pertinent or observations. No abbreviations or reference citations are to be used to the field of nuclear medicine in the following categories: clinical and in the abstract. basic sciences, case reports, technical notes, special contributions, edito rials, letters to the editor, and news items. Submitted manuscripts, includ TEXT ing illustrations and tables, must be original works and not have been published previously. Manuscripts must be submitted solely to the Jour The text of original scientific and technical articles is usually divided nal and not concurrently under consideration for publication elsewhere. into the following sections: Introduction. Materials and Methods. Re The Journal of Nuclear Medicine has agreed to receive manuscripts in sults. Discussion, and Summary or Conclusion. accordance with the "Uniform Requirements for Manuscripts Submitted Case Reports should contain a concise description of one to three to BiomÃ©dicalJournals." as cited in the following sources: Ann Intern patients, emphasizing the nuclear medicine aspects and including meth Med(l9S2; 96:766-770) and Br Med J (1982; 284:1766-1770). In pre odology, data, and correlative studies. paring manuscripts, authors should follow the "Uniform Requirements Letters should concern previously published material or matters of for Manuscripts Submitted to BiomÃ©dicalJournals." and specific author general interest and should be brief and to the poinl. All material is instructions detailed below. Also, helpful guidance in conforming to subject to editing and condensation. the "Uniform Requirements" may be found in Medical Style & Formal: Other articles, e.g., reviews, position papers, or editorials, should An International Manual for Authors, Editors, and Publishers by Edward introduce a problem or question, present evidence, and conclude with an J. Hum, M.D. (Philadelphia: ISI Press; 1987). answer. The sequence of topics will be determined by the overall subject. In general, reference should not be made in the text to institutions MANUSCRIPT SUBMISSION or locales except when germane to that particular article. Generic names should be used throughout the text. Identify instruments and radiophar- Manuscripts should be submitted to the Editor: Thomas P. Haynie. M. D.. maceuticals by manufacturer name and address in parentheses and de The Journal of Nuclear Medicine, Office of Special Publications-227. scribe procedures in sufficient detail to allow other investigators to repro The University of Texas M. D. Anderson Hospital and Tumor Institute. duce the results. 1515Holcombe Blvd., Houston, Texas 77030; (713)792-6015. One origi nal and two copies of the manuscript, with three complete sets of wn- mounted glossy illustrations (no smaller than 3 '/; x 5 in. or larger than ACKNOWLEDGMENTS 8 x 10 in.), are required for review. See Manuscript Format (below). Acknowledge persons or agencies contributing substantially to the work, including any grant support. REVIEW PROCEDURE REFERENCES The review procedure is two-tiered: Submitted manuscripts are reviewed for content on the basis of originality, significance, adequacy of docu References should be cited in consecutive numerical order at first mention mentation, reader interest, and composition. All manuscripts considered in the text and designated by the reference number underlined and in suitable for review are evaluated by a minimum of two reviewers. Manu parentheses. References appearing in a table or figure should be num scripts not submitted according to author instructions will be returned bered sequentially with those in the text. to the author for correction prior to review. Revised manuscripts are The Reference list must be typed double-spaced and numbered con submitted to impaniai referees for judgment of adequacy of response to secutively, as in the text. The Journal follows Index Medicas style for suggestions and criticisms made on initial review. All accepted manuscripts references and abbreviates journal names according to the List of Journals Indexed in Index Medicus. "Unpublished observations" and "personal are subject to editing for scientific accuracy and clarity by the Editor. communications" should not be used as references, although writtenâ€” not verbalâ€”communications may be noted as such in the text. References MANUSCRIPT FORMAT cited as "in press" must have been accepted and not merely in preparation Submit one original and two copies of the manuscript and three sets of or submitted. The author is responsible for the accuracy of all references unmounted glossy illustrations. Manuscripts must be written in English. and must verify them against the original document. Type the manuscript on white bond paper. 8'/2 x 11in. (21.6 x 27.9 For journal articles, list all authors when six or less; for seven or cm), with margins of at least l'A in. (4 cm). Type on one side of the more authors, list the first three and et al: paper only, double spacing even,- page. Do not justify right margins. Begin each of the following sections on separate pages and in the follow Baumier PL. Krohn KA. Carrasquillo JA. et al. Melanoma local ing order: title page, abstract, text, acknowledgments, references, tables ization in nude mice with monoclonal Fab against p97. J NucÃ Med 1985; 26:1172-1179. (each on a separate page), and legends. Number pages consecutively, beginning with the title page. Type the name of the senior author and Weissmann HS. Badia J. Sugarman LA. Kluger L, Rosenblatt page number in the upper right-hand corner of each page. Paragraphs R. Freeman LM. Spectrum of WmTc-IDA cholescintigraphic should begin with an indentation of at least five spaces. Handwritten patterns in acute cholecystitis. Radiology 1981; 138:167-175. changes are not acceptable. For books and book chapters, follow the examples below: TITLE PAGE DeGroot LJ. Evaluation of thyroid function and thyroid disease. In: DeGroot LJ. Stanbury JB, eds. The thvroid and its diseases. The title page of the manuscript should include: (1)concise but informa 4th ed. New York: Wiley; 1975:196-248. tive title (strive to eliminate from the title those terms that cannot be Dupont B. Bone marrow transplantation in severe combined readily indexed); (2) short running head or footline of no more than 40 characters (letters and spaces) placed at the bottom of the title page immunodeficiency with an unrelated MLC compatible donor. In: White HJ, Smith R. eds. Proceedings of the third annual and identified; (3) complete byline, with first name, middle initial, and meeting of the International Society of Experimental Hematology. last name of each author and highest academic degree(s); (4) complete affiliation for each author, with the name of department(s) and institu- Houston: International Society for Experimental Hematology; 1974:44-46. tion(s) to which the work should be attributed; (5) disclaimer, if any. (6) name, address, and telephone number of author responsible for cor TABLES respondence about the manuscript; and (7) name and address of author to whom reprint requests should be directed, or statement that reprints Type each table double-spaced on a separate page. Do not submit tables are not available from the author. as photographs.

34A The Journal of Nuclear Medicine Tables should be self-explanatory and should supplement, not dupli UNITS OF MEASUREMENT cate, the text. Each table must be cited in consecutive numerical order The International System of Units (SI) is standard. Measurements of in the text Number the tables consecutively with an arabic number fol length, height, weight, and volume should be reported in metric units lowing the word TABLE. The titles should be descriptive, brief, and typed centered in upper- and lower-case letters. Place horizontal rules or their decimal multiples. Other measurements should be reported in the units in which they were made. Alternative units (SI or non-Si units) below the title, column headings, and at the end of the table. Do not should be added in parentheses by the author if indicated. use vertical lines. Give each column a short or abbreviated heading Place explanatory matter in footnotes, not in the heading. Use the following symbols, in this sequence: *. t. |. Â§.t. **. Expand in the ABBREVIATIONS AND SYMBOLS footnote all nonstandard abbreviations used in each table. For footnotes, Use only standard abbreviations and symbols in the text. Avoid using identify statistical measures of variations, such as standard deviation and abbreviations in the title and abstract. At first mention, the complete standard error of the mean. If data from another published source are term, followed by the abbreviation in parentheses, should be used in used, obtain written permission from the publisher of the original source the text. Standard units of measure should not be expanded at first men and acknowledge fully. If data from an unpublished source are used, tion. Consult the following sources for approved abbreviations: CBE obtain permission from the principal investigator, and acknowledge fully. Sr\-leManual: A Guide for Authors. Editors, and Publishers in the Biolog ical Sciences, 5th ed. (Bethesda. MD: Council of Biology Editors; 1983). and "Uniform Requirements for Manuscripts Submitted to Biomedicai ILLUSTRATIONS Journals" (Ann Intern Med 1982; 96:766-770). Illustrations should clarify and augment the text. Because imaging is a major aspect of nuclear medicine, (he selection of sharp, high-quality SUBMISSION OF MANUSCRIPTS halftone illustrations is of paramount importance. Figures of inferior quality will be returned to the author for correction or replacement. Mail one original and two copies of the manuscript and three complete Submit three complete sets of glossy illustrations, no smaller than sets of glossy illustrations in a heavy paper envelope, packed to prevent 3'/2 x 5 in. or larger than 8 x 10 in. Do not send original artwork. bending of photographs during mail handling. Manuscripts should be Glossy photographs of line drawings rendered professionally on white accompanied by a covering letter from the author responsible for cor drawing paper in black India ink. with template or typeset lettering, respondence regarding the manuscript. The covering letter should contain should be submitted. No hand-drawn or typewritten art will be accepted. the following copyright statement in compliance with the Copyright Revi High quality computer-generated an may be accepted if it is profession sion Act of 1976. effective January 1. 1978. ally done and determined, after review, to be of sufficient reproducible "Upon acceptance by The Journal of Nuclear Medicine, all copy quality. Letters, numbers, and symbols (typeset or template) should be right ownership for the article (complete title of the article in clear and of sufficient size to retain legibility after reduction. this space] is transferred to The Society of Nuclear Medicine. Do not encumber illustrations unnecessarily; titles and detailed expla On behalf of any and all co-authors. I accept the responsibility nations should be incorporated into the legend and not placed on the for release of any part or all of the material contained within illustration itself. When necessary for clarity, arrows or letter designa the article noted above. The undersigned stipulates that the mate tions may be affixed to the illustration, but they must be of professional rial submitted to The Journal of Nuclear Medicine is original artistic quality; handwritten or typewritten designations are not accept and has not been submitted to another publication for concurrent able. All patient information and institutional identifying data must be consideration." removed from illustrations. Each illustration must be numbered and cited in consecutive order Copyright requirement does not apply to work prepared by United in the text. Illustrations should be identified on a gummed label affixed States government employees as part of their official duties. to the back of each illustration with the following information: figure The letter should also contain a statement that the manuscript has number, pan of figure (if more than one), senior author's name, and been seen and approved by all authors and should give any additional designation of "top." information helpful to the Editor. If there has been prior publication Color illustrations will be considered for publication, but the author of any part of the work, this should be acknowledged and appropriate is responsible for all charges relating to separations and printing. An written permission included. If color illustrations are included, a state estimage of these charges will be sent to the author at the time of produc ment thai the author(s) is (are) willing to assume the cost of color separa tion. Author approval of charges is required before production will con tion and reproduction is requested. tinue. Three complete sets of glossy color photographs (not transparen cies) must be submitted for review. Polaroid prints are not acceptable. MANUSCRIPT CHECKLIST All submitted illustrations become the property of The Society of Original double-spaced typed manuscript and 2 copies. Nuclear Medicine and will not be returned unless the manuscript is rejected. Three sets of unmounted glossy Figures (no smaller than 3'/i x 5 in. or larger than 8 x 10 in.).

Copyright transfer. LEGENDS FOR ILLUSTRATIONS Title page with title, authors' names, and complete affiliations; Type legends double-spaced on a separate page. Each figure should be corresponding author, complete address, and telephone num cited in consecutive numerical order in the text. Number the figures ber; author for reprint requests and complete address. with an arabic number following the word FIGURE. Use letters to desig nate parts of illustrations (e.g.. A. B, C) and describe each pan clearly Abstract (maximum. 150 words). in the legend. Any letter designations or arrows appearing on the illustra References in consecutive numerical order. Reference list tion should be identified and described fully. typed double-spaced. Original (not previously published) illustrations are preferred for publi Figures and Tables in consecutive numerical order. cation in the Journal; however, if illustrations have been published previ ously, authors are responsible for obtaining written permission from Legends for all Figures; typed double-spaced. the publisher to reprint. The source of the original material must be Consent forms for patient photographs. cited in the references and the following credit line included in the legend: (Reprinted by permission of Ref. X.) All permission releases must be Written permission from the publisher to reprint previously submitted to the Editor at the time of manuscript submission. published Figures and Tables.

Volume 29 â€¢Number 12 â€¢December 1988 35A Index to Advertisers

Advertiser Telephone Number Page Number Reader Service Number

Amersham International Buckshire, England HP7 9LL 02404 4488 29A. .81 Atomic Products. Inc. Shirley. NY (516)924-9000 30A. .29 Capintec, Inc. Ramsey, NJ (800)631-3826 7A. CIS-US Bedford. MA (800)221-7554 33A. .24 Diversified Diagnostic Products, Inc. Houston. TX (713)955-5323 31A .33 Fuji Medical Stamford, CT (800)431-1850 10A GE Medical Milwaukee. WI (800)624-5962 17A-18A 40

Mallinckrodt St. Louis, MO (314)895-2000 11A-12A . . 121 Medi-Physics, Inc. Paramus, NJ (800)451-7732 IFC, 1A, OBC 1, 30 NeoRx Seattle, WA (206)281-7001 47A. .50 National Institute of Health Bethesda, MD (301)496-5675 32A 25 Nuclear Associates Carle Place, NY (516)741-6360 2A Ohio Imaging Bedford. OH (216)475-1111 19A 127 Picker International Highland Heights. OH (800)343-5000 14A-15A 57

Siemens Medical Systems Des Plaines. IL (312)635-3160 8A-9A .126

Sopha Medical Columbia. MD (301)740-1100 24A. 128 Squibb New Brunswick, NJ (800)582-5913 20A-23A 17

Syncor International Sylmar, CA (818)423-5620 IBC 10 Toshiba Tustin, CA (800)421-1968 25A-26A 69

SNM Annual Meeting .28A SNM Winter Meeting 47A SNM Publications MIRD . 50A Fundamentals of Nuclear Medicine .27A Nuclear Medicine: Self-Study Program I . 16A Chromotrography ,49A New Titles 51A

54A The Journal of Nuclear Medicine